A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral Rociletinib in Patients With Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)
Phase: PHASE1
Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer
Sponsor: Clovis Oncology, Inc.

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 1 of 151 
Confidential 
A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy 
Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR 
Non-small Cell Lung Cancer (NSCLC) 
Protocol Number: 
CO-1686-008 
Investigational Product: 
CO-1686 
Eudra CT Number 
2011-005215-86 
IND Number: 
113,560 
Development Phase: 
Phase 1/2 
Indication Studied: 
Locally advanced or metastatic NSCLC with mutant 
epidermal growth factor receptor (EGFR) 
Sponsor Name and Address: 
Clovis Oncology, Inc. 
5500 Flatiron Parkway, Suite 100 
Boulder, CO 80301 USA 
Phone Number: 
303-625-5000 
Facsimile Number: 303-245-0360 
Responsible Medical Officer: 
Sergey Yurasov, M.D., Ph.D. 
Compliance Statement: 
This study will be conducted in accordance with the ethical 
principles that have their origin in the Declaration of 
Helsinki, clinical research guidelines established by the Code 
of Federal Regulations (Title 21, CFR Parts 50, 56, and 312), 
and International Conference on Harmonization (ICH) Good 
Clinical Practices (GCP) Guidelines.. Essential study 
documents will be archived in accordance with applicable 
regulations. 
Original Protocol Date: 
December 10 2011 
Amendment 1 Date: 
Amendment 2 Date: 
Amendment 3 Date: 
Amendment 4 Date: 
Amendment 5 Date: 
Amendment 6 Date: 
Amendment 7 Date: 
Amendment 8 Date: 
January 25 2012 
October 04 2012 
July 08 2013 
December 10 2013 
March 25 2014 
April 17 2014 
August 07 2014 
August 03 2016 
CONFIDENTIALITY STATEMENT 
The information in this document contains commercial information and trade secrets that are 
privileged or confidential and may not be disclosed unless such disclosure is required by 
applicable laws and regulations. In any event, persons to whom the information is disclosed must 
be informed that the information is privileged or confidential and may not be further disclosed 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 2 of 151 
Confidential 
by them. These restrictions on disclosure will apply equally to all future information supplied to 
you which is indicated as privileged or confidential. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 3 of 151 
Confidential 
Protocol Approval Signature Page 
Protocol: 
CO-1686-008 
 
Title: 
A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary 
Efficacy Study of Oral CO-1686 in Patients with Previously Treated 
Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) 
 
Date: 
 
August 03 2016 
 
Version: 
 
9.0 
 
 
 
 
Reviewed and Approved by: 
 
 
 
 
  
Sergey Yurasov, M.D., Ph.D 
Senior Vice President of Clinical Development 
 
 Date 
Clovis Oncology, Inc. 
 
 
  
Alan Newlands 
Head Of Global Regulatory Affairs 
Clovis Oncology, Inc. 
 Date 
 
 
 
  
Jeff Isaacson, Ph.D. 
Senior Director, Biostatistics and Data Management 
Clovis Oncology, Inc. 
 Date 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 4 of 151 
Confidential 
Protocol Acceptance Form 
Protocol: 
CO-1686-008 
 
Title: 
A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary 
Efficacy Study of Oral CO-1686 in Patients with Previously Treated 
Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) 
 
Date: 
 
Version: 
 
August 03 2016 
 
9.0 
 
I have carefully read this protocol and agree that it contains all of the necessary information 
required to conduct this study. I agree to conduct this study as described and according to the 
Declaration of Helsinki, ICH Guidelines for GCP, and all applicable regulatory requirements. 
 
 
 
  
Investigator’s Signature 
 Date 
 
 
 
  
Name (printed) 
  
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 5 of 151 
Confidential 
Table of Contents  
Description 
Page 
1 
SYNOPSIS ..................................................................................................................... 13 
2 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ........................... 31 
3 
INTRODUCTION ........................................................................................................ 34 
3.1 
CO-1686 Clinical Development Program Update ....................................... 34 
3.1.1 
Extension Phase ................................................................................ 34 
3.2 
Mutant EGFR Non-small Cell Lung Cancer ............................................... 34 
3.3 
Nonclinical Overview ..................................................................................... 36 
3.4 
Clinical Experience with CO-1686 ................................................................ 38 
3.4.1 
Safety ................................................................................................. 38 
3.4.1.1 
Tumor Responses Associated with CO-1686 .................... 44 
3.4.2 
Pharmacokinetics of CO-1686 ......................................................... 46 
3.5 
Rationale for Study and Starting Dose ......................................................... 49 
3.5.1 
Rationale ............................................................................................ 49 
3.5.2 
Starting Dose for Phase 1 ................................................................. 50 
3.5.3 
Doses for Phase 2 .............................................................................. 51 
4 
STUDY OBJECTIVES ................................................................................................ 52 
4.1 
Objectives and Endpoints .............................................................................. 52 
5 
STUDY DESIGN .......................................................................................................... 54 
5.1 
Overall Study Design and Plan ..................................................................... 54 
5.1.1 
Screening Period ............................................................................... 54 
5.1.2 
Phase 1 ............................................................................................... 54 
5.1.3 
Phase 2 ............................................................................................... 56 
5.1.4 
Treatment Post-progression (Phase 1 and Phase 2) ...................... 58 
5.1.5 
End of Treatment and Follow-up (Phase 1 and Phase 2) ............. 59 
5.1.6 
Extension Phase (Phase 1 and Phase 2) .......................................... 59 
5.2 
Study Schema .................................................................................................. 59 
5.3 
End of Treatment ........................................................................................... 62 
5.4 
Two Monthly Follow-up ................................................................................. 62 
6 
STUDY POPULATION ............................................................................................... 63 
6.1 
Number of Patients and Sites ........................................................................ 63 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 6 of 151 
Confidential 
6.2 
Inclusion Criteria ............................................................................................ 63 
6.3 
Exclusion Criteria ........................................................................................... 66 
6.4 
Patients or Partners of Patients of Reproductive Potential ........................ 67 
6.5 
Waivers of Inclusion/Exclusion Criteria ...................................................... 67 
7 
DESCRIPTION OF STUDY TREATMENTS AND DOSE MODIFICATIONS .. 68 
7.1 
Description of Investigational Product ......................................................... 68 
7.2 
Method of Assigning Patients to Treatment Groups ................................... 69 
7.3 
Preparation and Administration of Protocol-Specified Treatment ........... 69 
7.3.1 
Phase 1 Requirements for Fasting .................................................. 70 
7.3.2 
Phase 1 Requirements for Taking CO-1686 with Food ................ 70 
7.3.3 
Food-Effect PK Analysis Fed and Fasted Requirements .............. 70 
7.4 
Starting Dose and Dose Modifications of Protocol-specified Treatment... 71 
7.4.1 
Phase 1 ............................................................................................... 71 
7.4.1.1 
Dose Escalation ................................................................. 71 
7.4.1.2 
Maximum Tolerated Dose ................................................. 72 
7.4.1.3 
Dose-limiting Toxicity ...................................................... 72 
7.4.1.4 
Definition of DLT-evaluable Patient ................................. 72 
7.4.1.5 
Recommended Phase 2 Dose ............................................. 73 
7.4.1.6 
Intrapatient Dose Escalation .............................................. 73 
7.4.1.7 
Dose Expansion at Cleared Dose Levels ........................... 74 
7.4.2 
Phase 2 ............................................................................................... 74 
7.4.2.1 
Starting Dose ..................................................................... 74 
7.4.3 
Dose Modification Criteria (Phase 1, Phase 2 and the Extension 
Phase) ................................................................................................. 74 
7.5 
Accountability of Protocol-specified Treatment .......................................... 77 
7.6 
Blinding/Masking of Treatment .................................................................... 77 
7.7 
Treatment Compliance .................................................................................. 77 
8 
PRIOR AND CONCOMITANT THERAPIES ......................................................... 79 
8.1 
Anticancer or Experimental Therapy .......................................................... 79 
8.2 
Hematopoietic Growth Factors and Blood Products .................................. 79 
8.3 
CYP450 Isoenzyme Inhibitors and Inducers ............................................... 79 
8.4 
P-gp Substrates, Inhibitors and Inducers .................................................... 80 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 7 of 151 
Confidential 
8.5 
Other Concomitant Medications ................................................................... 80 
9 
STUDY PROCEDURES .............................................................................................. 81 
9.1 
Schedule of Assessments ................................................................................ 81 
9.2 
Screening Period ............................................................................................. 91 
9.3 
Phase 1 – Dose Escalation Period .................................................................. 92 
9.3.1 
Day 1 of Cycle 1 ................................................................................ 93 
9.3.2 
Days 8 and 15 of Cycle 1 .................................................................. 94 
9.3.3 
Phase 1:  Food-effect PK Evaluation .............................................. 94 
9.3.3.1 
Day -7 Prior to Cycle 1 ...................................................... 94 
9.3.3.2 
Day 1 of Cycle 1 ................................................................ 95 
9.4 
Phase 1 - Optional Treatment-Extension Period ......................................... 95 
9.4.1 
Day 1 of Cycle 2 and Subsequent Cycles ........................................ 95 
9.5 
Phase 2 ............................................................................................................. 96 
9.5.1 
Day 1 of Cycle 1 ................................................................................ 97 
9.5.2 
Day 4 of Cycle 1 (±1 Day) ................................................................ 98 
9.5.3 
Day 8 of Cycle 1 (±1 Day) ................................................................ 98 
9.5.4 
Day 15 of Cycle 1 (±1 Day) .............................................................. 98 
9.5.5 
Day 1 of Cycle 2 and Day 1 of Subsequent Cycles ......................... 99 
9.5.6 
Cycle 2 Day 15 (±1 Day) ................................................................. 100 
9.6 
End of Treatment Visit ................................................................................ 100 
9.7 
Follow-up ....................................................................................................... 101 
9.8 
Methods of Data Collection ......................................................................... 101 
9.8.1 
Safety Evaluations .......................................................................... 101 
9.8.1.1 
Adverse Event Assessment .............................................. 101 
9.8.1.2 
Clinical Laboratory Investigations .................................. 101 
9.8.1.3 
Vital Signs ....................................................................... 102 
9.8.1.4 
12-Lead Electrocardiograms............................................ 102 
9.8.1.5 
Body Weight and Height ................................................. 103 
9.8.1.6 
Physical Examinations ..................................................... 104 
9.8.1.7 
ECOG Performance Status .............................................. 104 
9.8.2 
Efficacy Evaluations ....................................................................... 104 
9.8.2.1 
Tumor Assessments ......................................................... 104 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 8 of 151 
Confidential 
9.8.3 
Pharmacokinetic Evaluations ........................................................ 104 
9.8.3.1 
Phase 1 ............................................................................. 104 
9.8.3.2 
Phase 2 (Cohorts A to C) ................................................. 105 
9.8.4 
Baseline Tumor Biopsy and Matched Blood Sampling 
Requirements .................................................................................. 106 
9.8.5 
Pharmacodynamic Evaluations ..................................................... 107 
9.8.6 
Optional Tumor Biopsy ................................................................. 107 
9.8.7 
Pharmacogenetic Evaluations ....................................................... 107 
9.8.8 
Optional Urine Sampling for Exploratory Research of Transrenal 
Nucleic Acids ................................................................................... 108 
9.8.9 
Quality-of-Life Assessments .......................................................... 108 
9.8.10 
Patient Diary Cards ........................................................................ 108 
10 
ADVERSE EVENT MANAGEMENT ..................................................................... 109 
10.1 
Definition of an Adverse Event.................................................................... 109 
10.2 
Definition of a Serious Adverse Event ........................................................ 109 
10.3 
Events or Outcomes Not Qualifying as Serious Adverse Events ............. 110 
10.4 
Clinical Laboratory Assessments and Other Abnormal Assessments as 
Adverse Events and Serious Adverse Events ............................................ 110 
10.5 
Pregnancy ...................................................................................................... 110 
10.6 
Recording of Adverse Events and Serious Adverse Events ...................... 111 
10.6.1 
Intensity of Adverse Events ........................................................... 111 
10.6.2 
Relationship of Adverse Events to Investigational Medicinal 
Products ........................................................................................... 111 
10.6.3 
Outcome and Action Taken ........................................................... 112 
10.7 
Follow-up of Adverse Events and Serious Adverse Events ...................... 112 
10.8 
Regulatory Aspects of Adverse Event Reporting ...................................... 112 
11 
STATISTICAL METHODS ...................................................................................... 114 
11.1 
Populations .................................................................................................... 114 
11.2 
Statistical Methods ....................................................................................... 114 
11.2.1 
General Considerations ................................................................. 114 
11.2.2 
Patient Disposition .......................................................................... 114 
11.2.3 
Baseline Characteristics ................................................................. 115 
11.2.4 
Efficacy Analyses ............................................................................ 115 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 9 of 151 
Confidential 
11.2.4.1 Phase 1 ............................................................................. 115 
11.2.4.2 Phase 2 (Cohorts A to C) ................................................. 115 
11.2.5 
Pharmacokinetic Analyses – Secondary Endpoint ...................... 116 
11.2.6 
Patient Reported Outcomes – Secondary Endpoint .................... 117 
11.2.7 
Relationship Between PK and QTc – Secondary Endpoint ....... 117 
11.2.8 
Time to Treatment Failure - Exploratory Endpoint ................... 118 
11.2.9 
Concordance of T790M in Tumor versus Blood – Exploratory 
Endpoint .......................................................................................... 118 
11.2.10 Safety Analyses ............................................................................... 118 
11.2.10.1 Extent of Exposure .......................................................... 118 
11.2.10.2 Adverse Events ................................................................ 118 
11.2.10.3 Clinical Laboratory Evaluations ...................................... 119 
11.2.10.4 Vital Sign Measurements ................................................ 120 
11.2.10.5 12-Lead Electrocardiograms............................................ 120 
11.2.10.6 Other Safety Measurements ............................................ 120 
11.3 
Interim Analyses ........................................................................................... 120 
11.4 
Sample Size Considerations ......................................................................... 121 
12 
PATIENT DISPOSITION ......................................................................................... 122 
12.1 
Patient Discontinuations .............................................................................. 122 
12.2 
Study Stopping Rules ................................................................................... 122 
13 
STUDY ADMINISTRATION ................................................................................... 123 
13.1 
Regulatory and Ethical Considerations ...................................................... 123 
13.1.1 
Regulatory Authority Approvals .................................................. 123 
13.1.2 
Independent Ethics Committee/Institutional Review Board...... 123 
13.2 
Confidentiality of Information .................................................................... 124 
13.3 
Patient Informed Consent ............................................................................ 124 
13.4 
Study Monitoring .......................................................................................... 124 
13.5 
Case Report Form ........................................................................................ 125 
13.6 
Study Termination and Site Closure .......................................................... 125 
13.7 
Modification of the Study Protocol ............................................................. 126 
13.8 
Retention of Study Documents .................................................................... 126 
13.9 
Clinical Study Report ................................................................................... 126 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 10 of 151 
Confidential 
13.10 
Study Publication .......................................................................................... 127 
13.11 
Quality Assurance Audits ............................................................................ 127 
14 
REFERENCES ........................................................................................................... 128 
15 
APPENDICES ............................................................................................................. 130 
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 11 of 151 
Confidential 
List of Tables 
Description 
Page 
Table 1: 
Cycle 1 DLTs Reported for Patients by Dose Level ........................................ 39 
Table 2: 
Treatment-related SAEs Reported in Any Patient ......................................... 40 
Table 3:  
Treatment-related AEs Reported in at Least 5% 
Patients or Treatment-related Events Associated with 
Inhibition of WT EGFR .................................................................................... 42 
Table 4: 
Electrocardiogram Test Results (QTc - Fridericia) ........................................ 43 
Table 5: 
Best Response, Objective Response, and Disease 
Control Rate in T790M-positive Patients ........................................................ 45 
Table 6: 
Estimated Human Starting Doses and Safety Factors 
Based on Body Surface Area ............................................................................. 51 
Table 7: 
Phase 1 Primary, Secondary and Exploratory 
Objectives and Endpoints.................................................................................. 52 
Table 8: 
Phase 2 (Part 2):  Primary, Secondary and Exploratory 
Objectives and Endpoints.................................................................................. 53 
Table 9:  
Final Dose Escalation Plan with CO-1686 HBr .............................................. 71 
Table 10: 
Protocol CO-1686-008 Schedule of Assessments – 
Phase 1:  All Cohorts ......................................................................................... 82 
Table 11: 
Protocol CO-1686-008 Schedule of Assessments – 
Phase 2:  All Patients ......................................................................................... 85 
Table 12: 
Protocol CO-1686-008 Schedule of Pharmacokinetic 
Sampling and Metabolite Sampling – Phase 1 and 2 ...................................... 89 
Table 13: 
Time Points for Pharmacokinetic and 12-Lead ECGs 
(Triplicate) Evaluations ..................................................................................... 90 
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 12 of 151 
Confidential 
List of Figures 
Description 
Page 
Figure 1: 
CO-1686 Generates Complete Responses in 
L858R/T790M Transgenic Model .................................................................... 37 
Figure 2: 
Best Response for Target Lesions in Centrally 
Confirmed T790M-positive Patients ................................................................ 45 
Figure 3: 
Kaplan-Meier Curves of Treatment Duration by 
T790M Status for 900 mg BID Free Base and All HBr 
Patients ................................................................................................................ 46 
Figure 4: 
Individual CO-1686 AUC0-24 on Day 1 Following 
500 mg to 1000 mg CO-1686 HBr BID............................................................. 48 
Figure 5: 
Individual and Mean CO-1686 Cmax Following a Single 
Dose of 900 mg CO-1686 Free Base vs. 500 mg CO-1686 
HBr ...................................................................................................................... 49 
Figure 6: 
Study Schema Phase 1 ....................................................................................... 60 
Figure 7:  
Study Schema Phase 2 ....................................................................................... 61 
Figure 8: 
Guidelines for Management of Hyperglycemia .............................................. 77 
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 13 of 151 
Confidential 
1 
SYNOPSIS 
Protocol Number 
CO-1686-008 
Title 
A Phase1/2, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral 
CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer 
(NSCLC)  
Phase 
Phase 1/2  
Introduction  
In mid-2015, Clovis submitted a New Drug Application for the use of rociletinib in patients 
with T790M-positive NSCLC.  In June 2016, the FDA issued a Complete Response Letter 
to Clovis stating that more data are required to approve rociletinib for use outside of a 
clinical trial.  Based on this outcome, Clovis decided to discontinue development of 
CO-1686 for NSCLC.  Patients will be informed of this change in the development plans in 
an update to the informed consent form for this study.  Those patients who continue to 
derive clinical benefit from study treatment, will be allowed to continue on the study at the 
discretion of the Principal Investigator in an extension phase.  No further patients will be 
enrolled in this study.  
The purpose of this protocol amendment (Amendment 8) is to add a new Extension Phase 
to allow patients to continue on the study but to avoid unnecessary collection of data that 
will no longer be analyzed or required for regulatory purposes, whilst maintaining an 
appropriate level of safety monitoring.  A new schedule of assessments for the Extension 
Phase as well as a complete description of procedures is provided in Appendix D.  This 
schedule replaces all schedules of assessments in Section 9.1 and should be followed for all 
patients. 
In addition, Amendment 8 (Appendix D) also introduces the availability of NAT2 testing 
for patients, an indirect indicator of the likelihood of developing hyperglycemia or QTc 
prolongation.  The availability and disclosure of this information to the patient’s treating 
physician will not affect the monitoring and associated treatment guidelines for these 
adverse events.  
For patients who wish to continue rociletinib treatment post progression, it is important that 
a full exploration of alternative treatment options between patients and their treating 
physicians takes place.  
Investigators and their staff are directed to the current Investigator’s Brochure for the most 
current efficacy and safety data, in which integrated summaries of the latest available data 
can be found and supersedes all safety and efficacy data in this protocol.  
CO-1686 is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI) that 
selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while 
sparing wild-type (WT) EGFR.  
Activating EGFR mutations are key drivers of NSCLC malignancy in 10% to 15% of 
patients of European descent and approximately 30% of patients of East Asian descent.1 
Patients with the most common EGFR activating mutations, exon 21 L858R and deletions 
in exon 19 (del19), typically have good responses to therapy with first-generation EGFR 
inhibitors such as erlotinib or gefitinib.2,3 Toxicity associated with both erlotinib and 
gefitinib includes skin-rash and diarrhea related to inhibition of the wild-type EGFR in skin 
and intestine, respectively.4,5,6 
Despite the impressive initial response to treatment, progression generally occurs after 9 to 
14 months of erlotinib or gefitinib therapy, driven in approximately 50% of cases by a 
second site T790M mutation (the “gatekeeper” mutation) in exon 20 of EGFR that 
mediates resistance to first-generation EGFR inhibitors.7,8 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 14 of 151 
Confidential 
Nonclinical data demonstrate that CO-1686 inhibits T790M as well as the common 
activating mutations (L858R, del19) and has minimal inhibitory activity towards WT 
EGFR at therapeutic doses. It is anticipated that CO-1686 will promote cell death in tumor 
cells with the T790M mutation, thus driving objective tumor responses and providing 
therapeutic benefit in patients who have developed T790M-mediated resistance to first 
generation EGFR inhibitors. Toxicities driven by WT EGFR inhibition should be minimal 
in treated patients. 
The goals of this study are: (A) to evaluate the pharmacokinetic (PK) and safety profile of 
oral CO-1686; (B) to determine the maximum tolerated dose (MTD) and/or recommended 
Phase 2 dose (RP2D) of oral CO-1686; (C) to assess the safety and efficacy of CO-1686 in 
previously treated NSCLC patients known to have the T790M EGFR mutation. 
CO-1686 was being developed with a companion diagnostic to identify patients whose 
tumors express activating EGFR mutations as well as the T790M resistance mutation. To 
evaluate alternative and less invasive procedures than tumor tissue biopsy to provide DNA, 
serial plasma samples from all patients will be analyzed for the presence of EGFR 
mutations including T790M in plasma. Patients will also have the option to provide serial 
urine specimens to determine whether EGFR mutations are detectable in transrenal nucleic 
acids.9 
The study was initiated in April 2012 using the free base form of CO-1686.  
Fifty-seven patients were treated with CO-1686 free base between April 2012 and 
August 2013. The highest dose of free-base CO-1686 administered was 900 mg BID; the 
MTD was not established. A hydrobromide (HBr) salt form of CO-1686 that has superior 
PK characteristics was introduced into the clinic in August 2013. CO-1686-HBr was tested 
at 500 mg BID, 625 mg BID, 750 mg BID, and 1000 mg BID in the dose escalation phase 
of the study. All doses tested had less than 33% incidence of dose limiting toxicities in 
Cycle 1. The dose of 750 mg BID was selected as suitable for further study and 2 
expansion cohorts (Cohorts A and B) were opened at that dose level. Subsequently, as the 
Phase 1 data matured, the recommended dose was adjusted to 625 mg BID based on robust 
antitumor activity at lower doses and anticipated optimal tolerability. 
RECIST responses have been observed across the range of doses studied in Phase 1. The 
current overall response rate in patients with T790M+ NSCLC is approximately 60%, 
based on a data cut from 40 patients in this study for the FDA end of Phase 2 meeting held 
in July 2014. The most common Grade 3 toxicity observed is hyperglycemia, occurring in 
approximately 30% of patients, which is most often managed with oral hypoglycemic 
monotherapy. Protocol Amendment 6 added dose levels of 500 mg BID and 625 mg BID to 
the Phase 2 cohorts to perform a comprehensive evaluation of dose and response and 
tolerability across multiple dose levels (Cohorts A and B), as well as an additional cohort 
(Cohort C – 625 mg BID regimen) to accommodate patients with a positive local T790M 
result but discrepant or inadequate central result. In Amendment 6, patients were to be 
allocated to the 500 mg or 625 mg BID regimens by 1:1 randomization. 
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 15 of 151 
Confidential 
 
Amendment 7 made the following changes: 
1. Clarification of CNS lesion exclusion criterion to ensure only patients with stable 
CNS disease are enrolled 
2. Removal of the requirement for 1:1 randomization to the 2 dose levels. This will 
allow additional early experience to be gained at the recommended dose (625 mg 
BID) in order to support the Phase 2/3 program where studies are enrolling at 
625 mg BID, as well as regulatory filings. 
3. Allowing for a potential increase in the size of Cohort A. Experience to date 
shows that Cohort A (later line patients) enrolls more rapidly than Cohort B 
(second line patients). Amendment 7 allows enrolment to continue in Cohort A 
until Cohort B is fully enrolled. Based on current enrollment rates, the size of 
Cohort A will increase from 150 patients to approximately 275 patients. 
4. Clarification that removal of 1:1 randomization allows patients to enroll in study 
before the central T790M status is obtained, in cases where the following 
conditions are met: 
a. 
Have undergone a biopsy of either primary or metastatic tumor tissue within 
60 days of dosing with study drug and have tissue available to send to the 
sponsor’s lab or are able to undergo a biopsy during screening. No change 
(except for washout or dose adjustment if required to manage adverse effects) 
in antitumor therapy regimen is allowed between the biopsy and CO-1686 
initiation (Study Inclusion Criterion 3); 
AND 
b. Local positive T790M result from biopsy taken at same time as central testing 
biopsy, with results available for sponsor review before enrollment 
5. Clarification of requirements for continued treatment of patients who progress on 
CO-1686. 
Study Overview 
This study will include 2 parts:  
• 
Phase 1:  Dose-escalation Period with 21-day cycles; optional Treatment Extension 
Period starting on Day 22 
• 
Phase 2: Evaluation of activity and safety in patients with the T790M EGFR mutation 
who have: 
Cohort A 
- 
Progressed on EGFR directed therapy (irrespective of the number and order of  
previous lines of NSCLC therapy) (Dose levels of 750 mg BID, 625 mg BID, and 
500 mg BID). 
OR 
Cohort B 
- 
Progression on the first single agent EGFR directed therapy received and also had 
no more than one previous line of chemotherapy (Dose levels of 750 mg BID, 
625 mg BID, and 500 mg BID). 
OR 
Cohort C 
- 
Signed consent for the study, and fulfils eligibility, but with discordance between 
local (T790M positive) and central (T790M negative) T790M results, or had no 
central test result due to inadequacy of the tissue specimen and known to be T790M 
positive by local test (Dose level of 625 mg BID). 
Planned Number 
of Patients 
Total number of patients – up to approximately 715 (Phase 1 N≈110; Phase 2 N≈605) 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 16 of 151 
Confidential 
• 
Phase 1: 
CO-1686 free base (completed) - 57 patients 
 
 
 CO-1686 HBr - approximately 53 patients 
• 
Phase 2:  Cohort A: Approximately 40 patients for dose level 750 mg BID, up to 
approximately 275 patients for combined dose levels of 
500 mg BID and 625 mg BID 
Cohort B: Approximately 40 patients for dose level 750 mg BID, up to 
approximately 150 patients for combined dose levels of 
500 mg BID and 625 mg BID 
Cohort C: Up to approximately 100 patients at 625 mg BID. 
Planned Number 
of Sites 
Phase 1: 
Approximately 8 investigative sites  
Phase 2: 
Approximately 50 investigative sites in the United States, European Union 
and Australia 
PART 1 
Study Objectives 
and Endpoints for 
Phase 1 
Primary, secondary and exploratory objectives and endpoints are shown in the following 
table. 
Phase 1 
Primary Objectives 
Primary Endpoints 
To evaluate the toxicity profile of escalating 
doses of CO-1686 and to determine the MTD 
and RP2D 
The incidence of Grade 3 or 4 adverse 
events (AEs) and clinical laboratory 
abnormalities defined as dose-limiting 
toxicities (DLTs)  
To characterize the PK profile of CO-1686  
PK parameters including area under 
the curve from time zero to time t 
(AUC0-t), AUC from time zero to 
infinity (AUC0-∞), maximum 
concentration (Cmax), time to 
maximum concentration (Tmax), 
elimination half-life (T1/2), elimination 
rate constant (kel), volume of 
distribution at steady state after 
nonintravenous administration (Vss/F), 
and total plasma clearance (Cl/F) for 
CO-1686 
Secondary Objective 
Secondary Endpoints 
To characterize the PK profile of CO-1686 
after a high-fat breakfast vs in the fasted state 
PK parameters Cmax and AUC for 
CO-1686 (fasted and fed)  
To evaluate the effects of CO-1686 on the 
QT/QTc interval 
Change from baseline in QT/QTc 
interval 
To evaluate tumor response (overall response 
rate [ORR] + duration of response) of 
CO-1686 
ORR and duration of response per 
Response Criteria in Solid Tumors 
(RECIST) Version 1.1 
Exploratory Objectives 
Exploratory Endpoints 
To characterize lung-cancer and 
treatment-related symptoms in patients at 
baseline and in response to CO-1686 using the 
Dermatology Life Quality Index, the EORTC 
QLQ - LC13, and the EORTC QLQ-C30. 
Change from baseline in 
patient-reported outcomes  
To explore the concordance of T790M 
detected in tumor versus that detected in blood.  
Concordance of  the presence of 
T790M mutation in blood and tumor 
tissue samples 
To determine if T790M is detectable in urine 
(optional sampling). 
Detection of T790M in urine samples 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 17 of 151 
Confidential 
PART 2 
Study Objectives 
and Endpoints for 
Phase 2 - 
Expansion 
Cohorts in 
T790M Positive 
Patients  
Primary, secondary and exploratory objectives and endpoints are shown in the following 
table. 
Phase 2  
Primary Objectives 
Primary Endpoints 
To evaluate tumor response (ORR + duration 
of response) to CO-1686 in patients with a 
T790M mutation 
ORR and duration of response per 
RECIST Version 1.1 by investigator 
assessment 
Secondary Objectives 
Secondary Endpoints 
To evaluate objective response rate (ORR), 
duration of response, and progression-free 
survival [PFS] in patients treated with 
CO-1686 
ORR, duration of response and PFS 
per RECIST Version 1.1 as 
determined by independent radiology 
review (IRR)  
To evaluate the toxicity and tolerability of 
CO-1686  
The incidence of AEs, clinical 
laboratory abnormalities, and ECG 
abnormalities  
To evaluate overall survival (OS), disease 
control rate (DCR), and progression-free 
survival [PFS] in patients treated with 
CO-1686 
OS, DCR and PFS per RECIST 
Version 1.1 as determined by 
investigator assessment  
To determine pharmacokinetics (PK) of 
CO-1686 using population PK (POPPK) 
methods and explore correlations between PK, 
exposure, response, and/or safety findings  
Plasma PK parameters for CO-1686 at 
Cycle 1 Day 1 and Cycle 1 Day 15 for 
a subset of patients; CO-1686 
metabolite profile in the Day 15 
plasma samples for a subset of 
patients; Plasma PK parameters for 
CO-1686 based on sparse sampling of 
all patients 
To characterize lung-cancer and 
treatment-related symptoms in patients at 
baseline and in response to CO-1686 using the 
Dermatology Life Quality Index, the EORTC 
QLQ - LC13, and the EORTC QLQ-C30. 
Change from baseline in 
patient-reported outcomes  
To evaluate the effects of CO-1686 on the 
QT/QTc interval 
Change from baseline in QT/QTc 
interval 
Exploratory Objectives 
Exploratory Endpoints 
To evaluate clinical benefit of continued 
CO-1686 treatment following disease 
progression 
Time-to-treatment failure  
To explore the concordance of T790M detected 
in tumor versus that detected in blood  
Concordance of the presence of 
T790M mutation in blood and tumor 
tissue samples 
  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 18 of 151 
Confidential 
Study Design 
This is a two-part, open-label, safety, PK, and efficacy study of oral CO-1686 administered 
daily in previously treated NSCLC patients who have documented evidence of an 
activating mutation in the EGFR gene and have failed treatment with an EGFR inhibitor 
such as erlotinib, gefitinib or afatinib.  
Part 1 - Phase 1 
The dose escalation phase of Part 1 was completed in January 2014. Eligible patients 
provided tumor tissue for T790M evaluation by the sponsor’s central laboratory but 
enrolment to Phase 1 was irrespective of T790M status. Each patient was treated with oral 
CO-1686 daily for a 21-day period and underwent assessments for safety (DLTs, AEs, vital 
signs, clinical laboratory tests, ECOG performance status, ECG and physical examinations) 
and PK according to the schedule of assessments. All dose escalation steps were agreed 
upon between the investigators and the sponsor. The safety monitoring window was 21 
days. 
As of 30 January 2014, 103 patients with advanced NSCLC have received at least one dose 
of CO-1686. In the initial stage of the study, 57 patients were treated with CO-1686 
administered as free base capsules at doses ranging from 150 mg up to 1800 mg daily. 
Subsequently, CO-1686 hydrobromide (HBr) tablets were introduced into the study and 46 
patients were treated with CO-1686 HBr at 500 mg BID, 625 mg BID, 750 mg BID and 
1000 mg BID in the dose escalation phase of the study. Dose escalation evaluation was 
completed in January 2014 and all doses tested had less than 33% incidence of dose 
limiting toxicities in Cycle 1). A MTD was not identified during Cycle 1 (Safety and PK 
Assessment Period).  
In Phase 1, intrapatient dose escalation was permitted by the sponsor if the maximum 
drug-related toxicity experienced by the patient was Grade 2 and provided that the dose 
level to which the patient escalate had already been cleared at the time of the proposed dose 
increase.  
Existing patients being treated with CO-1686 free base were transitioned to CO-1686 HBr 
500 mg BID once safety evaluation of this dose level was completed. When a patient was 
transitioned to CO-1686 HBr, the new formulation was to be initiated at Day 1of the cycle 
and, preferably, a full 24-hour PK profile on both Days 1 and 15 was to be repeated. At a 
minimum, however, the pre-dose PK blood samples were to be collected on Day 1 of each 
treatment cycle of CO-1686 HBr.  
Investigators could transition patients to a lower dose of CO-1686 HBr based on their 
clinical judgment. All Phase 1 patients on freebase were transitioned to CO-1686 HBr by 
November 2013. 
RP2D Selection 
The RP2D for evaluation in Phase 2 was to be selected based on overall safety and 
tolerability, PK, and estimates of efficacious exposures extrapolated from nonclinical data 
and Phase 1 of the study. The RP2D could or might not be the same as the MTD identified 
in Phase 1. If an MTD was not identified in the dose range expected, a dose that met the 
tolerability and PK criteria could be selected as the RP2D and dose escalation could 
continue concurrently to fully explore the exposure and dose relationship. If it is 
determined that a higher or lower dose in one of the further escalation cohorts is considered 
likely to be superior to the originally selected RP2D, patients in the Phase 2 cohort may be 
escalated to the new RP2D dose if they meet the intrapatient dose escalation criteria. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 19 of 151 
Confidential 
 
Food-effect PK Evaluation 
The effect of food on oral CO-1686 PK was assessed in a subset of patients.  
PK Evaluation of Once-daily Dosing Versus Twice-daily or Three-times-daily 
Dosing was started with once-daily (QD) dosing, and subsequently the effect of twice-daily 
(BID) and three-times-daily (TID) dosing on oral CO-1686 PK was assessed in a subset of 
patients.  
Effect on QTc 
In Phase 1, Serial ECG monitoring is performed: at baseline, on Cycle 1 Day 1 and Cycle 1 
Day 15 (prior to dosing and at multiple time points as described in Table 13 following 
dosing with CO-1686) and on Day 1 of all subsequent cycles [prior to dosing and at the 
estimated Tmax (2 hours) postdose], at the End of Treatment, and as clinically indicated in 
order to assess the effect of oral CO-1686 on the QTc interval. All ECGs are performed on 
equipment provided by the sponsor (or designee) and reviewed by site personnel and a 
core/central laboratory. 
Treatment-extension Period 
Upon completion of Cycle 1 (Safety and PK Assessment Period), Phase 1 patients could 
participate in an optional Treatment-extension Period, with ongoing safety and activity 
monitoring, which begins on Day 1 of Cycle 2. Oral CO-1686 is administered daily during 
this period (21-day cycles).  
Protocol-specified treatment will continue until there is progression by RECIST 
Version 1.1, clinical tumor progression or unacceptable toxicity as assessed by the 
investigator. Patients may opt to continue to receive treatment with CO-1686 following 
radiographic progression as outlined in the NCCN guidelines for treatment of NSCLC with 
EGFR TKIs if patient provides additional consent, the investigator feels it is in the patient’s 
best interest and with sponsor approval. In general, eligible patients may include those with 
asymptomatic systemic progression or locally symptomatic progression, such as brain 
metastases amenable to local treatment, with concomitant asymptomatic systemic 
progression or continued systemic disease control. Patients will undergo serial assessments 
for anti-tumor efficacy, drug safety, and patient reported outcomes. Serial blood sampling 
for longitudinal quantitative assessment of ctDNA will be conducted. Following disease 
progression on CO-1686, patients can consent to participate in an optional additional 
biopsy before subsequent-line therapy is initiated. 
As of 6 March 2014, 49 patients are continuing to receive treatment in Phase 1 of this 
study. 
Part 2 - Phase 2 
The additional dose levels added to cohorts A and B and increased patient numbers 
introduced in Amendment 6 allows a comprehensive assessment of dose and response 
across doses that have exhibited clinical activity to date. The addition of Cohort C will 
provide an estimate of activity in patients with a positive T790M local test, but discordant 
central test results or missing central test results due to inadequacy of the tissue specimen 
by central test, and will allow CO-1686 treatment based on a local T790M positive result 
only. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 20 of 151 
Confidential 
 
The Phase 2 portion of the study will consist of a screening phase to establish study 
eligibility and document baseline measurements, an open-label treatment phase, in which 
patients will receive CO-1686 to ascertain safety and efficacy until protocol-defined disease 
progression. Each 21-day period of treatment will represent one cycle, with dosing initiated 
on Cycle 1 Day 1. Eligible patients are those who are confirmed by the sponsor’s central 
laboratory (Cohorts A and B) or by local assessment (Cohort C) to have the T790M 
mutation in FFPE tumor tissue. 
The assessments for patients in each Phase 2 cohorts will be identical.  
Enrollment into Part 2 was initiated in January 2014 under Amendment 4 when a RP2D of 
750 mg BID was selected based on early efficacy Phase 1 data, and two expansion cohorts 
(Cohorts A and B) are enrolling at this dose. As the Phase 1 efficacy data matured, the 
recommended dose was adjusted to 625 mg BID, and under Amendment 6, patients will no 
longer enroll in the 750 mg BID dose level for Cohorts A and B, but will be assigned by the 
sponsor to receive either 625 mg BID or 500 mg BID. Patients who are already receiving 
750 mg BID will continue at this dose. 
Separately within each new dose level in Cohorts A and B combined (500 mg BID and 
625 mg BID), the objective response rate will be evaluated in the first 12 patients. Within 
Cohort C, the objective response rate will be evaluated separately for patients from the 2 
patient populations represented by Cohorts A and B. If 0 responses are observed in the first 
12 patients within each dose level (combined Cohorts A and B) or patient population 
(Cohort C) are observed then the respective level or population may be discontinued due to 
a lack of efficacy. If zero PR or CR responses are observed in 12 patients then there is a 
high probability that the true objective response rate is less than 20%. In addition to the 
futility analyses within each cohort, formal safety data reviews will occur following the 
enrollment of every 50 patients and approximately every 6 months once enrollment is 
completed and as long as patients remain on treatment. The review committee will include 
external experts and sponsor personnel. The external experts will include, but not be limited 
to, the coordinating PIs of the study. The sponsor’s reviewers will include the Medical 
Monitor, Chief Medical Officer, and Biostatistician. The protocol will be amended as 
appropriate to incorporate additional patient safety monitoring if new safety signals are 
noted at any review.  
If a dose level is closed for further evaluation because of lack of activity, ongoing patients 
in that dose level may be allowed to dose escalate to a higher dose level if they meet the 
intra-patient dose escalation criteria.  
For all Phase 2 patients, protocol-specified treatment will continue until there is 
progression by RECIST Version 1.1, clinical tumor progression or unacceptable toxicity as 
assessed by the investigator. Patients may opt to continue to receive treatment with 
CO-1686 following radiographic progression as outlined in the NCCN guidelines for 
treatment of NSCLC with EGFR TKIs if patient provides additional consent, the 
investigator feels it is in the patient’s best interest and with sponsor approval. In general, 
eligible patients may include those with asymptomatic systemic progression or locally 
symptomatic progression, such as brain metastases amenable to local treatment, with 
concomitant asymptomatic systemic progression or continued systemic disease control. 
Patients will undergo serial assessments for anti-tumor  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 21 of 151 
Confidential 
 
efficacy, drug safety, and patient reported outcomes. Serial blood sampling for longitudinal 
quantitative assessment of ctDNA will be conducted. Local laboratories will be used for 
hematology and chemistry assessment. A central laboratory will be used for ECG 
interpretation.  
Tumor assessments will be performed by the investigative site and scans will be evaluated 
locally for patient treatment decisions; however, copies of tumor scans will be collected 
centrally to facilitate independent evaluation for ORR, duration of response, PFS and other 
assessments if deemed necessary by the sponsor. Following disease progression on 
CO-1686, patients can consent to participate in an optional additional biopsy before 
subsequent-line therapy is initiated. 
Extension Phase (Phase 1 and Phase 2 Patients) 
In mid-2015, Clovis submitted a New Drug Application for the use of rociletinib in patients 
with T790M-positive NSCLC.  In June 2016, the FDA issued a Complete Response Letter 
to Clovis stating that more data are required to approve rociletinib for use outside of a 
clinical trial.  Based on this outcome, Clovis decided to discontinue development of CO-
1686 for NSCLC.  Patients will be informed of this change in development plans in an 
update to the informed consent form for this study.  Those patients who continue to derive 
clinical benefit from study treatment will be allowed to continue on the study at the 
discretion of the Principal Investigator in the Extension Phase.   
The purpose of this protocol amendment (Amendment 8) is to add a new Extension Phase 
to allow patients to continue on the study but to avoid unnecessary collection of data that 
will no longer be analyzed or required for regulatory purposes, whilst maintaining an 
appropriate level of safety monitoring.   
A new schedule of assessments for the Extension Phase has been provided in Appendix D 
that will be applicable to both ongoing Phase 1 and Phase 2 patients.  This schedule will 
replace all schedules of assessments in Section 9.1. 
In addition, Amendment 8 (Appendix D) also introduces the availability of NAT2 testing 
for patients, an indirect indicator of the likelihood of developing hyperglycemia or QTc 
prolongation.  The availability and disclosure of this information to the patient’s treating 
physician will not affect the monitoring and associated treatment guidelines for these 
adverse events.  
For patients who wish to continue rociletinib treatment post progression, it is important that 
a full exploration of alternative treatment options between patients and their treating 
physicians takes place.  
Finally, investigators and their staff are directed to the current Investigator’s Brochure for 
the most current efficacy and safety data, in which integrated summaries of the latest 
available data can be found and supersedes all safety and efficacy data presented in this 
protocol. 
CO-1686 PK and Metabolite Profiling 
A subset of 10 patients at dose levels of 500 mg BID and 625 mg BID, at a minimum, in 
Phase 2 will have a detailed PK profile taken over Cycle 1 Day 1 and Cycle 1 Day 15.  
In addition, at the 625 mg dose level, at a minimum, three of the subset of 10 patients will 
have additional blood samples collected on Day 1 (predose sample only) and Day 15 
(postdose) of Cycle 1 for assessment of plasma metabolites of CO-1686.  
All patients in Phase 2 will have PK samples collected on Cycle 1 Day 15, and on Day 1 of 
every subsequent cycle beginning with Cycle 2 up to and including Cycle 9 
(Section 9.8.3.2). 
Effect on QTc 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 22 of 151 
Confidential 
In the subset of patients for whom a detailed PK profile will be collected in Phase 2, ECG 
monitoring will be performed: at baseline, on Cycle 1 Day 1 and Cycle 1 Day 15 (prior to 
dosing and at the multiple time points as described in Table 13 following dosing with 
CO-1686), and on Day 1 of all subsequent cycles [prior to dosing and at the estimated Tmax 
(2 hours) postdose], at the End of Treatment, and as clinically indicated in order to assess 
the effect of oral CO-1686 on the QTc interval. In all other Phase 2 patients, serial ECG 
monitoring will be performed: at baseline, on Cycle 1 Day 1, Cycle 1 Day 15 and on Day 1 
of all subsequent cycles [prior to dosing and at the estimated Tmax (2 hours) postdose at 
these visits], at the End of Treatment, and as clinically indicated. All ECGs will be 
performed on equipment provided by the sponsor (or designee) and reviewed by site 
personnel and a core/central laboratory. 
Phase 1 and Phase 2:  End of Treatment and Safety Follow-up 
All patients should return to the clinic for End of Treatment assessments 28 (±7) days after 
the last dose of CO-1686 has been administered.  
All Phase 2 patients will be followed at approximately two monthly intervals to monitor 
survival status and subsequent NCSLC therapy until death or sponsor decision, whichever 
comes first. After discontinuation of protocol-specified treatment, subsequent anticancer 
therapy use will be recorded. 
Dose-limiting 
Toxicities 
DLTs are defined as any of the following events that occur during Cycle 1 (Safety and PK 
Assessment Period) in patients enrolled into a DLT evaluable cohort in Phase 1, and are 
assessed by the investigator as probably, possibly or definitively related to CO-1686. 
Where applicable, events will be classified according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0.10 Dose 
limiting toxicities include:  
• 
Grade 3 or 4 skin eruption, nausea, vomiting, diarrhea or hyperglycemia despite the 
use of adequate/maximal medical intervention and/or prophylaxis 
• 
Any Grade 4 skin rash/eruption with extensive superinfection requiring IV antibiotics 
and with life-threatening consequences (e.g., rash acneiform, papulopustular rash, 
Stevens-Johnson Syndrome) 
• 
Any nonhematological CTCAE Grade 3 or greater AE (except alopecia or nausea, 
vomiting, diarrhea or hyperglycemia if well-controlled by systemic medication) 
• 
Absolute neutrophil count (ANC) < 0.5 × 109/L > 5 days duration or febrile 
neutropenia (i.e., fever > 38.3°C with ANC < 1.0 × 109/L) 
• 
Platelets < 25 × 109/L or platelets < 50 × 109/L with bleeding requiring a platelet 
transfusion 
• 
Grade 4 anemia (life-threatening consequences, urgent intervention indicated). 
Delayed recovery from toxicity related to CO-1686 treatment that delays scheduled 
retreatment for > 14 days 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 23 of 151 
Confidential 
Study Population 
Inclusion Criteria 
All patients enrolling into either Phase 1 or Phase 2 must meet all of the following 
inclusion criteria: 
1. Histologically or cytologically confirmed metastatic or unresectable locally advanced 
NSCLC 
2. Documented evidence of a tumor with one or more EGFR mutations excluding exon 
20 insertion 
3. Have undergone a biopsy of either primary or metastatic tumor tissue within 60 days of 
dosing with study drug and have tissue available to send to the sponsor’s lab or are 
able to undergo a biopsy during screening 
• 
No change (except for washout or dose adjustment if required to manage 
adverse effects) in antitumor therapy regimen is allowed between the 
biopsy and CO-1686 initiation. 
4. Life expectancy of at least 3 months 
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 
6. Age 18 years 
7. Adequate hematological and biological function, confirmed by the following screening 
laboratory values: 
Bone Marrow Function 
1. Absolute neutrophil count (ANC)  1.5 x 109/L 
2. Platelets 100.0 × 109/L  
3. Hemoglobin 9 g/dL (or 5.6 mmol/L) 
Hepatic Function 
4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 3 × upper 
limit of normal (ULN); if liver metastases, 5 × ULN  
5. Bilirubin 2 × ULN* 
Renal Function  
6. Serum creatinine 1.5 × ULN 
Electrolytes 
1. Potassium and magnesium within normal range. Patients may receive supplements 
to meet this requirement 
2. Written consent on an Institutional Review Board/Independent Ethics Committee-
approved Informed Consent Form (ICF) prior to any study-specific evaluation  
*Patients with documented Gilbert’s syndrome and conjugated bilirubin within the normal 
range may be allowed into the study. In this event it will be documented that the patient 
was eligible based on conjugated bilirubin levels  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 24 of 151 
Confidential 
 
Patients enrolling into Phase 1 must also meet the following inclusion criteria: 
• 
Prior treatment with EGFR-directed therapy (e.g. erlotinib, gefitinib, neratinib, 
afatinib, or dacomitinib [PF299804]). Prior chemotherapy, including intervening 
chemotherapy, is allowed. 
- 
The washout period for an EGFR TKI is a minimum of 3 days 
- 
The washout period for chemotherapy is a minimum of 14 days 
- 
Any toxicity related to prior treatment must have resolved to Grade 1 or less  
Be willing and able to eat a high-fat breakfast on Day 1 of the study  
(only applicable to food-effect cohort). 
Patients enrolling into Phase 2 Cohort A must also meet the following inclusion criteria: 
• 
Disease progression confirmed by radiologic assessment while on treatment 
with EGFR- TKI (e.g. erlotinib, gefitinib, neratinib, afatinib, or 
dacomitinib). Prior chemotherapy, including intervening chemotherapy 
before planned initiation of CO-1686, is allowed. 
- 
The washout period for an EGFR TKI is a minimum of 3 days before 
planned Cycle 1 Day 1 
- 
The washout period for chemotherapy is a minimum of 14 days before 
planned Cycle 1 Day 1 
- 
Any toxicity related to prior treatment must have resolved to Grade 1 or 
less by Cycle 1 Day 1  
• 
Documented evidence of T790M mutation in EGFR determined by PCR-
based testing of the tumor tissue using the sponsor’ central lab following 
disease progression on the most recent EGFR TKI therapy. 
• 
Measurable disease according to RECIST Version 1.1.  
• 
Do not qualify for enrolment to Phase 2 Cohort B*  
*Patients meeting eligibility criteria for Cohort B must be enrolled into this 
cohort rather than Cohort A. 
 
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 25 of 151 
Confidential 
 
Patients enrolling into Phase 2 Cohort B must also meet the following inclusion criteria: 
• 
Disease progression confirmed by radiologic assessment while on treatment 
with the first single agent EGFR TKI (e.g. erlotinib, gefitinib, afatinib, or 
dacomitinib)  
- 
EGFR TKI treatment discontinued ≤ 30 days prior to planned initiation 
of CO-1686  
- 
The washout period for an EGFR TKI is a minimum of 3 days before 
planned Cycle 1 Day 1 
- 
No intervening  treatment between cessation of single agent EGFR TKI 
and planned initiation of CO-1686 
- 
Previous treatment with ≤1 prior chemotherapy (excluding prior neo-
adjuvant or adjuvant chemotherapy or chemoradiotherapy with curative 
intent)  
- 
Any toxicity related to prior EGFR inhibitor treatment must have 
resolved to Grade 1 or less by Cycle 1 Day 1  
• 
Documented evidence of T790M mutation in EGFR as determined by PCR-
based testing of tumor tissue using the sponsor’s central lab following 
disease progression on the first single agent EGFR TKI. 
• 
Measureable disease according to RECIST Version 1.1 
Patients enrolling into Phase 2 Cohort C must also meet the following inclusion criteria: 
• 
Must meet all inclusion criteria of other Phase 2 Cohorts A or B except for 
documented evidence of T790M mutation using the sponsor’s central lab 
• 
Only patients with evidence of a positive T790M mutation result from a local lab 
but with an insufficient specimen for central lab analysis (judged by the central lab 
analysis) or a negative central T790M mutation result from the same biopsy 
specimen collected within 60 days of treatment with CO-1686 
Exclusion Criteria 
Any of the following criteria will exclude patients from study participation: 
1. Documented evidence of an Exon 20 insertion activating mutation in the EGFR gene  
2. Active second malignancy, i.e. patient known to have potentially fatal cancer present 
for which he/she may be (but not necessarily) currently receiving treatment 
• 
Patients with a history of malignancy that has been completely treated, with no 
evidence of that cancer currently, are permitted to enroll in the trial provided all 
chemotherapy was completed > 6 months prior and/or bone marrow transplant > 2 
years prior 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 26 of 151 
Confidential 
 
3. Known pre-existing interstitial lung disease 
4. Patients with Leptomeningeal carcinomatosis are excluded. Other CNS metastases are 
only permitted if treated, asymptomatic, and stable (not requiring steroids for at least 4 
weeks prior to start of study treatment). 
5. Treatment with prohibited medications [e.g., concurrent anticancer therapy including 
other chemotherapy, radiation therapy,  or hormonal treatment (except corticosteroids 
and megesterol acetate), or immunotherapy] 14 days prior to treatment with CO-1686 
6. Patients who are currently receiving treatment with any medications that have the 
potential to prolong the QT interval and the treatment cannot be either discontinued or 
switched to a different medication before starting CO-1686 
• 
see http://crediblemeds.org/ for a list of QT-prolonging medications 
7. Prior treatment with CO-1686 or other drugs that target T790M positive, mutant EGFR 
with sparing of wild type EGFR, e.g. AZD9291, HM61713, TAS-121 
8. Any of the following cardiac abnormalities or history: 
a. 
Clinically significant abnormal 12-lead ECG, QT interval corrected using 
Fridericia’s method (QTCF) > 450 msec  
b. 
Inability to measure QT interval on ECG 
c. 
Personal or family history of long QT syndrome 
d. 
Implantable pacemaker or implantable cardioverter defibrillator 
e. 
Resting bradycardia < 55 beats/min 
9. Non-study related surgical procedures 7 days prior to administration of CO-1686. In 
all cases, the patient must be sufficiently recovered and stable before treatment 
administration 
10. Females who are pregnant or breastfeeding 
11. Refusal to use adequate contraception for fertile patients (females and males) for 
12 weeks  after the last dose of CO-1686 
12. Presence of any serious or unstable concomitant systemic disorder incompatible with 
the clinical study (e.g., substance abuse, uncontrolled intercurrent illness including 
active infection, arterial thrombosis, and symptomatic pulmonary embolism) 
Any other reason the investigator considers the patient should not participate in the study 
Study Treatment 
Under Amendment 6 and subsequent amendments, CO-1686 will be administered to 
patients as oral tablets in a twice daily regimen. Patients will be instructed to take CO-1686 
at the specified dose for the dosing level with a meal or within 30 minutes after a meal. 
Interim Safety 
Monitoring and 
Futility Analyses 
Separately within each new dose level in Cohorts A and B (500 mg BID and 625 mg BID), 
the objective response rate will be evaluated in the first 12 patients. Within Cohort C, the 
objective response rate will be evaluated separately for patients from the 2 patient 
populations represented by cohorts A and B. If 0 responses are observed in the first 12 
patients within each dose level (Cohorts A and B) or patient population (Cohort C) are 
observed then the respective level or population may be discontinued due to a lack of 
efficacy. If zero PR or CR responses are observed in 12 patients then there is a high 
probability that the true objective response rate is less than 20%. In addition to the futility 
analyses within each cohort, formal safety data reviews will occur following the enrollment 
of every 50 patients and approximately every 6 months once enrollment is completed and 
as long as patients remain on treatment. The review committee will include external experts 
and sponsor personnel. The external experts will include, but not be limited to, the 
coordinating PIs of the study. The sponsor’s reviewers will include the Medical Monitor, 
Chief Medical Officer, and Biostatistician. The protocol will be amended as appropriate to 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 27 of 151 
Confidential 
incorporate additional patient safety monitoring if new safety signals are noted at any 
review.  
Dose-modification 
Criteria 
Dose reduction steps are allowed for each patient in Phase 1 or Phase 2, with the overall 
number of dose reduction steps at the investigator’s discretion. Dose reductions can occur 
in 125 mg increments BID from the starting dose (e.g. from 625 mg BID to 500 mg BID). 
For non-serious adverse events, a TID dosing regimen may be used to maintain plasma 
exposure, whilst reducing the peak plasma concentrations which may drive toxicity (e.g. 
from 625 mg BID (1250 mg total dose/day) to 375 mg TID (1175 mg total dose/day) or 
500 mg BID (1000 mg total dose/day) to 250 mg TID (750 mg total dose/day)].  
For Grade 3 or 4 hematologic and non-hematologic toxicities (except for nausea/vomiting, 
alopecia, QTc prolongation and hyperglycemia), the dose should be initially reduced to the 
next lower dose BID and, if persistent, can be further reduced (250 mg increment BID less 
than starting dose) for subsequent doses if the investigator and the sponsor do not believe 
treatment discontinuation is required. Re-escalation of dose after resolution of adverse 
events must be discussed and approved by the sponsor. Dose reductions below 250 mg 
increment BID less than starting dose must be discussed and agreed with the sponsor before 
they are implemented.  
ECGs will be measured throughout the study as described in the protocol. If QTC 
prolongation of CTCAE Grade 3 is observed, CO-1686 will be held until the event has 
improved to Grade 1. CO-1686 can then be re-started at a reduced dose after sponsor 
approval. After two dose reduction evaluations, if CTCAE Grade 3 or above QTC 
prolongation recurs, then CO-1686 will be discontinued unless agreed with the sponsor that 
additional dose reduction can be evaluated. If QTC prolongation changes of CTCAE 
Grade 4 are observed at any time, CO-1686 will be discontinued permanently. 
If a patient experiences hyperglycemia, dose management should be as outlined in 
Section 7.4.3. 
Concomitant 
Medications 
Supportive care (e.g., antiemetics, analgesics for pain control) may be used at the 
investigator’s discretion and in accordance with institutional procedures.  
Withdrawal 
Criteria 
A patient must be discontinued from protocol-prescribed therapy if any of the following 
apply: 
• 
Consent withdrawal at the patient’s own request or at the request of their legally 
authorized representative 
• 
Progression of patient’s underlying disease, except as described in Section 5.1.4 
• 
Any event, adverse or otherwise, that, in the opinion of the investigator, would pose an 
unacceptable safety risk to the patient 
• 
An intercurrent illness that, in the opinion of the investigator, would affect assessments 
of the clinical status to a significant degree and requires discontinuation of therapy 
• 
Non-compliance as described in Section 7.7 
• 
A positive pregnancy test at any time during the study 
Pharmaco-genetic 
Assessments 
For patients who provide additional consent, genomic DNA will be extracted from a blood 
sample from each patient in Phase 1 and Phase 2 to detect genetic polymorphisms in CYP 
isoenzymes in order to explore the correlation between CYP polymorphism and drug 
exposure.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 28 of 151 
Confidential 
Biomarker and 
Exploratory 
Assessments  
Tumor tissue from the primary tumor, or an accessible metastatic lesion, will be obtained 
within 60 days prior to dosing as described in Section 9.8.4 of the protocol. When sufficient 
tissue is available from the baseline tumor biopsy, samples may be tested for molecular 
alterations that may modulate response or resistance to EGFR-targeted therapy. Patients 
who provide additional consent will undergo an optional tumor biopsy at disease 
progression. This tissue may be analyzed for molecular alterations that modulate resistance 
to EGFR-targeted therapy. 
Blood will be collected for detection and quantification of mutant EGFR from plasma. 
Blood may also be used to test for biomarkers of response or resistance to EGFR-targeted 
therapy. Analysis may not be performed or only performed on a subset of patients if it 
becomes clear that the analysis will have limited scientific value (e.g., because of a very 
low titer of ctDNA in some patients, or if there are not enough serially collected samples 
from individual patients to allow for adequate biomarker evaluation). 
Patients who provide additional consent in Phase 1 and Phase 2 will provide urine 
specimens pre-dose on Day 1 of Cycles 1 to 6 and at the End of Treatment visit to 
determine whether biomarkers including T790M are detectable in transrenal nucleic acids. 
Pharmacokinetic 
Assessments  
Patients enrolled in Phase 1 and a subset of 10 patients at the dose levels of 500 mg BID 
and 625 mg BID in Phase 2 will have PK sampling during Cycle 1, with collection time 
points predose and from 15 min through 24 hr postdose on Days 1 and 15. For Phase 1 
patients in Cycles 2 and beyond, and for Phase 2 patients not participating in the full PK 
evaluation, only single trough-level PK samples will be collected during the treatment 
period. Patients participating in the in the food-effect PK evaluation will have an additional 
PK sampling on Day -7. 
PK evaluations will be based on the determination of the following parameters for 
CO-1686 including (but not limited to):  AUC0–t, AUC0–∞, Cmax, Tmax, T1/2, and kel Vss/F, 
and Cl/F. A central/core laboratory will be used for the PK assay. 
A profile of circulating metabolites of CO-1686 at steady state will be evaluated in at least 
three patients at the RP2D (625 mg BID). 
Quality of Life 
Assessments 
Quality of life will be measured using the EORTC QLQ C30 and LC13 and the 
Dermatology Life Quality Index (DLQI), which will be administered at baseline, every 2 
cycles through Cycle 6, and then every 3 cycles thereafter.11,12 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 29 of 151 
Confidential 
Efficacy 
Assessments 
Efficacy measures (Phase 1 and Phase 2) will include tumor assessments, consisting of 
clinical examination and appropriate imaging techniques (preferably computed tomography 
(CT) scans of the chest, abdomen, and pelvis with appropriate slice thickness per RECIST 
Version 1.1); other studies (magnetic resonance imaging [MRI] and X-ray) may be 
performed if required.  
Patients with an initial PR or CR at Cycle 7 or beyond will have confirmatory scan 
performed 4 to 6 weeks later. In the case of SD, follow-up measurements must have met 
the SD criteria at least once after study entry at a minimum interval of no less than 6 to 8 
weeks. 
All patients require baseline brain scans and those with brain metastases at baseline will 
require repeat brain imaging as part of the follow-up tumor assessments. Tumor 
assessments will be performed at screening; at the end of Cycles 2, 4, and 6 (between 
Days 14 and 21); every three cycles after Cycle 6 (between Days 14 and 21); and at the End 
of Treatment visit, if disease progression has not been documented previously.  
Safety 
Assessments 
Safety measures will include:  
• 
AEs 
• 
Hematology, including reticulocyte count, clinical chemistry including fasting glucose 
and HbA1c, and urinalysis 
• 
12-lead ECGs  
• 
Physical examination 
• 
Vital signs and body weight 
• 
Concomitant medications/procedures 
• 
ECOG performance status 
Statistical 
Procedures 
Analysis Populations 
• 
PK-evaluable population:  all patients who received CO-1686 and have adequate PK 
blood draws for determination of the PK profile. Adequacy will be determined on a 
case-by-case basis and will be assessed prior to analysis of the blood samples. 
• 
DLT-evaluable population:  all patients enrolled into Phase 1 who received at least 
80% of the scheduled doses of CO-1686 and completed Cycle 1 of treatment, or who 
experienced a DLT in Cycle 1. 
• 
Food-effect PK population:  all patients who enrolled into a food effect PK evaluation 
cohort who received CO-1686 on both Day -7 and Day 1, complied with the fed and 
fasted requirements, and have sufficient PK data for a comparison to be made between 
the fasted and fed state. 
• 
ECG/PK comparison-evaluable population:  all patients in Phase 1 and Phase 2 who 
have received CO-1686 and have had adequate PK and ECG assessments performed 
for determination of the ECG effects and the relationship between PK and ECG. 
• 
Safety population:  all patients who have received at least one dose of CO-1686. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 30 of 151 
Confidential 
 
• 
Tumor-evaluable population:  all patients who received at least one dose of CO-1686, 
have at least one measurable tumor lesion at baseline, and have at least one post-
baseline tumor assessment. 
Sample Size Justification 
Amendment 6 allowed for up to approximately 380 efficacy-evaluable patients to be 
enrolled into Cohorts A, B and approximately 100 efficacy-evaluable patients in Cohort C 
for the Phase 2 portion of the study. Amendment 7 increased the total patient number in 
Cohort A to allow for patients to continue to enroll in Cohort A as long as Cohort B was 
still open to enrollment, which was estimated to increase the total patient number in this 
study by approximately 125 patients. 
Pharmacokinetic Analyses 
PK parameters will be determined using non-compartmental methods. 
 
Relationship Between PK and QTc 
The effects of CO-1686 on the QT/QTc interval of the electrocardiogram (ECG) will be 
measured by the change in baseline-adjusted QTcF (ΔQTcF) from Day 1 (at selected time 
points outlined in Table 13), Day 15 (at selected time points outlined in Table 13), on 
Day 1 of all subsequent cycles (prior to dosing and at the estimated Tmax (2 hours) 
postdose), and at End of Treatment for all Phase 1 and a subset of Phase 2 patients 
participating in full PK profiling.  
Other QTc analyses will repeat the analysis using other heart rate correction methods. 
Efficacy Analysis 
The overall response rate will be summarized with frequencies and percentages. The 
duration of response for complete response (CR),  partial response (PR), overall survival 
(OS) and duration of stable disease will be summarized with descriptive statistics (N, mean, 
standard deviation, median, minimum, and maximum) as well as categorically. 
Disease control rate (DCR) is defined as the percentage of patients who have achieved CR, 
PR, and SD for a minimum of 12 weeks. 
Kaplan-Meier methodology will be used to summarize PFS and OS. 
Safety Analyses 
Data from all patients who receive one or more doses of CO-1686 will be included in the 
safety analyses. AEs, clinical laboratory information, vital signs, ECOG performance 
status, body weight, and concomitant medications/procedures will be tabulated and 
summarized.  
Population PK  
Blood sampling for population PK analyses will be conducted in all patients treated with 
CO-1686. A specific population PK data analysis plan will be developed and will outline 
the detailed approach to data handling, model development and diagnostics, individual 
model parameter estimation, exploration of covariate effects, and final model evaluation 
techniques.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 31 of 151 
Confidential 
2 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
AAG 
alpha-1 acid glycoprotein 
AE 
adverse event 
ALK 
anaplastic lymphoma kinase 
ALT 
alanine transaminase 
ANC 
absolute neutrophil count 
ANOVA 
analysis of variance 
AST 
aspartate transaminase 
AUC 
area under the curve 
AUC0-24 
area under the curve from time zero to 24 hours 
AUC0-∞ 
area under the curve from time zero to infinity 
AUC0-t 
area under the curve from time zero to time t 
BID 
twice daily 
BUN 
blood urea nitrogen 
CFR 
Code of Federal Regulations 
CI 
confidence interval 
Cl/F 
total plasma clearance after oral administration  
Cmin 
minimum concentration 
Cmax 
maximum concentration 
CR 
complete response  
CRO 
contract research organization  
CT 
computed tomography 
CTCAE 
Common Terminology Criteria for Adverse Events (Version 4.0) 
CYP 
cytochrome P450 
DLQI 
Dermatology Life Quality Index 
DLT 
dose-limiting toxicity 
DNA 
deoxyribonucleic acid 
ECG 
Electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
eCRF 
electronic case report form 
EDC 
electronic data capture 
EGFR 
epidermal growth factor receptor 
EORTC QLQ 
LC13 
European Organization for the Research and Treatment of Cancer Quality of Life 
Questionnaire, Lung Cancer 13 
EOT 
End of Treatment 
EU  
European Union 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 32 of 151 
Confidential 
EURTAC 
European Tarceva versus Chemotherapy Study 
FACT-L 
Functional Assessment of Cancer Therapy-Lung questionnaire  
FDA 
Food and Drug Administration 
FFPE 
Formalin-fixed paraffin-embedded 
FOB 
functional observation battery 
GCP 
Good Clinical Practice 
GI50 
concentration required to reduce growth of treated cells to 50% of untreated cells 
GLP 
Good Laboratory Practice 
GRAS 
generally regarded as safe 
hERG 
human ether-a-go-go-related gene 
HIPAA 
Health Information Portability and Accountability Act  
HNSTD 
highest non-severely toxic dose 
HPLC-UV-
MS/MS 
high-performance liquid chromatography coupled with ultraviolet 
spectrophotometric and tandem mass spectrometric detection  
HPMC 
hydroxyprophyl methylcellulose 
HR 
hazard ratio 
IC50 
concentration at 50% maximal inhibition 
ICH 
International Conference on Harmonization 
IEC 
Independent Ethics Committee 
ILD 
interstitial lung disease 
iPASS 
Iressa Pan-Asian Study 
IRB 
Institutional Review Board  
IV 
Intravenous 
Kd 
dissociation constant 
kel 
elimination rate constant  
MAPK 
mitogen-activated protein kinase 
MRI 
magnetic resonance imaging 
MRSD 
maximum recommended starting dose 
MTD 
maximum tolerated dose 
NCI 
National Cancer Institute 
NOAEL 
no-observed-adverse-effect level 
NSAID 
nonsteroidal anti-inflammatory drug 
NSCLC 
non-small cell lung cancer 
ORR 
objective response rate or overall response rate 
OS 
overall survival 
PCR 
polymerase chain reaction 
PD 
progressive disease 
PE 
Polyethylene 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 33 of 151 
Confidential 
PEG 
polyethylene glycol 
PET 
positron emission tomography 
PFS 
progression-free survival 
P-gp 
P-glycoprotein 
PK 
pharmacokinetic(s) 
PO 
Oral 
PPI 
proton pump inhibitor 
PR 
partial response 
PT 
prothrombin time 
PTT 
partial thromboplastin time 
QD 
once daily 
QTcF 
QT interval corrected using Fridericia’s method 
RECIST 
Response Evaluation Criteria in Solid Tumors, Version 1.1 
RP2D 
recommended Phase 2 dose 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SAS 
statistical analysis software 
SCID 
severe combined immunodeficiency 
STD10 
severely toxic dose in 10% of animals 
SUSAR 
suspected unexpected serious adverse reaction 
T1/2 
elimination half-life 
T790M 
EGFR mutation in exon 20, gatekeeper mutation 
TGI 
tumor growth inhibition 
TID 
three times daily 
TKI 
tyrosine kinase inhibitor 
Tmax 
time to maximum concentration 
TNM 
tumor/node/metastasis 
TOI 
Trial Outcome Index 
TPGS 
tocopherol polyethylene glycol succinate 
ULN 
upper limit of normal 
US 
United States 
Vss/F 
volume of distribution at steady state after non-IVadministration 
WBC 
white blood cell 
WT 
wild type 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 34 of 151 
Confidential 
3 
INTRODUCTION 
3.1 
CO-1686 Clinical Development Program Update 
In mid-2015, Clovis submitted a New Drug Application for the use of rociletinib in patients with 
T790M-positive NSCLC.  In June 2016, the FDA issued a Complete Response Letter to Clovis 
stating that more data are required to approve rociletinib for use outside of a clinical trial.  Based 
on this outcome, Clovis decided to discontinue development of CO-1686 for NSCLC.  Patients 
will be informed of this change in the development plans in an update to the informed consent 
form for this study.  Those patients who continue to derive clinical benefit from study treatment, 
will be allowed to continue on the study at the discretion of the Principal Investigator in an 
extension phase.  No further patients will be enrolled in this study. 
3.1.1 Extension Phase 
The purpose of this protocol amendment (Amendment 8) is to add a new Extension Phase to 
allow patients to continue on study but to avoid unnecessary collection of data that will no longer 
be analyzed or required for regulatory purposes, whilst maintaining an appropriate level of safety 
monitoring.  A new schedule of assessments for the Extension Phase as well as a complete 
description of procedures is provided in Appendix D. This schedule replaces all schedules of 
assessments in Section 9.1 and should be followed for all patients. 
In addition, Amendment 8 (Appendix D) also introduces the availability of NAT2 testing for 
patients, an indirect indicator of the likelihood of developing hyperglycemia and QTc 
prolongation. The availability and disclosure of this information to the patient’s treating 
physician will not affect the monitoring and associated treatment guidelines for these adverse 
events.  
For patients who wish to continue rociletinib treatment post progression, it is important that a full 
exploration of alternative treatment options between patients and their treating physicians takes 
place.  
Investigators and their staff are directed to the current Investigator’s Brochure for the most 
current efficacy and safety data, in which integrated summaries of the latest available data can be 
found and supersedes all safety and efficacy data in this protocol.  
3.2 
Mutant EGFR Non-small Cell Lung Cancer 
Despite years of research and prevention strategies, lung cancer remains the most common 
cancer worldwide with approximately 1.35 million new cases annually, and non-small cell lung 
cancer (NSCLC) accounting for almost 85% of all lung cancers.1  Additionally, lung cancer 
continues to be the most common cause of cancer-related deaths worldwide13 with a 5-year 
survival rate of less than 10%14 in patients with advanced disease.  
Cytotoxic chemotherapy has been the mainstay of treatment of patients with NSCLC, however 
survival rates remain low and toxicity is significant. Recent breakthroughs in NSCLC treatment 
have been a result of molecular characterization of NSCLC and development of molecularly 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 35 of 151 
Confidential 
targeted agents that have demonstrated superiority to chemotherapy in those patients whose 
tumors express the targeted genetic mutation.  
One timely example is the recent approval of crizotinib, used to treat NSCLC patients whose 
tumors harbor anaplastic lymphoma kinase (ALK) rearrangements. In two single-arm studies of 
crizotinib in previously treated ALK-positive patients, the tumor response rates were 50% and 
61% and the duration of responses were 42 and 48 weeks, respectively.15  These response rates 
and the duration of response are significantly higher that what would be expected with 
chemotherapy in this patient population.16  
Molecularly targeted therapies also have proven to be superior to chemotherapy for NSCLC 
patients whose tumors have mutations in the epidermal growth factor receptor (EGFR). 
Activating EGFR mutations are key drivers of NSCLC malignancy in 10% to 15% of patients of 
European descent and approximately 30% of patients of East Asian descent.3  Two recent 
Phase 3 trials comparing tyrosine kinase inhibitors (TKIs) versus chemotherapy have established 
TKIs as the gold standard for treating EGFR-mutation-positive NCSLC. In the Iressa Pan-Asia 
Study (iPASS) trial, treatment with gefitinib was compared to treatment with 
carboplatin/paclitaxel in previously untreated NSCLC patients. In EGFR-mutation-positive 
patients, the response rate was significantly higher with gefitinib treatment (71.2%) than with 
chemotherapy (47.3%).2  Furthermore, EGFR-mutation-positive patients experienced a 
significantly longer progression free survival (PFS) of 9.5 months compared to 6.3 months for 
those on chemotherapy.17  Quality of life was also evaluated in this study; more patients treated 
with gefitinib versus chemotherapy had clinically meaningful improvement in quality of life, as 
assessed by the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire and 
Trial Outcome Index (TOI).2  Although survival was an endpoint of the study, the analysis of 
overall survival was complicated by the fact that EGFR-mutation-positive patients assigned to 
the chemotherapy arm crossed over to gefitinib upon progression.17  A second Phase 3 
randomized trial, the European Tarceva (erlotinib) versus chemotherapy (EURTAC) study, 
compared treatment with erlotinib to chemotherapy in previously untreated patients with 
EGFR-mutation-positive NSCLC. Data from this study show that patients demonstrate a 
response rate of 58% in the erlotinib arm compared to 15% in the chemotherapy arm 
(p < 0.0001). Furthermore, PFS was 9.7 months in the erlotinib arm versus 5.2 months in the 
chemotherapy arm [hazard ratio (HR) = 0.37; p < 0.0001].18  At an interim analysis, overall 
survival was 22.9 months in the erlotinib arm and 18.8 months in the chemotherapy arm 
(HR = 0.80; p = 0.42). Again, crossover from chemotherapy to erlotinib confounds interpretation 
of survival data in this study. These data demonstrate that gefitinib and erlotinib improve 
response rates and PFS compared to chemotherapy. 
While the toxicity profile is also improved with first-generation TKIs compared to 
chemotherapy, significant toxicities do occur. Toxicity associated with both erlotinib and 
gefitinib includes skin rash and diarrhea related to inhibition of the wild-type (WT) EGFR in 
skin and intestine, respectively.4,5,6  
Despite the initial response, progression occurs in most patients. In the most comprehensive 
analysis to date, Sequist, et al. analyzed serial biopsies from EGFR-mutation-positive NSCLC 
patients who progressed on TKIs.19  Through this research, Sequist demonstrated that acquired 
resistance occurs through a number of different mechanisms, while the activating mutation is 
maintained. The most common cause of progression (in 50% of patients) was found to a second 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 36 of 151 
Confidential 
site EGFR mutation in exon 20 called T790M (the “gatekeeper” mutation), which prevents drug 
from binding to the receptor.3,7,8,19  This mutation was sometimes associated with amplification 
of the EGFR gene as well. Some patients developed amplification of another gene that drives 
tumor growth (MET gene amplification). Still others showed mutations in the PIK3CA gene. 
Interestingly, a few patients had tumors that transitioned to a small cell lung cancer, or to a more 
aggressive mesenchymal cell morphology.19 
The differences in the mechanisms of resistance have a direct impact on patient treatment 
algorithms; specific therapies are needed to target these different mutations or changes in cellular 
morphology. For patients with the T790M mutation, there are currently no approved therapies. 
Several compounds that target the T790M mutation are in development. Second generation TKIs 
such as neratinib and afatinib have been shown to be more potent than erlotinib and gefitinib 
against the T790M mutation in vitro, but only at concentrations higher than the drug 
concentration required to maximally inhibit WT-EGFR.20 Consequently, although there are 
several compounds in development, to date they have failed to demonstrate significant 
anti-T790M activity in the clinic, likely because of dosing limitations caused by toxicity from 
WT-EGFR inhibition. Hence, patients who have failed first generation TKIs have limited 
treatment options. Assessment of post-progression survival in patients treated with EGFR TKI 
indicated patients with EGFR T790M positive tumors had a median post-progression survival of 
1.9 years (95% CI, 1.6–2.6 years).21 These patients are usually offered chemotherapy, which is 
known to cause increased toxicities compared to targeted therapies and does not offer a cure; 
progression eventually occurs. Thus, NSCLC patients who have failed treatment with TKIs and 
whose tumors express T790M mutation represent a group with fatal disease and unmet need. 
In this patient population, CO-1686 may provide improved activity by inhibiting a key resistance 
pathway. Furthermore, as CO-1686 has only minimal activity against WT-EGFR, patients 
receiving CO-1686 may not experience the toxicities noted with first generation TKIs (e.g., skin 
rash and diarrhea).  
3.3 
Nonclinical Overview 
CO-1686 is a novel, potent, small molecule irreversible TKI that selectively targets mutant forms 
of the EGFR. Clovis Oncology, Inc. (Clovis), is developing CO-1686 as a therapeutic agent to be 
administered orally to patients with mutant EGFR NSCLC. CO-1686 inhibits the EGFR 
gatekeeper mutation (T790M) which is associated with clinical resistance to Tarceva (erlotinib) 
and Iressa (gefitinib) as well as the common EGFR activating mutations (L858R, del19) and has 
minimal inhibitory activity towards the EGFRWT at clinically relevant doses.  
CO-1686 has been evaluated as a free base formulation (CO-1686 free base) and as a 
hydrobromide salt formulation (CO-1686 HBr). The pharmacologically active moiety, 
irrespective of formulation, is CO-1686.  
Pharmacology  
CO-1686 exhibits nonclinical anti-tumor activity as a single agent in cell lines expressing the 
most common activating and T790M EGFR mutations. The in vitro activity of CO-1686 was 
evaluated against common and rare lung-cancer associated EGFR mutants. CO-1686 was active 
against del19, L858R, G719S, an exon 19 insertion mutant, and L861Q, but not against an exon 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 37 of 151 
Confidential 
20 insertion. Therefore patients with exon 20 insertions have been excluded from participation in 
this study.  
At clinically achievable doses CO-1686 shows potent activity in the NCI-H1975 
(EGFRL858R/T790M) and primary LUM1868 (EGFRL858R/T790M) subcutaneous xenograft models.22 
In addition, the efficacy of CO-1686 was examined in an EGFRL858R/T790M transgenic model and 
compared with that of afatinib. Complete responses were observed in all mice treated with 
CO-1686, with very limited activity in the afatinib group (Figure 1). 
Figure 1: 
CO-1686 Generates Complete Responses in L858R/T790M Transgenic Model 
 
Metabolism  
In liver microsomes, CO-1686 was slowly metabolized, with CYP2C8 playing a role, and 
CYP2D6 playing a minor role at most. There is no evidence to suggest the involvement of the 
polymorphically-expressed CYP2C9 and CYP2C19 in CO-1686 metabolism, implying a low 
potential for ethnic sensitivity variability in humans.  CO-1686 is a substrate and an inhibitor of 
P-glycoprotein (P-gp) and caution should be exercised when CO-1686 is co-administered with 
P-gp inhibitors and inducers (see Section 8.4 for further information).  Caution should also be 
exercised in patients receiving oral CO-1686 and requiring concomitant medication with 
warfarin (Coumadin), nonsteroidal anti-inflammatory drugs (NSAIDs), or clopidogrel, as 
CO-1686 moderately inhibited CYP2C8, CYP2C9 and CYP2C19 activities in vitro. Please see 
Section 8.3 for further information.  
Safety Pharmacology and Toxicology  
Safety pharmacology and toxicology studies were performed in rats and dogs with CO-1686 
HBr. 
Primary indices of toxicity in rats included dose-dependent clinical signs (thinning haircoat 
(females), squinting, pale ears or body and hunched posture), loss in body weight and decreased 
body weight gain and food consumption. Increased neutrophil count, decreased white blood cell 
count, lymphocyte count and red blood cell parameters were also noteworthy.  Squinting was 
-1 0 0
-8 0
-6 0
-4 0
-2 0
0
2 0
4 0
6 0
8 0
1 0 0
2 0 0
4 0 0
6 0 0
C h a n g e  fro m  B a s e lin e  (% )
P D
S D
P R
C R
A fa tin ib
2 0 m g /k g
C O -1 6 8 6
5 0 m g /k g  B ID
L 8 5 8 R /T 7 9 0 M
T ra n s g e n ic  M o d e l
CO-1686: Baseline
CO-1686: 3W
Afatinib: Baseline 
Afatinib : 3W

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 38 of 151 
Confidential 
observed in high dose rats administered CO-1686 HBr and was associated with atrophy of 
meibomian gland in the eyelid; both effects were reversible. The correlate of this finding in 
humans is dry eye. Other microscopic findings after 28 days of repeated-dosing in rats included 
minimal to moderate atrophy of other glands (Harderian gland, mammary gland and prostate). 
Pathological findings were minor glandular atrophy in all four tissues which was reversible and 
principally occurred in the high dose group. Only minor effects were observed with CO-1686 
HBr on hematopoietic tissue   
Primary indices of toxicity in the dog included dose-related clinical signs which included 
abnormal feces (liquid and/or non-formed feces), vomiting and redness of gingival and lips. 
These observations were not considered adverse due to the overall good health of the animals. 
All clinical observations were reversible, except for non-formed feces. The redness of gingiva or 
lips noted, had no microscopic correlation at total exposures of AUC of up to 23,100 ng.h/mL.  
No evidence of elevated serum glucose levels were observed in the rat and dog studies. There 
were no CO-1686-related cardiac safety or neurobehavioral findings from the GLP repeat-dose 
toxicity studies. CO-1686 did not have any genotoxic activity in 2 in vitro assays, and was not 
phototoxic when evaluated in a phototoxicity study with Long Evans pigmented rats. 
Please refer to the Investigator’s Brochure for detailed information on the preclinical program.  
3.4 
Clinical Experience with CO-1686  
CO-1686 has been evaluated in Study CO-1686-008, an ongoing first-in-human Phase 1/2 study 
in patients with advanced NSCLC, and one completed Phase 1 study in healthy volunteers 
(CO-1686-016).  
3.4.1 Safety 
Study CO-1686-008 
CO-1686-008 is a two-part, open-label, safety, PK, and preliminary efficacy study of CO-1686 
in patients with advanced NSCLC. As of 30 January 2014, 103 patients with advanced NSCLC 
have received at least one dose of CO-1686. In the initial stage of the study, 57 patients were 
treated with CO-1686 administered as free base capsules at doses ranging from 150 mg up to 
1800 mg daily. Subsequently, CO-1686 hydrobromide tablets were introduced into the study to 
be used in the later dose escalation cohorts. Forty-six patients have been treated with CO-1686 
administered as hydrobromide tablets at doses of 500 mg BID (N = 15), 625 mg (N = 16), 
750 mg BID (N = 9) and 1000 mg BID (N = 6). At the time of this summary, preliminary safety 
data are available in the clinical database for 93 patients. 
Dose-limiting Toxicities: The dose limiting toxicity (DLT) evaluable population includes all 
patients who have completed Cycle 1, and who were enrolled while the dose escalation part of 
the study was ongoing. 7 patients have experienced DLTs across 6 dose levels (Table 1). A DLT 
rate > 33% was not reached at any dose.  The most frequently reported DLT was 
hyperglycemia/glucose tolerance impaired which occurred at a similar frequency (11% to 25%) 
across all CO-1686 HBr dose levels (500 mg BID, 625 mg BID, 750 mg BID and 1000 mg BID). 
Hyperglycemia can be effectively managed with the addition of oral anti-hyperglycemic therapy 
and/or dose reductions.  Guidance for the management of hyperglycemia associated with 
CO-1686 treatment is provided in Section 7.4.3. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 39 of 151 
Confidential 
Table 1: 
Cycle 1 DLTs Reported for Patients by Dose Level 
Starting Dose and 
Formulation 
N evaluated 
N with 
DLT 
Description of Event 
150 mg QD 
Free base 
6 
1 (17%) 
One patient experienced hypoglycaemia (Grade 4) on 
Day 15, a PK fasting day. The patient was known to 
have diabetes, and the overnight fast and concurrent 
use of the oral hypoglycemic agents glipizide and 
metformin significantly contributed to the event. The 
patient discontinued from the study. 
200 mg  - 1200 mg daily, Free base,  N =18, No DLTs 
900 mg BID 
Free base 
6 
1 (17%) 
One patient experienced an acute illness on day 3 with 
dehydration (Grade 3), aspartate aminotransferase 
(AST) elevation (Grade 3), anorexia (Grade 3), and 
diarrhea and abdominal cramps. The patient recovered 
2-4 days later. 
500 mg BID 
HBr 
6 
1 (17%) 
One patient experienced hyperglycemia (Grade 3) and 
was diagnosed with pancreatitis (Grade 2), 3 weeks 
after initiating CO-1686. The patient recovered and 
continued with dose reduction and anti-hyperglycemic 
medication. 
625 mg BID 
HBr 
8 
2 (25%) 
One patients experienced fatigue (Grade 3) 
approximately a week into treatment. The patient 
recovered 6 days later. 
One patients experienced hyperglycemia (Grade 3) 
approximately a week into treatment. The patient 
recovered and continued with dose reduction and anti-
hyperglycemic medication. 
750 mg BID 
HBr 
9 
1(11%) 
One patient experienced hyperglycemia (Grade 3) and 
electrocardiogram QT prolongation (Grade 3) and T 
wave inversion (Grade 3). The patient recovered, but 
withdrew consent before drug was restarted. 
1000 mg BID 
HBr 
6 
1 (17%) 
One patient experienced hyperglycemia (Grade 3) and 
an increase in INR (Grade 3). The patient recovered 
and continued with dose reduction and anti-
hyperglycemic medication. 
SAEs:  A total of 28 patients experienced at least 1 SAE and 10 patients have reported an SAE 
assessed as related to study drug. Treatment related SAEs are summarized in Table 2. 
There were six deaths while on study or within 28 days after last dose. All deaths were due to 
progression of NSCLC and assessed as not related to study drug.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 40 of 151 
Confidential 
Table 2: 
Treatment-related SAEs Reported in Any Patient  
 
Daily Dose 
< 1800 mg  
1800 mg FB 
1000 mg  
1250 mg  
1500 mg  
2000 mg  
Overall 
Formulation 
Free base 
Free base 
HBr 
HBr 
HBr 
HBr 
 
Frequency 
Various a 
900 mg BID 
500 mg  BID 
625 mg  BID 
750 mg  BID 
1000 mg  BID 
 
N 
38 
19 
9 
12 
9 
6 
93 
Overall 
4 (11%) 
1 (5%) 
1 (11%) 
1 (8%) 
2 (22%) 
1 (17%) 
10 (11%) 
Cardiac Disorders 
Pericarditis 
1 (3%) 
0 
0 
0 
0 
0 
1 (1%) 
Gastrointestinal Disorders 
Diarrhea 
1 (3%) 
1 (5%) 
0 
0 
0 
0 
2 (2%) 
Nausea 
1 (3%) 
0 
0 
0 
0 
0 
1 (1%) 
Pancreatitis 
0 
0 
1 (11%) 
0 
0 
0 
1 (1%) 
Vomiting 
2 (5%) 
0 
0 
0 
0 
0 
2 (2%) 
Investigations 
Electrocardiogram 
QT prolonged 
0 
0 
0 
0 
1 (11%) 
0 
1 (1%) 
Electrocardiogram T 
wave inversion 
0 
0 
0 
0 
1 (11%) 
0 
1 (1%) 
Transaminases 
increased 
0 
1 (5.3%) 
0 
0 
0 
0 
1 (1%) 
Metabolism and Nutrition Disorders 
Decreased Appetite 
0 
1 (5%) 
0 
0 
0 
0 
1 (1%) 
Hyperglycemia 
1 (3%) 
0 
1 (11%) 
1 (8%) 
2 (22%) 
1 (17%) 
6 (7%) 
Hypoglycemia 
1 (3%) 
0 
0 
0 
0 
0 
1 (1%) 
a 150 mg  to 900 mg QD, 100 mg to 600 mg BID, 400 mg TID  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 41 of 151 
Confidential 
Treatment related AEs:  Treatment related adverse events reported in at least 5% of patients 
are summarized in Table 3. 
The most frequently reported treatment-related AEs (all grades) were nausea (24%), and 
hyperglycemia/glucose tolerance impaired (22%). The majority of adverse events are mild or 
moderate. The most frequently reported Grade 3 or higher AE, occurring in 12% of patients 
overall, was hyperglycemia/glucose tolerance impaired; hyperglycemia improves or resolves in 
patients following treatment with oral anti-hyperglycemic therapy and/or dose reductions.  
As expected due to CO-1686 selectivity for mutant EGFR, dose related WT-driven rash and 
diarrhea has not been observed.  All reported events of diarrhea were either Grade 1 or Grade 2.  
The most common skin reaction reported in patients treated with EGFR-TKIs is a follicular 
acneiform eruption. In Study CO-1686-008, rash, irrespective of causality, was reported 
infrequently (overall 5 patients; 5%) and events were mild. No events of dermatitis acneiform or 
follicular rash have been reported. 
There have been two AEs of pneumonitis. Both were judged related to CO-1686 by the 
investigator. Both patients recovered when CO-1686 was held and steroids were administered. 
Neither was re-challenged with CO-1686.  
ECGs:  ECG results are available for 91 patients. CO-1686 causes an increase in the QTc 
interval of the ECG, with onset between Day 1 and 15 of treatment. ECG changes are 
summarized in Table 4. Three (3%) patients have experienced a QTcF > 500 msec, which was 
managed effectively through dose reduction.  
All patients with increased QTc have been asymptomatic. In the overall population, there have 
been no adverse events suggestive of cardiac arrhythmia (dizziness, presyncope, syncope, sudden 
death).  
There were no electrolyte abnormalities associated with the ECG changes in any of the patients 
and there was no correlation between the plasma PK parameters of CO-1686 (Cmax, AUC and 
C12h) and increase in QTc. 
All CO-1686 protocols contain patient selection criteria and specific guidance for the 
management of patients who develop prolonged QTc.  
In summary, CO-1686 has a manageable safety profile at all doses evaluated. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 42 of 151 
Confidential 
Table 3:  
Treatment-related AEs Reported in at Least 5% Patients or Treatment-related Events Associated with 
Inhibition of WT EGFR  
Total Daily Dose 
< 1800 mg 
 
1800 mga 
 
1000 mg 
 
1250 mg 
 
1500 mg 
 
2000 mg 
 
Total 
Formulation 
Free base 
Free base 
HBr 
HBr 
HBr 
HBr 
 
Frequency 
Variousb 
900 mg BID 
500 mg  BID 
625 mg  BID 
750 mg  BID 
1000 mg  BID 
 
N 
38 
19 
9 
12 
9 
6 
93 
Overall 
26 (68%) 
18 (94%) 
5 (55%) 
5 (41%) 
7 (78%) 
5 (83%) 
66 (71%) 
Blood and lymphatic System Disorders 
Thrombocytopenia 
1 (3%) 
3 (16%) 
0 
0 
2 (22%) 
0 
6 (7%) 
Gastrointestinal Disorders 
Diarrhea 
6 (16%) 
6 (32%) 
1 (11%) 
2 (17%) 
1 (11%) 
0 
16 (17%) 
Nausea  
7 (18%) 
7 (37%) 
1 (11%) 
2 (17%) 
3 (33%) 
2 (33%) 
22 (24%) 
Vomiting 
5 (13%) 
2 (11%) 
1 (11%) 
2 (17%) 
2 (22%) 
0 
12 (13%) 
General Disorders and Administrative Site Conditions 
Fatigue 
8 (21%) 
5 (26%) 
2 (22%) 
1 (8%) 
1 (11%) 
0 
17 (18%) 
Investigations 
AST increased 
1 (3%) 
4 (21%) 
0 
0 
0 
0 
5 (5%) 
ECG QT prolonged 
0 
2 (11%) 
0 
0 
3 (33%) 
2 (33%) 
7 (8%) 
Metabolism and Nutrition Disorders 
Glucose Tolerance 
Impaired/Elevated 
Glucose/ 
Hyperglycemia 
3 (8%) 
6 (32%) 
3 (33%) 
1 (8%) 
4 (44%) 
3 (50%) 
20 (22%) 
Musculoskeletal and Connective Tissue Disorders 
Arthralgia 
3 (8%) 
2 (11%) 
0 
0 
0 
0 
5 (5%) 
Muscle Spasms 
3 (8%) 
3 (16%) 
0 
0 
0 
0 
6 (7%) 
Myalgia 
3 (8%) 
4 (21%) 
2 (22%) 
1 (8%) 
0 
1 (17%) 
11 (12%) 
Skin and Subcutaneous Tissue Disorders 
Rash  
1 (3%) 
1 (5%) 
0 
0 
0 
0 
2 (2%) 
a10 patients transitioned to 500 mg BID HBr on availability; b 150 mg  to 900 mg QD, 100 mg to 600 mg BID, 400 mg TID  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 43 of 151 
Confidential 
Table 4: 
Electrocardiogram Test Results (QTc - Fridericia) 
Total Daily Dose 
< 1800 mg 
 
 
1800 mg 
 
1000 mg 
 
1250 mg 
 
1500 mg 
 
2000 mg 
 
Total 
 
Formulation 
Free base 
Free base 
HBr 
HBr 
HBr 
HBr 
 
Frequency 
Variousa 
900 mg BID 
500 mg  BID 
625 mg  BID 
750 mg  BID 
1000 mg  BID 
 
N 
37 
18 
9 
12 
9 
6 
91 
Post Baseline Results 
QTc > 500 ms 
No 
37 (100%) 
17 (94%) 
7 (78%) 
12 (100%) 
9 (100%) 
6 (100%) 
88 (97%) 
Yes 
0 (0%) 
1 (6%) 
2 (22%) 
0 (0%) 
0 (0%) 
0 (0%) 
3 (3%) 
 
 
 
 
 
 
 
 
CFB QTc > 30 ms 
No 
23 (62%) 
7 (39%) 
3 (33%) 
6 (50%) 
2 (22%) 
1 (17%) 
42(46%) 
Yes 
10 (27%) 
7 (39%) 
6 (67%) 
6 (50%) 
7 (78%) 
5 (83%) 
41 (45%) 
NA 
4 (11%) 
4 (22%) 
0 (0%) 
0 (0%) 
0 (0%) 
0 (0%) 
8 (9%) 
 
 
 
 
 
 
 
 
CFB QTc > 60 ms 
No 
33 (89%) 
14 (78%) 
6 (67%) 
12 (100%) 
7 (78%) 
5 (83%) 
77 (85%) 
Yes 
0 (0%) 
0 (0%) 
3 (33%) 
0 (0%) 
2 (22%) 
1 (17%) 
6 (7%) 
NA 
4 (11%) 
4 (22%) 
0 (0%) 
0 (0%) 
0 (0%) 
0 (0%) 
8 (9%) 
a 150 mg  to 900 mg QD, 100 mg to 600 mg BID, 400 mg TID 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 44 of 151 
Confidential 
Study CO-1686-016  
CO-1686-016 was a 3-part study in healthy male subjects which investigated the PK and safety 
of single and short course repeat doses of CO-1686 HBr salt. In this study, CO-1686 HBr was 
administered at single doses up to 1000 mg in the fasted state and at 500 mg BID in the fed state 
without significant adverse effects. 
Following CO-1686 HBr dosing over 4 days at 500 mg BID in a fed state, 3 of 6 healthy male 
subjects were noted to show asymptomatic increase in QTc on day 4 of dosing which resolved 
when CO-1686 was discontinued.  
Activity of CO-1686  
The dose escalation phase of this study is completed and enrolment is ongoing in the dose 
expansion phase of the study. Although the primary objectives of Phase 1 of Study CO-1686-008 
were to evaluate the safety, toxicity and pharmacokinetic profile of CO-1686, encouraging 
signals of activity have been observed in an EGFR mutation positive patient population 
previously treated with one of more lines of an EGFR TKI (e.g., erlotinib, gefitinib, afatinib) and 
chemotherapy. A preliminary analysis of efficacy has been conducted using overall response 
rate, duration of response, and PFS as efficacy parameters with a cutoff date of 06 March 2014. 
The efficacy analysis population includes T790M-positive and T790M-unknown patients with 
measurable disease who have received CO-1686 free base at 900 mg BID or CO-1686 HBr at 
doses of 500 mg, 625 mg, 750 mg, or 1000 mg BID. Data from the initial dose escalation cohorts 
using CO-1686 free base indicate that dose levels below 900 mg BID CO-1686 are much less 
effective than higher doses, are associated with lower plasma exposure, and are therefore likely 
to be below the therapeutic window.  
3.4.1.1 
Tumor Responses Associated with CO-1686 
Although the data are immature, there is evidence of activity for CO-1686 across the therapeutic 
doses for patients confirmed as T790M-positive by central testing (Figure 2) with 14 of 
22 patients achieving a partial response per RECIST as of the data cut-off date. The ORR in this 
group of patients is approximately 64% (Table 5) and the disease control rate is approximately 
91%. Some of the responses have occurred too recently to allow confirmation. Of the 
9 responses that have had the opportunity to be confirmed, 7 (78%) have indeed been confirmed. 
As shown in Figure 2, 10 of the 14 patients (71%) who achieved a partial response had 
discontinued from EGFR-directed therapy immediately prior to enrolling in Clinical 
Study CO-1686-008. Median PFS has not been reached in the T790M-positive subgroup, but 
will exceed 120 days (Figure 3). 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 45 of 151 
Confidential 
Figure 2: 
Best Response for Target Lesions in Centrally Confirmed T790M-positive 
Patients 
 
Table 5: 
Best Response, Objective Response, and Disease Control Rate in 
T790M-positive Patients 
 
900 mg 
BID FB 
(N = 9) 
500 mg 
BID HBr 
(N = 4) 
625 mg 
BID HBr 
(N = 4) 
750 mg 
BID HBr 
(N = 4) 
1000 mg 
BID HBr 
(N = 3) 
Overall 
(N = 24) 
Best Response a 
PR 
7 
(77.8%) 
2 
(50.0%) 
2 
(50.0%) 
0 
(0.0%) 
3 
(100.0%) 
14 
(58.3%) 
SD 
2 
(22.2%) 
0 
(0.0%) 
0 
(0.0%) 
4 
(100.0%) 
0 
(0.0%) 
6 
(25.0%) 
PD 
0 
(0.0%) 
2 
(50.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
2 
(8.3%) 
End of Cycle 2 scan not 
yet reached 
0 
(0.0%) 
0 
(0.0%) 
2 
(50.0%) 
0 
(0.0%) 
0 
(0.0%) 
2 
(8.3%) 
Objective Response a, b 
(CR, PR) 
7 
(87.5%) 
2 
(50.0%) 
2 
(100.0%) 
0 
(0.0%) 
3 
(100.0%) 
14 
(63.6%) 
Disease Control Rate a, b 
(CR, PR, SD)  
9 
(100.0%) 
2 
(50.0%) 
2 
(100.0%) 
4 
(100.0%) 
3 
(100.0%) 
20 
(90.9%) 
a 
Data shown are for patients with measurable disease at baseline 
b 
Percentage based on patients with non-missing best response 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 46 of 151 
Confidential 
Figure 3: 
Kaplan-Meier Curves of Treatment Duration by T790M Status for 900 mg 
BID Free Base and All HBr Patients 
 
3.4.2 Pharmacokinetics of CO-1686  
In Phase 1 of this study, the PK of single dose and multiple doses of CO-1686 free base capsules 
demonstrated that Cmax and AUC0-24h increased with dose (PK data analyzed for doses escalated 
from 150 mg once daily to 900 mg once daily and 100 mg twice daily to 900 mg twice daily). 
Time of occurrence of Cmax (Tmax; 1.5 to 4 hours) and terminal half-life (T1/2; 3.5 to 5.5 hours) 
were consistent across doses and there was no accumulation of CO-1686 at any dose.  
The single dose PK of 150 mg QD was compared in the fasted and fed state, and it was 
concluded that a high-fat meal increased the plasma drug concentration at 24 hours post the 
morning dose (C24h;+ 71% to + 300%) and AUC0-24 (+ 44% to > + 110%) with no change in T1/2; 
a lower Cmax and delayed Tmax was also seen in a majority of patients.  
With CO-1686 free base, moderate inter-and intra-patient PK variability was observed at all 
doses in the Phase 1 portion of this study. CO-1686 free base is best absorbed at low pH, and its 
bioavailability is susceptible to factors such as gastric pH and food. These factors may have 
contributed to the PK variability seen in the study at doses up to 1800 mg daily. 
In Phase 1, dose escalation of CO-1686 free base capsules reached 1800 mg daily (900 mg BID). 
This dose was not the MTD. Dose escalation was stopped with CO-1686 free base at 1800 mg 
daily with view to continuing dose escalation with a hydrobromide salt formulation of CO-1686 
which, based on preclinical data,  was anticipated to improve drug dissolution across a wider 
range of pH and thus increase oral absorption and decrease PK variability. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 47 of 151 
Confidential 
In healthy volunteers (Study CO-1686-016), Cmax and AUC0–24  of CO-1686 increased with 
ascending single doses of CO-1686 HBr (50 mg to 1000 mg), with CO-1686 plasma levels 
increasing in a less than dose proportional manner above 125 mg. 
The single dose PK of CO-1686 HBr was compared in the fasted and fed state, and it was 
concluded that a high-fat meal increased the plasma drug concentrations from 3 to 12 hours post 
dose with a mean increase of 172% at 12 hours post dose (C12h: –22% to +400%) and a mean 
increase of 77% in AUC0–24 (+10% to 146%) with no change in T1/2; a slight mean increase of 
12% in Cmax was observed and a delayed Tmax was seen in a majority of subjects. 
Six healthy subjects were dosed, in the fed state, with 500 mg BID CO-1686 HBr for 4 days.  PK 
profiles of CO-1686 following morning and evening dosing were similar, with low intra-subject 
variability (Day 1 and Day 4 comparison). There was no accumulation of CO-1686. 
In Phase 1 of this study, dose escalation was re-started with CO-1686 HBr at a starting dose of 
1000 daily (500 mg BID) as this dose was anticipated to provide exposures comparable to that 
observed with CO-1686 free base at 900 mg BID. The simulated concentration – time profile at 
500 mg BID CO-1686 HBr suggested an AUC0-24 range of 11200 to 43200 ng.h/mL, which was 
comparable to the 95% confidence interval of AUC0-24 of 10400 to 42300 ng.h/mL in patients 
receiving 900 mg BID CO-1686 free base. The Cmin levels were projected to be 94 to 703 ng/mL, 
which is comparable to the observed Cmin of 109 to 1560 ng/mL in patients receiving 900 mg 
BID CO-1686 free base. 
In the Study CO-1686-008, PK data following administration of the HBr salt formulation were 
available from a total of 44 patients (4 started at 500 mg BID, 10 switched from CO-1686 free 
base to 500 mg BID HBr, 15 started at 625 mg BID, 9 started at 750 mg BID, and 6 started at 
1000 mg BID). CO-1686 HBr showed increased absorption and thus, higher exposure than free 
base. The median Tmax was 2.5 to 3.25 hours and T1/2 ranged from 1.7 to 4.7 hours, which was 
slightly shorter than free base in the majority of patients in the ≤750 mg BID cohorts while the 
T1/2 was more similar to free base in the 1000 mg BID cohort. Following CO-1686 HBr 
administration, exposure (measured as Cmax and AUC0-24) increased dose-proportionally from 
500 mg to 1000 mg BID (Figure 4). Comparative PK were available in 8 patients who originally 
started CO- 1686 treatment at 900 mg CO-1686 free base BID and then switched to 500 mg 
CO-1686 HBr BID. Results suggest that CO-1686 HBr delivered a higher exposure, assessed by 
Cmax, and lower variability mainly due to a much improved absorption in patients who had low 
exposure when receiving free base (Figure 5). 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 48 of 151 
Confidential 
Figure 4: 
Individual CO-1686 AUC0-24 on Day 1 Following 500 mg to 1000 mg CO-1686 
HBr BID 
 
 
5 0 0
7 5 0
1 0 0 0
0
1 2 5 0 0
2 5 0 0 0
3 7 5 0 0
5 0 0 0 0
6 2 5 0 0
8 0 0 0 0
1 2 0 0 0 0
H B r D o s e  v s  A U C
B ID  D o s e  (m g )
625
C O -1 6 8 6  A U C 0 -2 4 (n g .h /m L )

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 49 of 151 
Confidential 
Figure 5: 
Individual and Mean CO-1686 Cmax Following a Single Dose of 900 mg 
CO-1686 Free Base vs. 500 mg CO-1686 HBr 
 
3.5 
Rationale for Study and Starting Dose 
3.5.1 Rationale  
As noted previously, there are limited treatment options for mutant EGFR NSCLC patients who 
have failed treatment with first generation TKIs and have acquired resistance through the T790M 
mutation. Currently there are no targeted therapies for these patients, who are usually treated 
with cytotoxic chemotherapy that has limited efficacy, but significant toxicity, in the second or 
third-line setting. Consequently, these patients represent a group with fatal disease and unmet 
need. 
With potent activity against activating EGFR mutations and the T790M resistance mutation, and 
minimal inhibitory activity towards the wild type, CO-1686 may provide an effective therapy for 
a patient population with few alternative treatment options. Preclinical data point to potential key 
benefits of treatment with CO-1686: 
The drug is active against the T790M EGFR mutation, for which there is currently no approved 
treatment. 
• CO-1686 is WT-sparing; toxicities known to be associated with first generation TKIs, such 
as rash and diarrhea, will likely not be experienced with CO-1686 treatment. 
300
800
1300
1800
2300
2800
3300
CO-1686 Cmax (ng/mL)
Day 1 Cmax
1-00-01
2-00-01
4-00-03
4-00-04
4-00-05
6-00-04
6-11-01
6-12-01
mean+/- SD
900 FB BID
500 HBr BID

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 50 of 151 
Confidential 
Initial development will focus on patients with mutant EGFR NSCLC who have failed prior 
EGFR-directed therapy and have T790M-mediated resistant NSCLC. CO-1686 is being 
developed with a companion diagnostic to identify patients whose tumors express the activating 
EGFR mutations as well as the T790M resistance mutation.  
3.5.2 Starting Dose for Phase 1 
The starting dose for the proposed Phase 1 study was calculated according to the Food and Drug 
Administration’s (FDA’s) General Guide for Starting Dose Selection for a Cytotoxic Agent in 
Cancer Patients after evaluation of all toxicity data. 
In rats and dogs, the STD10 and HNSTD were determined to be 400 and 1000 mg/kg/day, 
respectively, in the 28-day GLP studies, and these dose levels were used for the purposes of 
calculating the safe human starting dose. 
The rat was the most sensitive species in all the toxicity studies conducted and an appropriate 
species to use for the calculation of the maximum recommended starting dose for Phase 1. 
One-tenth of the rat STD10 is 240 mg/m2/day (6.49 mg/kg) or 420 mg/day using 1.75 m2 for a 
standard adult human body surface area (Table 6). The dose of 420 mg/day is the maximum 
starting dose for Phase 1. However, CO-1686 is a poorly soluble compound exhibiting 
absorption-limited exposure in vivo in nonclinical species despite showing a high permeability 
in vitro in Caco-2 cells. In addition, exposure variability was consistently observed in all 
nonclinical species following PO administration, presumably due to the low solubility of 
CO-1686 and its pH-sensitive solubility profile. Therefore, taking into account these 
absorption-related PK uncertainties, the starting dose for the proposed Phase 1 trial is set at 
150 mg/day QD, which is approximately one-third of the maximum starting dose allowed by the 
guideline.  
Although the tumor growth inhibition and in vitro data are suggestive of increased antitumor 
activity with BID dosing, a QD schedule will be used for the initial doses in the proposed 
Phase 1 study to allow determination of the full PK profile. Depending on the time course of 
exposure in humans, BID dosing may be explored in later dose cohorts. 
Based on an evaluation of the nonclinical toxicology and safety pharmacology results, the 
proposed starting dose for PO administration of CO-1686 to adult advanced cancer patients, 
150 mg/day QD, is expected to be tolerated by patients.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 51 of 151 
Confidential 
Table 6: 
Estimated Human Starting Doses and Safety Factors Based on Body Surface 
Area 
Species 
GLP Toxicology 
Study Reference 
Dose (mg/kg/day) 
Converted to 
BSAa (mg/m2) 
Applied 
Safety Factor 
Estimated Human MRSD 
mg/m2b 
mg/dayc 
Rat 
STD10 = 400d 
2400 
10 
240e 
420 
Dog 
HNSTD = 1000d 
20,000 
6 
3333 
5832 
BSA = body surface area; GLP = Good Laboratory Practice; HNSTD = highest non-severely toxic dose; 
MRSD = maximum recommended starting dose; STD10 = severely toxic dose in 10% of rodents 
a 
Conversion for mg/kg to mg/m2: rat (mg/kg) X 6; dog (mg/kg) X 20. 
b 
MRSD = 1/10 STD10 (mg/m2) in rodents or 1/6 HNSTD (mg/m2) in non-rodents. 
c 
Conversion factor from mg/m2 to mg/day in humans using 1.75 m2 for a standard adult body surface area. 
d 
STD10 and HNSTD were determined in rat and dog 28-day GLP toxicology studies. 
e 
One tenth of the rat STD10 is 240 mg/m2/day. 
3.5.3 Doses for Phase 2 
A MTD was not reached in Phase 1 for any doses studied with the free-base or HBr CO-1686 
formulations. The RP2D of 750 mg BID CO-1686 HBr was selected based on review of the 
pharmacokinetic, overall safety and preliminary efficacy data available in early 2014, and 
patients are actively enrolling in cohorts A (later-stage) and B (earlier-stage disease) at 750 mg 
BID under Amendment 4. Subsequently, as the Phase 1 data matured, the recommended dose 
was adjusted to 625 mg BID based on robust antitumor activity at lower doses (Figure 2) and 
anticipated optimal tolerability. 
Amendment 6 allowed for the addition of 2 doses levels of CO-1686 (500 mg BID and 625 mg 
BID) in patients who have progressed on initial EGFR inhibitor therapy (Cohort B), and in 
patients with later line disease (Cohort A). Patients will no longer enroll in the 750 mg BID dose 
level for Cohorts A and B, but will be assigned to receive either 625 mg BID or 500 mg BID by 
the sponsor. Patients who are already receiving 750 mg BID will continue at this dose. Patients 
will be allocated to Cohorts A and B based on the results of central EGFR testing for T790M 
status (Therascreen, Qiagen). As it is expected that some patients who test negative for T790M 
with the central test will have tested positive using local tests, a new cohort (Cohort C, 625 mg 
BID) has been added to assess activity of CO-1686 in such cases. This last cohort will also be 
open to patients in whom the central test did not provide an EGFR result because the biopsy 
specimen was not suitable for analysis by the central lab. Building on the observed efficacy of 
CO-1686, a more precise estimate of optimum dose will be derived from the augmented cohorts. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 52 of 151 
Confidential 
4 
STUDY OBJECTIVES 
4.1 
Objectives and Endpoints 
Primary, secondary and exploratory objectives and endpoints of Phase 1 (Part 1) are shown 
Table 7; Primary, secondary and exploratory objectives and endpoints of Phase 2 (Part 2) are 
shown in Table 8. 
Table 7: 
Phase 1 Primary, Secondary and Exploratory Objectives and Endpoints 
Phase 1 
Primary Objectives 
Primary Endpoints 
To evaluate the toxicity profile of escalating doses 
of CO-1686 and to determine the MTD and RP2D 
The incidence of Grade 3 or 4 adverse events (AEs) 
and clinical laboratory abnormalities defined as dose-
limiting toxicities (DLTs)  
To characterize the PK profile of CO-1686  
PK parameters including area under the curve from 
time zero to time t (AUC0-t), AUC from time zero to 
infinity (AUC0-∞), maximum concentration (Cmax), 
time to maximum concentration (Tmax), elimination 
half-life (T1/2), elimination rate constant (kel), volume 
of distribution at steady state after nonintravenous 
administration (Vss/F), and total plasma clearance 
(Cl/F) for CO-1686 
Secondary Objective 
Secondary Endpoints 
To characterize the PK profile of CO-1686 after a 
high-fat breakfast vs in the fasted state  
PK parameters Cmax and AUC for CO-1686 (fasted 
and fed)  
To evaluate the effects of CO-1686 on the QT/QTc 
interval    
Change from baseline in QT/QTc interval 
To evaluate tumor response (overall response rate 
[ORR] + duration of response) of CO-1686 
ORR and duration of response per Response Criteria 
in Solid Tumors (RECIST) Version 1.1 
Exploratory Objectives 
Exploratory Endpoints 
To characterize lung-cancer and treatment-related 
symptoms in patients at baseline and in response to 
CO-1686 using the Dermatology Life Quality 
Index, the EORTC QLQ - LC13, and the EORTC 
QLQ-C30. 
Change from baseline in patient-reported outcomes 
To explore the concordance of T790M detected in 
tumor versus that detected in blood.  
Concordance of  the presence of T790M mutation in 
blood and tumor tissue samples 
To determine if T790M is detectable in urine 
(optional sampling). 
Detection of T790M in urine samples 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 53 of 151 
Confidential 
Table 8: 
Phase 2 (Part 2):  Primary, Secondary and Exploratory Objectives and 
Endpoints 
Phase 2  
Primary Objectives 
Primary Endpoints 
To evaluate tumor response 
(ORR + duration of response) to CO-1686 in patients 
with T790M mutation 
ORR and duration of response per RECIST 
Version 1.1 by investigator assessment 
Secondary Objectives 
Secondary Endpoints 
To evaluate objective response rate (ORR), duration of 
response, and progression-free survival [PFS] in 
patients treated with CO-1686 
ORR, duration of response and PFS per 
RECIST Version 1.1 as determined by 
independent radiology review (IRR) 
To evaluate the toxicity and tolerability of CO-1686  
The incidence of AEs, clinical laboratory 
abnormalities, and ECG abnormalities  
To evaluate overall survival (OS), disease control rate 
(DCR) and progression-free survival [PFS] in patients 
treated with CO-1686 
OS, DCR and PFS per RECIST Version 1.1 
as determined by investigator assessment  
To determine pharmacokinetics (PK) of CO-1686 using 
population PK (POPPK) methods and explore 
correlations between PK, exposure, response, and/or 
safety findings  
Plasma PK parameters for CO-1686 at 
Cycle 1 Day 1 and Cycle 1 Day 15 for a 
subset of patients; CO-1686 metabolite 
profile in the Day 15 plasma samples for a 
subset of patients; Plasma PK parameters for 
CO-1686 based on sparse sampling of all 
patients 
To characterize lung-cancer and treatment-related 
symptoms in patients at baseline and in response to 
CO-1686 using the Dermatology Life Quality Index, 
the EORTC QLQ - LC13, and the EORTC QLQ-C30. 
Change from baseline in patient-reported 
outcomes  
To evaluate the effects of CO-1686 on the QT/QTc 
interval    
Change from baseline in QT/QTc interval 
Exploratory Objectives 
Exploratory Endpoints 
To evaluate clinical benefit of continued CO-1686 
treatment following disease progression 
Time-to-treatment failure  
To explore the concordance of T790M detected in 
tumor versus that detected in blood  
Concordance of  the presence of T790M 
mutation in blood and tumor tissue samples 
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 54 of 151 
Confidential 
5 
STUDY DESIGN 
5.1 
Overall Study Design and Plan 
This is a two-part, open-label, safety, PK, and efficacy study of oral CO-1686 administered daily 
in previously treated NSCLC patients who have documented evidence of an activating mutation 
in the EGFR gene and have failed treatment with an EGFR inhibitor such as erlotinib or 
gefitinib. Part 1 of the study is the Phase 1 dose-escalation period, Part 2 is the Phase 2 
dose-expansion period in patients with T790M positive tumors.  
5.1.1 Screening Period 
Patients will undergo screening assessments within 28 days of the first dose of CO-1686. 
Patients will be monitored for AEs from the time the first dose of CO-1686 is administered 
through 28 days after the last dose. Study procedure-related AEs that occur after signing of the 
ICF and before administration of CO-1686 will also be collected.  
5.1.2 Phase 1 
Dose escalation with CO-1686 free base reached 1800 mg daily. This dose was not the MTD. 
Dose escalation was re-started with CO-1686 HBr in August 2013, with dose escalation and 
de-escalation guided by a CRM algorithm in accordance with the rules defined in 
Section 7.4.1.1. The CRM is described in Appendix C. 
Dose Escalation 
The dose escalation phase of Part 1 was completed in January 2014. Eligible patients provided 
tumor tissue for T790M evaluation by the sponsor’s central laboratory but enrolment to Phase 1 
was irrespective of T790M status. Each patient was treated with oral CO-1686 daily for a 21-day 
period and underwent assessments for safety (DLTs, AEs, vital signs, clinical laboratory tests, 
ECOG performance status, ECG and physical examinations) and PK according to the schedule of 
assessments. All dose escalations were agreed upon between the investigators and the sponsor. 
The safety monitoring window was 21 days. 
As of 30 January 2014, 103 patients with advanced NSCLC have received at least one dose of 
CO-1686. In the initial stage of the study, 57 patients were treated with CO-1686 administered as 
free base capsules at doses ranging from 150 mg up to 1800 mg daily. Subsequently, CO-1686 
hydrobromide tablets were introduced into the study and 46 patients were treated with CO-1686 
administered as hydrobromide tablets. CO-1686-HBr was tested at 500 mg BID, 625 mg BID, 
750 mg BID and 1000 mg BID in the dose escalation phase of the study. The MTD was defined 
as the maximum daily oral dose at which < 33% of patients experience a DLT during Cycle 1 
(Safety and PK Assessment Period). Dose escalation evaluation was completed in January 2014 
and all doses tested were judged safe (i.e. less than 33% incidence of dose limiting toxicities in 
Cycle 1). A MTD for free-base or HBr CO-1686 was not reached in the Phase 1 portion of the 
study.  
Transition of Patients on CO-1686 Free Base Capsules to CO-1686 HBr Tablets 
Existing patients being treated with CO-1686 free base were transitioned to CO-1686 HBr 
500 mg BID once safety evaluation of this dose level was completed. When a patient was 
transitioned to CO-1686 HBr, the new formulation was to be initiated at Day 1of the cycle and, 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 55 of 151 
Confidential 
preferably, a detailed-hour PK profile on both Days 1 and 15 was to be repeated. At a minimum, 
however, the pre-dose PK blood samples were to be collected on Day 1 of each treatment cycle 
of CO-1686 HBr. All Phase 1 patients on freebase were transitioned to CO-1686 HBr by 
November 2013. 
Investigators could transition patients to a lower dose of CO-1686 HBr based on their clinical 
judgment.  
RP2D Selection  
The RP2D for evaluation in Phase 2 was to be selected based on overall safety and tolerability, 
PK, and estimates of efficacious exposures extrapolated from nonclinical data and Phase 1 of the 
study. The RP2D could or might not be the same as the MTD identified in Phase 1. For example, 
if the MTD was not reached with a plateau of exposures despite increasing drug dose, or if 
exposure at the MTD was much higher than the level believed to be required for efficacy, or if 
subsequent cycles of treatment provided additional insight on the safety profile, then the RP2D 
might be different, though not higher, dose than the MTD. 
Additionally, if an MTD was not identified in the dose range expected, a dose that met the 
tolerability and PK criteria could be selected as the RP2D and dose escalation could continue 
concurrently to fully explore the exposure and dose relationship. If it is determined that a higher 
dose in one of the further escalation cohorts is considered likely to be superior to the originally 
selected RP2D, patients in the Phase 2 or RP2D expansion cohort may be escalated to the new 
RP2D dose if they meet the intrapatient dose escalation criteria. 
Under Amendment 4, the RP2D initially identified in Phase 1 was to be the starting dose for 
patients enrolled into Phase 2. The RP2D was selected as 750 mg BID based on early efficacy 
data from the dose escalation portion of the study and patients are actively enrolling in cohorts A 
(later-stage) and B (earlier-stage disease) at 750 mg BID under Amendment 4. Subsequently, as 
the Phase 1 data matured, the recommended Phase 2 dose was adjusted to 625 mg BID based on 
robust antitumor activity at lower doses (Figure 2) and anticipated optimal tolerability. However, 
since an MTD was not reached in Phase 1 and the small sample size of each Phase 1 cohort, it 
was not possible to demonstrate a clear dose response for either efficacy or toxicity and 
consequently the recommended Phase 2 dose at 625 mg BID is an estimation. Amendment 6 
allowed for the evaluation of 2 additional doses of CO-1686 (500 mg BID and 625 mg BID) in 
patients who have progressed on initial EGFR inhibitor therapy and in patients with later line 
disease. Amendment 7 allowed the sponsor to enroll the RP2D of 625 mg BID before the 500 mg 
BID dose in order to increase experience with the RP2D to support the ongoing Phase 2 and 
Phase 3 CO-1686 programs. In addition, Amendment 7 allowed the later-line patient population 
in Cohort A (more prevalent population) to continue enrollment as long as the earlier line patient 
population, Cohort B, is open for enrollment. Building on the observed efficacy of CO-1686, a 
more precise estimate of optimum dose will be derived from these expanded dose levels. 
Food-Effect PK Evaluation  
The effect of food on CO-1686 PK parameters was assessed in a subset of patients.  
PK Evaluation of Once-daily Dosing versus Twice-daily or Three-times-daily Dosing 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 56 of 151 
Confidential 
Dosing was started with QD dosing, and subsequently the effect of BID and three-times-daily 
(TID) dosing on CO-1686 PK parameters was assessed in a subset of patients.  
ECG Monitoring and Effect on QTc 
Serial ECG monitoring is performed on all patients in Phase 1, at baseline, on Cycle 1 Day 1 and 
Cycle 1 Day 15 (prior to dosing and at the multiple time points as described in Table 13 
following dosing with CO-1686), and on Day 1 of all subsequent cycles (prior to dosing and at 
the estimated Tmax (2 hours) postdose), at the End of Treatment, and as clinically indicated on all 
patients in order to assess the effect of oral CO-1686 on the QTc interval. All Phase 1 ECGs will 
be performed on equipment provided by the sponsor (or designee) and reviewed by site 
personnel and a core/central laboratory.  
Triplicate ECG monitoring will be conducted as indicated up to and including Cycle 12 for all 
patients. For patients who are ongoing at this time and for whom QT has been < 470 ms 
throughout the study, ECG monitoring may be subsequently reduced to predose evaluation and 
taken every 3rd cycle thereafter.  
Treatment-Extension Period 
Upon completion of Cycle 1, Phase 1 patients could participate in an optional 
Treatment-extension Period, which begins on Day 1 of Cycle 2, if the patient has tolerated the 
drug, has not progressed and if the treating physician believes it is in the patient’s best interest to 
continue treatment. Oral CO-1686 will be administered daily during this period (21-day cycles) 
until disease progression, except as described below, unacceptable toxicity, patient or physician 
request to discontinue, death, or termination of the study.  
5.1.3 Phase 2 
This phase of the study will consist of a screening phase to establish study eligibility and 
document baseline measurements, an open-label treatment phase, in which patients will receive 
CO-1686 to ascertain safety and efficacy until protocol-defined disease progression. Each 21-day 
period of treatment will represent one cycle, with dosing initiated on Cycle 1 Day 1. Eligible 
patients are those who are confirmed by the sponsor’s central laboratory (Cohorts A and B) or by 
local assessment (Cohort C) to have the T790M mutation in FFPE tumor tissue. 
The assessments for patients in each Phase 2 cohort will be identical.  
Enrollment into Part 2 was initiated in February 2014 under Amendment 4 when a RP2D of 
750 mg BID was selected. This initial RP2D of 750 mg BID was selected based on early Phase 1 
efficacy data and two expansion cohorts (Cohorts A and B) are currently enrolling at this dose. 
As the Phase 1 efficacy data matured, the recommended dose was adjusted to 625 mg BID, and 
under this amendment patients will no longer enroll in the 750 mg BID dose level for Cohorts A 
and B, but will be assigned by the sponsor to receive either 625 mg BID or 500 mg BID in these 
cohorts. Patients who are already receiving 750 mg BID will continue at this dose. Cohort A 
comprises later-line patients who have previously received one or more prior EGFR TKI, and 
irrespective of the number and order of previous lines of NSCLC therapy, and who are not 
eligible for Cohort B. Cohort B comprises earlier-line patients who have had radiologic 
progression on one prior single agent EGFR TKI for advanced/metastatic NSCLC, and have had 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 57 of 151 
Confidential 
no intervening chemotherapy between EGFR TKI and planned treatment with CO-1686. 
Amendment 6 expanded the size of cohorts A and B from up to approximately 40 patients each 
to approximately 190 patients each, and creates 1 additional cohort (Cohorts C with up to 
100 patients), in order to assess safety and efficacy at 2 dose levels, and to compare ORR 
between dose levels. Cohort C (625 mg BID) consists of patients that fulfill eligibility for 
Cohorts A or B, has signed consent for the study, has a positive local T790M biopsy within 
60 days of C1D1 but T790M negative or inadequate test by central laboratory. Patients will be 
allocated to the 500 mg BID or 625 mg BID dose levels as defined in Section 7.2. Amendment 7 
allowed the sponsor to enroll the RP2D of 625 mg BID before the 500 mg BID dose in order to 
increase experience with the RP2D in order to support the ongoing Phase 2 and Phase 3 
CO-1686 programs. In addition, Amendment 7 allowed the later-line patient population in 
Cohort A (more prevalent population) to continue enrollment as long as the earlier line patient 
population, Cohort B, is open for enrollment. Patients will be able to enroll in Cohort C as long 
as the study is recruiting patients for the other cohorts and may contain up to approximately 
100 patients. 
Separately within each new dose level in Cohorts A and B (500 mg BID and 625 mg BID), the 
objective response rate will be evaluated in the first 12 patients. Within Cohort C, the objective 
response rate will be evaluated separately for patients from the 2 patient populations represented 
by cohorts A and B. If 0 responses are observed in the first 12 patients within each dose level 
(Cohorts A and B) or patient population (Cohort C) are observed then the respective level or 
population may be discontinued due to a lack of efficacy. If zero PR or CR responses are 
observed in 12 patients then there is a high probability that the true objective response rate is less 
than 20%. In addition to the futility analyses within each cohort, formal safety data reviews will 
occur following the enrollment of every 50 patients and approximately every 6 months once 
enrollment is completed and as long as patients remain on treatment. The review committee will 
include external experts and sponsor personnel. The external experts will include, but not be 
limited to, the coordinating PIs of the study. The sponsor’s reviewers will include the Medical 
Monitor, Chief Medical Officer, and Biostatistician. The protocol will be amended as appropriate 
to incorporate additional patient safety monitoring if new safety signals are noted at any review.  
If a dose level is closed for further evaluation, ongoing patients in that dose level may be allowed 
to dose escalate to a higher dose level if they meet the intra-patient dose escalation criteria.  
In Phase 2, CO-1686 will be administered daily in 21-day cycles and patients will undergo serial 
assessments for anti-tumor efficacy, drug safety, and patient reported outcomes. Serial blood 
sampling for longitudinal quantitative assessment of circulating tumor DNA (ctDNA) will be 
conducted. For all Phase 2 patients, protocol-specified treatment will continue until there is 
progression by RECIST Version 1.1, clinical tumor progression or unacceptable toxicity as 
assessed by the investigator. Patients will undergo serial assessments for anti-tumor efficacy, 
drug safety, and patient reported outcomes. Serial blood sampling for longitudinal quantitative 
assessment of ctDNA will be conducted. 
Tumor assessments will be performed by the investigative site and scans will be evaluated 
locally for patient treatment decisions; however, copies of tumor scans will be collected centrally 
to facilitate independent evaluation for ORR, duration of response, PFS and other assessments as 
deemed necessary by the sponsor. Following disease progression on CO-1686, patients can 
consent to participate in an optional additional biopsy before subsequent-line therapy is initiated.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 58 of 151 
Confidential 
CO-1686 PK Profile at Doses Evaluated in Phase 2 and Metabolite Profiling 
A subset of 10 patients at 500 mg BID and 625 mg BID, at a minimum, in Phase 2 will have 
blood samples collected over 24 hours on Cycle 1 Day 1 and Cycle 1 Day 15 to fully 
characterize the PK profile of CO-1686 at the dose level. Additionally, at the 625 mg dose level, 
at a minimum, three of the subset of 10 patients will have additional blood samples collected on 
Day 1 (predose sample only) and Day 15 (postdose samples) of Cycle 1 for assessment of plasma 
metabolites. If the three-patient subset is deemed insufficient, additional patients in Phase 2 will 
have additional blood samples collected for the assessment of plasma metabolites. The CO-1686 
parent and metabolite profiling will be conducted at a subset of sites. 
All patients in Phase 2 will have trough level PK samples collected on Cycle 1 Day 15, and on 
Day 1 of all subsequent cycles beginning at Cycle 2 up to and including Cycle 9 
(Section 9.8.3.2). 
ECG Monitoring and Effect on QTc 
In the subset of 10 patients at 500 mg BID and 625 mg BID, at a minimum, for whom a detailed 
PK profile will be collected in Phase 2, on Cycle 1 Days 1 and 15 ECGs will be monitored over 
the PK profiling period as outlined in Table 13. Additionally, serial ECG monitoring will be 
performed: at baseline and on Day 1 of all subsequent cycles (prior to dosing and at the 
estimated Tmax (2 hours) postdose), at the End of Treatment, and as clinically indicated in order 
to assess the effect of oral CO-1686 on the QTc interval.  
In all other Phase 2 patients, serial ECG monitoring will be performed: at baseline, on Cycle 1 
Day 1, Cycle 1 Day 15 and on Day 1 of all subsequent cycles (prior to dosing and at the 
estimated Tmax (2 hours) postdose at these visits), at the End of Treatment, and as clinically 
indicated. All ECGs will be performed on equipment provided by the sponsor (or designee) and 
reviewed by site personnel and a core/central laboratory. 
Triplicate ECG monitoring will be conducted as indicated up to and including Cycle 12 for all 
patients. For patients who are ongoing at this time and for whom QT has been < 470 ms 
throughout the study, ECG monitoring may be subsequently reduced to predose evaluation and 
taken every 3rd cycle thereafter.  
5.1.4 Treatment Post-progression (Phase 1 and Phase 2) 
Patients may opt to continue to receive treatment with CO-1686 following radiographic 
progression as outlined in the NCCN guidelines for treatment of NSCLC with EGFR TKIs if 
patient provides additional consent, the investigator feels it is in the patient’s best interest and 
with sponsor approval. In general, eligible patients may include those with asymptomatic 
systemic progression or locally symptomatic progression, such as brain metastases amenable to 
local treatment, with concomitant asymptomatic systemic progression or continued systemic 
disease control. This must be discussed with the sponsor and will be reviewed on a case-by-case 
basis.  
If a patient continues treatment post-progression, all study assessments including safety 
assessments, efficacy assessments, QOL administration, and blood collection for biomarker 
analysis and exploratory research should continue per protocol and data should be captured in the 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 59 of 151 
Confidential 
eCRF. The patient should be discontinued from treatment once it is clear that no further clinical 
benefit can be achieved. 
5.1.5 End of Treatment and Follow-up (Phase 1 and Phase 2) 
All patients should return to the clinic for End of Treatment assessments 28 (±7) days after the 
last dose of oral CO-1686 has been administered. During Phase 1 and Phase 2, AEs will be 
assessed from the time of informed consent through 28 days after the last dose. 
5.1.6 Extension Phase (Phase 1 and Phase 2) 
In mid-2015, Clovis submitted a New Drug Application for the use of rociletinib in patients with 
T790M-positive NSCLC.  In June 2016, the FDA issued a Complete Response Letter to Clovis 
stating that more data are required to approve rociletinib for use outside of a clinical trial.  Based 
on this outcome, Clovis decided to discontinue development of CO-1686 for NSCLC.  Patients 
will be informed of this change in the development plans in an update to the informed consent 
form for this study.  Those patients who continue to derive clinical benefit from study treatment 
will be allowed to continue on the study at the discretion of the Principal Investigator in an 
extension phase.   
The purpose of this protocol amendment is to add a new Extension Phase to allow patients to 
continue on study but to avoid unnecessary collection of data that will no longer be analyzed or 
required for regulatory purposes, whilst maintaining an appropriate level of safety monitoring. A 
new schedule of assessments for the Extension Phase as well as a complete description of 
procedures has been provided in Appendix D.  This schedule will replace all schedules of 
assessments in Section 9.1 and should be followed for all patients. 
For patients who wish to continue rociletinib treatment post progression, it is important that a full 
exploration of alternative treatment options between patients and their treating physicians takes 
place. 
5.2 
Study Schema 
The study schema in Figure 6 and Figure 7 summarize the treatment designs for Phase 1 and 
Phase 2 of the study.

Clovis Oncology, Inc. 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
 
Clovis-CO-1686-008__PROTOCOL 
Page 60 of 151 
Confidential 
Figure 6: 
Study Schema Phase 1 
Dose-Escalation Period 
(Cycle 1)a
EOS 
Evaluation
28 (±7) 
days after 
last dose of 
CO-1686
Screening Period
(Day -28 to Day 0)
Treatment 
Extension 
CO-1686 
daily
 
21 day 
cycles
Optional Treatment-Extension Period
(Cycle 2 and subsequent cycles)c
Screening 
Assessments
Within 28 
days of first 
dose of
 CO-1686
Tumor Scans
Every even 
cycle up to 
Cycle 6, then 
every 3 cycles
Between Days 
14-21
HBr Salt 
Cohort X 
(MTD 
exceeded)
(n=3-6)
After completion of Cycle 1, patients may 
enter optional Treatment-Extension Period
Define RP2D and 
Proceed to 
Phase 2 
Patients with 
EGFR T790M 
mutation 
(n=up to 80)
Oral CO-1686 (dose to be determined per cohort)
Safety 
Evaluations 
 
(through 28 
days after last 
dose of
 CO-1686)  
Freebase 
Cohort 1
150 mg daily
q.d.
(n=3)
Food Effect 
PK 
Evaluationb 
(in a subset of 
patients)
Freebase 
Subsequent 
Cohorts 
(Escalate dose 
17-100%, up to 
1800mg daily)
(n=3-6)
Disease 
progression, 
unacceptable 
toxicity, or other 
reason for 
discontinuation of 
CO-1686
HBr Salt
Cohort 1
1000 mg daily
(dose equivalent to 
1800mg daily 
freebase)
(n=3-10)
HBr Salt 
Subsequent 
Cohorts
(escalate dose 
10-25%)
(n=3-10)
 
a The Dose-escalation Period comprises one cycle of treatment (21-day cycle) within each cohort. 
b The food-effect PK evaluation will be conducted in a subset of patients (see Table 10 and Table 12). 
c After completing Cycle 1, patients may enter an optional Treatment-extension Period 
 

Clovis Oncology, Inc. 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
 
Clovis-CO-1686-008__PROTOCOL 
Page 61 of 151 
Confidential 
Figure 7:  
Study Schema Phase 2 
At Cycle 1 and Cycle 2, patients will undergo assessments on Days 1, 4 (Cycle 1 only), 8 (Cycle 1 only)  and 15. Assessments will be 
on Day 1 of all subsequent Cycles. * ICF signature required before any protocol specific assessments, but signature of ICF does not 
start screening period timing. The first screening activity performed after ICF signature will begin the 28 day screening period.  
 
 
 
EOS 
Evaluation
28 (±7) days 
after last 
dose of 
CO-1686
and
Safety
Evaluations
(through 28 
days after last 
dose of CO-
1686)
Screening 
Assessments
Within 28 days 
of first dose of 
CO-1686
Phase 2:  Dose-Expansion Period
Screening 
Period
(Day -28 to Day 
0)
End of Study 
(EOS)
Oral CO-1686
COHORT A
T790M+ patients, 
progressing on >1 prior TKI 
and any number of prior 
NSCLC therapy
COHORT B
T790M+patients 
progressing directly after 
1st single agent TKI, with 
no intervening therapy
Study assessments every 21 (3) days and tumor assessments at the end of 
Cycles 2, 4, and 6, and every 3 cycles after Cycle 6 until study drug 
discontinuation. Additional glucose monitoring during Cycle 1 (Day 4, Day 8) 
and Cycle 2 (Day 15).
D
A
Y
1
Cycle 2
Cycle 3 and 
subsequent cycles
Cycle 1
D
A
Y
15
D
A
Y
1
D
A
Y
15
D
A
Y
4
D
A
Y
8
D
A
Y
1
625 mg BID; N~75
500mg BID; N~75
625 mg BID; N~75
500 mg BID; N~75
DISEASE PROGRESSION
(Optional post-progression tumor biopsy)
CO-1686 treatment post-progression (approval by sponsor required), 
with continued study assessments and tumor assessments per protocol
T
R
E
A
T
M
E
N
T 
D
I
S
C
O
N
T
I
N
U
A
T
I
O
N
Follow-Up 
for 
Subsequent 
therapies 
and survival 
(~every 2 
months)
Follow-Up 
Period
 (FU)
S
I
G
N
I
C
F
*
COHORT C
Qualifies for Cohorts A or B 
except central T790M not + 
T790M + by local test 
625mg BID; N~100
750 mg BID; N~ 40
750 mg BID; N~ 40

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 62 of 151 
Confidential 
5.3 
End of Treatment 
The trial will be completed when all enrolled patients have discontinued treatment and 
completed the End of Treatment follow-up visit.  
5.4 
Two Monthly Follow-up 
All patients in Phase 2 will be followed at approximately two monthly intervals to monitor 
survival status and subsequent NCSLC cancer therapy until death or sponsor decision, whichever 
comes first. After discontinuation of protocol-specified treatment, subsequent anticancer therapy 
use will be recorded. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 63 of 151 
Confidential 
6 
STUDY POPULATION 
6.1 
Number of Patients and Sites 
In Phase 1, 57 patients have initiated treatment with CO-1686 free base and approximately 
53 patients have been treated with CO-1686 HBr at approximately 8 study sites. Amendment 6 
expanded the Phase 2 portion of the study to a total of around 490 patients, with up to 
approximately 40 patients from both Cohort A and B at the dose level of 750 mg BID and up to 
approximately 75 patients from both Cohort A and B for each dose level of 500 mg BID and 
625 mg BID. Cohort C will also enroll up to approximately 100 patients from approximately 
50 study sites. Amendment 7 allowed the sponsor to enroll the RP2D of 625 mg BID before the 
500 mg BID dose in order to increase experience with the RP2D to support the ongoing Phase 2 
and Phase 3 CO-1686 programs and to increase the total number of patients by approximately 
125 patients in Cohort A, for a total of approximately 725 patients (Phase 1 N≈110; Phase 2 
N≈605). Cohort A will contain approximately 40 patients for dose level 750 mg BID and up to 
approximately 275 patients for combined dose levels of 500 mg BID and 625 mg BID. Cohort B 
will contain approximately 40 patients for dose level 750 mg BID, and up to approximately 150 
patients for combined dose levels of 500 mg BID and 625 mg BID. Cohort C will contain up to 
approximately 100 patients at 625 mg BID dose. 
6.2 
Inclusion Criteria 
All patients enrolling into either Phase 1 or Phase 2 must meet all of the following inclusion 
criteria: 
1. Histologically or cytologically confirmed metastatic or unresectable locally advanced 
NSCLC 
2. Documented evidence of a tumor with one or more EGFR mutations excluding exon 20 
insertion 
3. Have undergone a biopsy of either primary or metastatic tumor tissue within 60 days of 
dosing with study drug and have tissue available to send to the sponsor lab or are able to 
undergo a biopsy during screening 
a. 
No change (except for washout or dose adjustment if required to manage adverse 
effects) in antitumor therapy regimen is allowed between the biopsy and CO-1686 
initiation. 
4. Life expectancy of at least 3 months 
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 
6. Age 18 years 
7. Adequate hematological and biological function, confirmed by the following screening 
laboratory values: 
- Bone Marrow Function 
o Absolute neutrophil count (ANC) 1.5 x 109/L 
o Platelets 100.0 × 109/L  
o Hemoglobin 9 g/dL (or 5.6 mmol/L) 
- Hepatic Function 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 64 of 151 
Confidential 
o Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 3 × upper 
limit of normal (ULN); if liver metastases, 5 × ULN  
o Bilirubin 2 × ULN* 
- Renal Function  
o Serum creatinine 1.5 × ULN 
- Electrolytes 
o Potassium and magnesium within normal range. Patients may receive supplements to 
meet this requirement 
8. Written consent on an Institutional Review Board/Independent Ethics Committee-approved 
Informed Consent Form (ICF) prior to any study-specific evaluation  
* In Phase 1 and Phase 2, patients with documented Gilbert’s syndrome and conjugated bilirubin within the normal 
range may be allowed into the study. In this event it will be documented that the patient was eligible based on 
conjugated bilirubin levels. 
 
Patients enrolling into Phase 1 must also meet the following inclusion criteria: 
• 
Prior treatment with EGFR-directed therapy (e.g. erlotinib, gefitinib, neratinib, afatinib, or 
dacomitinib [PF299804]). Prior chemotherapy, including intervening chemotherapy, is 
allowed. 
- 
The washout period for an EGFR TKI is a minimum of 3 days  
- 
The washout period for chemotherapy is a minimum of 14 days  
- 
Any toxicity related to prior treatment must have resolved to Grade 1 or less  
Be willing and able to eat a high-fat breakfast on Day 1 of the study (only applicable to 
food-effect cohort). 
 
Patients enrolling into Phase 2 Cohort A must also meet the following inclusion criteria:  
• 
Disease progression confirmed by radiologic assessment while on treatment with EGFR- 
TKI (e.g. erlotinib, gefitinib, neratinib, afatinib, or dacomitinib). Prior chemotherapy, 
including intervening chemotherapy before planned initiation of CO-1686, is allowed. 
- The washout period for an EGFR TKI is a minimum of 3 days before planned Cycle 1 
Day 1 
- The washout period for chemotherapy is a minimum of 14 days before planned 
Cycle 1 Day 1 
- Any toxicity related to prior treatment must have resolved to Grade 1 or less by 
Cycle 1 Day 1  
• 
Documented evidence of T790M mutation in EGFR determined by PCR-based testing of 
the tumor tissue using the sponsor’s central laboratory following disease progression on 
the most recent EGFR TKI therapy 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 65 of 151 
Confidential 
• Measurable disease according to RECIST Version 1.1.  
• Do not qualify for enrolment to Phase 2 Cohort B*  
*Patients meeting eligibility criteria for Cohort B must be enrolled into this cohort rather than Cohort A. 
 
Patients enrolling into Phase 2 Cohort B must also meet the following inclusion criteria: 
• 
Disease progression confirmed by radiologic assessment while on treatment with the first 
single agent EGFR TKI (e.g., erlotinib, gefitinib, afatinib, or dacomitinib)  
- EGFR TKI treatment discontinued ≤ 30 days prior to planned initiation of CO-1686  
- The washout period for an EGFR TKI is a minimum of 3 days before planned Cycle 1 
Day 1 
- No intervening  treatment between cessation of single agent EGFR TKI and planned 
initiation of CO-1686 
- Previous treatment with ≤1 prior chemotherapy (excluding prior neo-adjuvant or 
adjuvant chemotherapy or chemoradiotherapy with curative intent)  
- Any toxicity related to prior EGFR inhibitor treatment must have resolved to Grade 1 
or less by Cycle 1 Day 1  
• 
Documented evidence of T790M mutation in EGFR as determined by PCR-based testing 
of tumor tissue using the sponsor’s central lab following disease progression on the first 
single agent EGFR TKI. 
• 
Measureable disease according to RECIST Version 1.1 
 
Patients enrolling into Phase 2 Cohort C must also meet the following inclusion criteria: 
• 
Must meet all inclusion criteria of either Phase 2 Cohorts A or B except for documented 
evidence of T790M mutation using the sponsor’s central lab. 
• 
Only patients with evidence of a positive T790M mutation result from a local lab but with 
an insufficient specimen for central lab analysis (judged by the central lab analysis) or a 
negative central T790M mutation result from the same biopsy specimen collected within 
60 days of treatment with CO-1686. 
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 66 of 151 
Confidential 
6.3 
Exclusion Criteria 
Any of the following criteria will exclude patients from study participation: 
1. Documented evidence of an Exon 20 insertion activating mutation in the EGFR gene  
2. Active second malignancy, i.e. patient known to have potentially fatal cancer present for 
which he/she may be (but not necessarily) currently receiving treatment. 
• Patients with a history of malignancy that has been completely treated, with no evidence 
of that cancer currently, are permitted to enroll in the trial provided all chemotherapy was 
completed > 6 months prior and/or bone marrow transplant > 2 years prior 
3. Known pre-existing interstitial lung disease 
4. Patients with Leptomeningeal carcinomatosis are excluded. Other CNS metastases are only 
permitted if treated, asymptomatic, and stable (not requiring steroids for at least 4 weeks 
prior to start of study treatment). 
5. Treatment with prohibited medications [e.g., concurrent anticancer therapy including other 
chemotherapy, radiation treatment  or hormonal treatment (except corticosteroids and 
megesterol acetate), or immunotherapy]  14 days prior to treatment with CO-1686 
6. Patients who are currently receiving treatment with any medications that have the potential to 
prolong the QT interval and the treatment cannot be either discontinued or switched to a 
different medication before starting CO-1686 
• see http://crediblemeds.org/ for a list of QT-prolonging medications 
7. Prior treatment with CO-1686 or other drugs that target T790M positive, mutant EGFR with 
sparing of wild type EGFR, e.g., AZD9291, HM61713, TAS-121 
8. Any of the following cardiac abnormalities or history: 
a. 
Clinically significant abnormal 12-lead ECG, QT interval corrected using Fridericia’s 
method (QTCF) > 450 msec  
b. Inability to measure QT interval on ECG 
c. 
Personal or family history of long QT syndrome 
d. Implantable pacemaker or implantable cardioverter defibrillator 
e. 
Resting bradycardia < 55 beats/min 
9. Non-study related surgical procedures 7 days prior to administration of CO-1686. In all 
cases, the patient must be sufficiently recovered and stable before treatment administration 
10. Females who are pregnant or breastfeeding 
11. Refusal to use adequate contraception for fertile patients (females and males) for 12 weeks 
after the last dose of CO-1686 
12. Presence of any serious or unstable concomitant systemic disorder incompatible with the 
clinical study (e.g., substance abuse, uncontrolled intercurrent illness including active 
infection, arterial thrombosis, and symptomatic pulmonary embolism) 
13. Any other reason the investigator considers the patient should not participate in the study 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 67 of 151 
Confidential 
6.4 
Patients or Partners of Patients of Reproductive Potential 
Pregnancy is an exclusion criterion and women of childbearing potential must not be considering 
getting pregnant during the study. Female patients who are more than 2 years postmenopausal or 
have had a hysterectomy will not be considered of childbearing potential. Female patients of 
childbearing potential must have a negative serum pregnancy less than 3 days prior to 
administration of the first dose of CO-1686. If the serum pregnancy results are not available on 
Day 1, a urine pregnancy test can be performed on Day 1 to confirm that the patient is not 
pregnant prior to dosing. Both values should be entered in the eCRF. Another serum pregnancy 
test will be performed at the End of Treatment visit. 
Patients of reproductive potential (males and females) must practice double-barrier methods of 
contraception during treatment and for 12 weeks following the last dose of CO-1686. Adequate 
contraception is defined as double-barrier protection (i.e., condom plus spermicide in 
combination with a diaphragm, cervical/vault cap, or intrauterine device). Patients using birth 
control pills, a birth control patch, or getting injections of hormones to prevent pregnancy must 
switch to a double barrier method while on study and for 12 weeks after last dose.  
Patients will be instructed to notify the investigator if pregnancy is discovered either during or 
within 12 weeks of completing treatment with CO-1686. This also applies to male patients 
whose partners become pregnant within the 12 week period. 
6.5 
Waivers of Inclusion/Exclusion Criteria 
No waivers of these inclusion or exclusion criteria will be granted by the investigator and the 
sponsor or its designee for any patient enrolling into the study.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 68 of 151 
Confidential 
7 
DESCRIPTION OF STUDY TREATMENTS AND DOSE 
MODIFICATIONS 
7.1 
Description of Investigational Product  
CO-1686 Capsule (Used in Phase 1 Only until November 2013) 
CO-1686 free base is provided as white, hard capsules for PO administration in two dosage 
strengths:  50 mg and 150 mg. Each capsule consists of CO-1686 drug substance, Vitamin E 
polyethylene glycol succinate (Vitamin E TPGS) and polyethylene glycol (PEG 400) filled in a 
hypromellose capsule shell. Each 50 mg CO-1686 capsule contains approximately 23 IU of 
Vitamin E in the form of Vitamin E TPGS. Each 150 mg CO-1686 capsule contains 
approximately 70 IU of Vitamin E in the form of Vitamin E TPGS. Excipients used are generally 
regarded as safe (GRAS) and commonly used as food additives. The capsules are packaged in 
blisters. Capsules will be supplied to the study sites by the sponsor. CO-1686 capsules should be 
stored at room temperature (15°C to 30°C; 59°F to 86°F) in their original packaging. 
Child-resistant wallets containing CO-1686 capsules are labeled according to applicable 
regulations for investigational products. Patients should be advised not to open or crush capsules. 
Additionally, patients should be advised not to take capsules with visible cracks or leaks. 
Defective capsules should be returned to the study site.  
CO-1686 HBr Tablet (Used in Phase 1 from August 2013 and in All Phase 2 Cohorts) 
All patients in Phase 1 who had initiated treatment with CO-1686 free base capsules and were 
ongoing in the study when CO-1686 HBr 500 mg BID was cleared for safety, were transitioned 
to CO-1686 HBr. This transition was completed in November 2013 and after this date only 
CO-1686 HBr tablets are used in this study. 
CO-1686 HBr is provided as yellow, film-coated tablets for PO administration in two dosage 
strengths made from the same drug blend. The strengths are achieved by adjusting the total tablet 
weight. The strengths are differentiated by tablet shapes: 125 mg strength is a round tablet and 
250 mg strength tablet is an oval tablet. Each tablet consists of CO-1686 HBr drug substance, 
silicified microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, 
copovidone, magnesium stearate and hypromellose based film coat. Excipients used are 
generally regarded as safe (GRAS). Tablets are packaged along with desiccant in high density 
polyethylene bottles closed with a child-resistant cap. Tablets will be supplied to the study sites 
by the sponsor. CO-1686 HBr tablets should be stored in their original packaging at room 
temperature (15°C to 30°C; 59°F to 86°F). 
Child-resistant bottles containing CO-1686 HBr tablets are labeled according to applicable 
regulations for investigational products. Patients should be advised not to split or crush tablets. 
Additionally, patients should be advised not to take tablets with chips or other gross visual 
defects. Defective tablets should be returned to the study site. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 69 of 151 
Confidential 
7.2 
Method of Assigning Patients to Treatment Groups 
All patients enrolled in the study will receive oral CO-1686. Patients in Phase 2 will receive one 
of 3 dose levels of CO-1686.  
Phase 2 Cohorts A and B were initiated under Amendment 4 at a dose of 750 mg BID and are 
currently enrolling at this dose. As the Phase 1 efficacy data matured, the recommended dose 
was adjusted to 625 mg BID, and under Amendment 6, patients were no longer enrolled in the 
750 mg BID dose level for Cohorts A and B, but were to be assigned by the sponsor to receive 
either 625 mg BID or 500 mg BID in Cohorts A and B. Patients who are already receiving 
750 mg BID will continue at this dose. Amendment 6 also increased the size of cohorts A and B 
from up to approximately 40 patients each to approximately 190 patients each (up to 
approximately 75 patients per dose level of 500 mg BID and 625 mg BID, with up to 
approximately 40 patients for 750 mg BID), and created 1 additional cohort (Cohort C) with up 
to 100 patients. Amendment 7 allowed the sponsor to enroll the RP2D of 625 mg BID before the 
500 mg BID dose in order to increase experience with the RP2D to support the ongoing Phase 2 
and Phase 3 CO-1686 program. Note that, under Amendment 7, as allocation to dose level is not 
randomized, availability of the central T790M testing result will not be required before 
enrollment, so long as the following criteria are met: 
a. 
Have undergone a biopsy of either primary or metastatic tumor tissue within 60 days of 
dosing with study drug and have tissue available to send to the sponsor’s lab or are able 
to undergo a biopsy during screening. No change (except for washout or dose adjustment 
if required to manage adverse effects) in antitumor therapy regimen is allowed between 
the biopsy and CO-1686 initiation (Study Inclusion Criterion 3); 
AND 
b. Local positive T790M result from biopsy taken at same time as central testing biopsy, 
with results available for sponsor review before enrollment 
7.3 
Preparation and Administration of Protocol-Specified Treatment 
Patients should take CO-1686 as directed by the treating physician. Each dose should be taken 
with 8 oz. (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should 
be swallowed whole.  
If a patient misses a dose (i.e. does not take it within 6 hours of the scheduled time), he or she 
should resume taking CO-1686 with their next scheduled dose. Missed or vomited doses will not 
be made up. 
The investigator or designee will be responsible for distributing the appropriate strength(s) of 
oral CO-1686 tablets to all patients. A sufficient number of tablets will be provided to the patient 
to last until the next scheduled visit. Patients will be instructed to record daily doses taken or not 
taken on a patient diary, and will be instructed to bring their CO-1686 tablets and diary to the 
next scheduled visit for reconciliation by site personnel. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 70 of 151 
Confidential 
7.3.1 Phase 1 Requirements for Fasting 
During the initial stages of Phase 1, patients were asked to fast before and after ingestion of 
CO-1686. Patients who are asked to fast were required to avoid consuming food for 2 hours prior 
to, and for 2 hours after, ingesting the dose, except as noted below.  
On Cycle 1, Day 1 and Day 15, the patient was required to fast for 8 hours prior to and 2 hours 
after ingesting the dose.  
7.3.2 Phase 1 Requirements for Taking CO-1686 with Food 
During Phase 1, after the PK data for the fed/fasted comparison was available, patients were 
asked to ingest CO-1686 with food. Patients who are asked to take CO-1686 with food were 
required to ingest the drug with a meal or within 30 minutes of a meal.  
7.3.3 Food-Effect PK Analysis Fed and Fasted Requirements 
Patients participating in the food-effect PK evaluation were required to take a single dose of 
CO-1686 1 week prior to the start of continuous daily dosing. On this day, patients underwent 
blood sampling for PK at the time points specified in Section 9.8.3.  
Fasted Condition on Day -7 
The patient was instructed to arrive for the visit on Day -7 having fasted for at least 8 hours. The 
patient was instructed to ingest oral CO-1686 with 8 oz. (240 mL) of room temperature water. 
No food or water was allowed for at least 2 hours postdose.   
Fed Condition Day 1 
Patients participating in the food-effect PK evaluation were required to consume a high-fat, high-
calorie breakfast meal just prior to taking the dose of CO-1686 on Day 1 of the first cycle. On 
this day, patients will undergo blood sampling for PK at the time points specified in 
Section 9.8.3. 
Following an overnight fast of at least 8 hours, and following performance of all required 
predose assessments, patients consumed a high-fat (approximately 50% of total caloric content), 
high-calorie (approximately 800 to 1000 calories total) breakfast meal containing approximately 
500 to 600 calories from fat, approximately 250 calories from carbohydrates, and approximately 
150 calories from protein, in the clinic. Patients began eating the meal 30 (±5) minutes prior to 
the planned administration of oral CO-1686. Patients were required to eat this meal in 30 minutes 
or less; however, oral CO-1686 had to be administered 30 minutes after the start of the meal, 
regardless of whether the meal was completed or not. Patients ingested oral CO-1686 with 8 oz. 
(240 mL) of room temperature water. No food was allowed for at least 4 hours postdose. No 
water was allowed for at least 2 hours postdose.  
The breakfast meal was provided by the clinical site or patient. A list of appropriate breakfast 
meals was provided to clinical sites and patients by the sponsor. An example test meal would be 
two eggs fried in butter, two strips of bacon (or ham or cheese of similar caloric content), two 
slices of toast with butter, 4 oz. of hash brown potatoes, and 8 oz. (240 mL) of whole-fat milk. A 
different breakfast meal to suit specific dietary requirements could be substituted by the clinical 
site or patient, provided that it has a similar amount of calories and protein, and carbohydrate and 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 71 of 151 
Confidential 
fat content. The nutrient content of the proposed meal must be calculated and submitted to the 
sponsor (or designee) for review and approval at least 3 days in advance of the patient’s 
scheduled fed day. 
7.4 
Starting Dose and Dose Modifications of Protocol-specified Treatment 
7.4.1 Phase 1  
7.4.1.1 
Dose Escalation  
In Phase 1, dose-escalation and de-escalation with CO-1686 HBr was guided by a CRM as 
described in Appendix C. 
The key attributes of this method are: 
• The results of the CO-1686 free base dose escalation from this study along with the 
results of Study CO-1686-016 were used to develop a prior distribution for dose-toxicity 
relationship that is expected with CO-1686 HBr  
• In addition, this study applied a stopping rule to bring the trial to an early halt if the MTD 
has been established before including the entire sample size of patients for Phase 1 
• After completing the toxicity assessment for each patient, the probability that a certain 
dose level administered was the final RP2D was calculated 
• The target toxicity level was set at 33%. The RP2D of this study, if guided by the safety 
data, was determined to be the next lowest dose below the level at which 33% of patients 
would experience the DLT 
Dose escalation was initiated with three patients enrolled at 500 mg twice daily as this dose had 
been determined to provide exposure comparable to that of CO-1686 free base at 900 mg BID, 
which was a dose level that has been cleared for safety.  
Following the first cohort, subsequent cohorts of at least three patients were treated at the dose 
level with an estimated probability of DLT closest to the target toxicity level (33%).  
Dose escalation with CO-1686 HBr proceeded as described in Table 9.  All dose increments 
were following discussion and agreement with the investigators.  
Table 9:  
Final Dose Escalation Plan with CO-1686 HBr 
Maximum Daily Dose 
BID Dosing 
% increase in Exposure from Previous Dose 
1000 mg daily  
500 mg BID 
Exposure similar to CO-1686 free base 900 mg BID 
1500 mg daily  
750 mg BID  
50% 
2000 mg daily 
1000 mg BID  
33% 
1250 mg daily  
625 mg BID  
n/a 
All dose escalations and de-escalations were agreed upon between the investigators and sponsor. 
The safety monitoring window was 21 days. Subsequent dose cohorts were opened after at least 
three patients had completed the 21 day safety monitoring window without a DLT.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 72 of 151 
Confidential 
There was open enrollment into the study with the following restrictions: 
• There could be no more than six patients with unknown DLT information at any time. We 
refer to the number of patients waiting for DLT information as the “queue.” 
• Complete DLT information was required for at least three patients at a dose before escalation 
to a higher dose.  
Dose escalation evaluation was completed in January 2014 and all doses tested were judged safe 
(i.e., less than 33% incidence of dose limiting toxicities in Cycle 1). 
7.4.1.2 
Maximum Tolerated Dose 
The MTD was defined as the maximum daily oral dose at which < 33% of patients experience a 
DLT during Cycle 1. If a DLT was observed dose escalation was adjusted in accordance with the 
dose escalation/de-escalation criteria defined in Amendment 4.  
7.4.1.3 
Dose-limiting Toxicity  
DLTs in Phase 1 are defined as any of the following events that occur during Cycle 1 (Safety and 
PK Assessment Period) in patients enrolled into a DLT evaluable cohort  and are assessed by the 
investigator as probably, possibly or definitively related to CO-1686. Where applicable, events 
will be classified according to the National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI CTCAE) Version 4.0.10 Dose limiting toxicities include: 
• Grade 3 or 4 skin eruption, nausea, vomiting, diarrhea or hyperglycemia despite the use of 
adequate/maximal medical intervention and/or prophylaxis 
• Any Grade 4 skin rash/eruption with extensive superinfection requiring IV antibiotics and 
with life-threatening consequences (e.g., rash acneiform, papulopustular rash, 
Stevens-Johnson Syndrome) 
• Any nonhematological CTCAE Grade 3 or greater AE (except alopecia,  nausea, vomiting, 
diarrhea or hyperglycemia if well controlled by systemic medication) 
• ANC < 0.5 × 109/L > 5 days duration or febrile neutropenia (i.e., fever > 38.3°C with ANC 
< 1.0 × 109/L) 
• Platelets < 25 × 109/L or platelets < 50 × 109/L with bleeding requiring a platelet transfusion 
• Grade 4 anemia (life-threatening consequences, urgent intervention indicated) 
• Delayed recovery from toxicity related to CO-1686 treatment that delays scheduled 
retreatment for > 14 days 
7.4.1.4 
Definition of DLT-evaluable Patient  
In order to be considered evaluable for dose-escalation decisions, a patient in Phase 1 must have: 
• Received at least 80% of scheduled doses and have completed Cycle 1, Day 21, without a 
DLT, or 
• Have experienced a DLT in Cycle 1 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 73 of 151 
Confidential 
If a patient withdrew from the study without having met either of these criteria, then an 
additional patient was to be enrolled in that cohort.  
7.4.1.5 
Recommended Phase 2 Dose 
The RP2D for evaluation in Phase 2 was to be selected based on overall safety and tolerability, 
PK, and estimates of efficacious exposures extrapolated from nonclinical data and Phase 1 of the 
study. The RP2D could or might not be the same as the MTD identified in Phase 1. For example, 
if the MTD was not reached, if exposure at the MTD was much higher than the level believed to 
be required for efficacy, or if subsequent cycles of treatment provide additional insight on the 
safety profile, then the RP2D might be a different, although not a higher, dose than the MTD. 
Additionally, if an MTD was not identified in the dose range expected, a dose that met the 
tolerability and PK criteria could be selected as the RP2D and dose escalation could continue 
concurrently to fully explore the exposure and dose relationship. If it was determined that a 
higher dose in one of the further escalation cohorts was considered likely to be superior to the 
originally selected RP2D, patients in the Phase 2 or RP2D expansion cohort could be escalated to 
the new RP2D dose if they met the intrapatient dose escalation criteria. 
Under Amendment 4, the RP2D initially identified in Phase 1 was to be the starting dose for 
patients enrolled into Phase 2. The RP2D was selected as 750 mg BID based on early efficacy 
data from the dose escalation portion of the study and patients are actively enrolling in cohorts A 
(later-stage) and B (earlier-stage disease) at 750 mg BID under Amendment 4. As the Phase 1 
efficacy data matured, the recommended dose was adjusted to 625 mg BID, and under 
Amendment 6 patients will no longer enroll in the 750 mg BID dose level for Cohorts A and B, 
but will be assigned by the sponsor to receive either 625 mg BID or 500 mg BID in Cohorts A 
and B. However, since an MTD was not reached in Phase 1, the overall safety profile is similar 
across all CO-1686 HBr dose ranges, and additional efficacy data indicates viable responses 
occur across all CO-1686 HBr dose ranges, under Amendments 6 and 7 the dose response 
relationship of two doses (500 mg BID and 625 mg BID) will be further explored in Phase 2 with 
the introduction of additional dose levels for patients in earlier stage and later stage of disease. 
7.4.1.6 
Intrapatient Dose Escalation 
Intrapatient dose escalation may be permitted by the sponsor if the maximum drug-related 
toxicity experienced by the patient is Grade 2 and provided that the dose level to which the 
patient will escalate has already been cleared at the time of the proposed dose increase. More 
than one dose escalation may be allowed per patient after approval by the sponsor and the patient 
has completed 2 cycles at the previous escalated dose without experiencing > Grade 2 
drug-related adverse event.  
In the event that a patient’s dose is escalated, the new dose should be initiated at Day 1 of the 
cycle and a full PK profile will be repeated. It is preferable that the 24-hour PK is repeated on 
Days 1 and 15 of the cycle at the higher dose. At a minimum, however, the 24-hour PK should 
be repeated on Day 15. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 74 of 151 
Confidential 
7.4.1.7 
Dose Expansion at Cleared Dose Levels 
Once a dose level had been cleared as described in Section 7.4.1.1, additional patients could be 
enrolled at a dose lower than the current projected MTD for the purpose of further characterizing 
pharmacokinetics and efficacy. The data from these additional patients was used to help inform 
subsequent dose escalation decisions; however, these patients were not formally included in the 
CRM algorithm.   
7.4.2 Phase 2 
7.4.2.1 
Starting Dose 
Under Amendment 4, the RP2D initially identified in Phase 1 was the starting dose for patients 
enrolled into Phase 2. The RP2D selected on completion of dose escalation in Phase 1 was 
750 mg BID. As the Phase 1 efficacy data matured, the recommended dose was adjusted to 
625 mg BID, and under Amendment 6, patients will no longer enroll in the 750 mg BID dose 
level for Cohorts A and B, but will be assigned by the sponsor to receive either 625 mg BID or 
500 mg BID in Cohorts A and B. Patients who are already receiving 750 mg BID will continue 
at this dose. 
Since an MTD was not reached in Phase 1 and the overall safety profile looked similar across the 
CO-1686 HBr dose range evaluated, and efficacy was observed across the whole dose range, 
under Amendments 6 and 7 the dose response relationship of two doses will be further explored 
in Phase 2 (500 mg BID and 625 mg BID).  
If emerging dose-response information supports the termination of a cohort or cohorts, then this 
decision will be shared with sites. If a cohort is closed for further evaluation, ongoing patients in 
that cohort may be allowed to dose escalate to a higher dose level if they meet the intra-patient 
dose escalation criteria.  
7.4.3 Dose Modification Criteria (Phase 1, Phase 2 and the Extension Phase) 
Under Amendment 6, dose reduction steps are allowed for each patient (Phase 1 and Phase 2), 
with the overall number of dose reduction steps at the investigator’s discretion. Dose reductions 
can occur in 125 mg increments BID from the starting dose (e.g., from 625 mg BID to 500 mg 
BID). For non-serious adverse events, and upon sponsor approval, a TID dosing regimen may be 
used to maintain plasma exposure, whilst reducing the peak plasma concentrations which may 
drive toxicity [e.g., from 625 mg BID (1250 mg total dose/day) to 375 mg TID (1175 mg total 
dose/day) or 500 mg BID (1000 mg total dose/day) to 250 mg TID (750 mg total dose/day)].  
For Grade 3 or 4 hematologic and non-hematologic toxicities (except for nausea/vomiting, 
alopecia, QTc prolongation and hyperglycemia), the dose should be initially reduced to the next 
lower dose BID and, if persistent, can be further reduced (250 mg increment BID less than 
starting dose) for subsequent doses if the investigator and the sponsor do not believe treatment 
discontinuation is required. Re-escalation of dose after resolution of adverse events must be 
discussed and approved by the sponsor. Dose reductions below 250 mg increment BID less than 
starting dose must be discussed and agreed with the sponsor before they are implemented.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 75 of 151 
Confidential 
Once the dose has been reduced, treatment continues at that dose level until the next visit; no 
dose escalation is possible between visits. If a patient continues to experience toxicity after three 
dose reduction steps, or if dosing with CO-1686 is interrupted for > 14 consecutive days due to 
toxicity, treatment should be discontinued unless otherwise agreed between the investigator and 
the sponsor before reintroduction of study drug. 
Management of Prolonged QTc 
ECGs will be measured throughout the study as described in the protocol. Readings for QT 
prolongation will be based on the average seen in the ECGs for each time point. Patients are 
required to have within-normal-range potassium and magnesium at enrollment, and these 
electrolytes should be maintained within range during CO-1686 treatment, if necessary using 
supplementation. If QTC prolongation of CTCAE Grade 3 are observed, CO-1686 will be held 
until the event has improved to Grade 1. CO-1686 can then be re-started at a reduced dose upon 
approval by the sponsor. After two dose reduction evaluations, if CTCAE Grade 3 or above QTC 
prolongation recurs, then CO-1686 will be discontinued unless agreed with the sponsor that 
additional dose reduction can be evaluated. If QTC prolongation changes of CTCAE Grade 4 are 
observed at any time, CO-1686 will be discontinued permanently. 
Management of Hyperglycemia 
CO-1686 causes hyperglycemia in some patients and those with pre-existing diabetes may 
require more frequent monitoring and/or adjustments of diabetic medication. Clinical experience 
with CO-1686 suggests hyperglycemia generally occurs within the first 3 weeks of treatment, 
leading to the need for more intensive glucose monitoring during the first several weeks of the 
study. In order to minimize the risk of symptomatic hyperglycemia, the following schedule is 
recommended: 
Fasting glucose will be measured at the following visits: Screening/baseline visit, Cycle 1/Day 1, 
Cycle 1/Day 4 (±1 day), Cycle 1/Day 8 (±1 day), Cycle 1/Day 15 (±1 day), Cycle 2/Day 1, 
Cycle 2/Day 15 (±1 day), Cycle 3/Day 1, Cycle 4/Day 1, Cycle 5/Day 1, etc. and End of 
Treatment visit. 
The following guidelines for management of hyperglycemia have been developed by consulting 
an endocrinologist and based on experience in the Phase 1 study. Whilst the blood glucose 
thresholds for intervention outlined below should be followed, management of individual 
patients should be based on local practices and the treating physician’s judgment. In all cases, the 
prescribing information should be followed and maximum approved dose of the 
anti-hyperglycemic agent should not be exceeded. 
1. Additional monitoring outside of per protocol schedule is not needed if fasting glucose is 
less than 125 mg/dL (< 6.94mmol/L). 
2. If fasting glucose ≥125 mg/dL (≥6.94 mmol/L) and ≤160 mg/dL (≤8.88 mmol/L), 
patients will be asked to perform self-monitoring of blood glucose using finger stick 
blood testing. Tests should be performed at home once a day for 2 weeks, making note of 
time, fasted/fed state and glucose levels in a monitoring log provided. Patients should 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 76 of 151 
Confidential 
bring this monitoring log to scheduled visits and review with treating physician. If patient 
observes at home 2 or more fasting glucose measurements > 160 mg/dL (> 8.88 mmol/L) 
and/or 2 or more random glucose measurements > 200 mg/dL (> 11.01 mmol/L) (or a 
combination of the two) before their next scheduled clinic visit, they should call their 
health care professional (HCP), inform the study site and schedule a visit as soon as 
possible with the treating physician. If glucose > 160 mg/dL (> 8.88 mmol/L) (fasting) or 
> 200 mg/dL (> 11.01 mmol/L) (random) is confirmed, then start treatment with 
metformin or anti-hyperglycemic agent of choice (See Figure 8). 
3. If fasting glucose > 160 mg/dL (> 8.88 mmol/L) and < 250 mg/dL (< 13.87 mmol/L) on 
more than 2 occasions, start metformin or anti-hyperglycemic agent of choice. Patients 
should perform self-monitoring of blood glucose using finger stick blood testing. Tests 
should be performed at home once a day, making note of time, fasted/fed state and 
glucose levels in a monitoring log provided. Patients should bring this monitoring log to 
scheduled visits and review with treating physician. 
4. If fasting glucose ≥250 mg/dL (≥13.87 mmol/L), and the patient is not symptomatic, 
manage as for step 3 above. If the patient is symptomatic, then hold CO-1686 and bring 
glucose under control acutely, if necessary using insulin with conversion to metformin or 
anti-hyperglycemic agent of choice once plasma glucose is controlled. Once patient is 
asymptomatic and deemed appropriate for additional therapy, CO-1686 may be 
re-introduced at a reduced dose, with concomitant metformin/anti-hyperglycemic agent of 
choice. Patients should perform self-monitoring of blood glucose using finger stick blood 
testing. Tests should be performed at home twice a day, before breakfast and before 
dinner, making note of time, fasted/fed state and glucose levels in a monitoring log 
provided. Patients should bring this monitoring log to scheduled visits and review with 
treating physician.  
Use of metformin or other anti-hyperglycemic agents should follow package insert/label. 
Metformin is contraindicated in patients with renal disease or renal dysfunction, among others, 
and use should follow package insert and approved label. In order to minimize known GI toxicity 
associated with metformin use, the extended release form is recommended to improve 
tolerability.23 Additional recommendations to avoid GI toxicity with metformin include starting 
treatment at a reduced dose (500 mg QD) for 72 hours, increasing to 500 mg BID for 72 hours, 
and only if necessary, and increasing up to 1000 mg BID. If plasma glucose is not adequately 
controlled after 2 weeks with the regimen outlined above, reduce dose of CO-1686 and consider 
consultation with an endocrinologist. 
End of Treatment 
When CO-1686 is discontinued, need and use of anti-diabetic medications should be reassessed 
and patients treated appropriately. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 77 of 151 
Confidential 
Figure 8: 
Guidelines for Management of Hyperglycemia 
 
 
*Guidelines intend to assist in managing patients that are non-diabetic at study start only. FG = fasting plasma or 
serum glucose (in mg/dL) 
7.5 
Accountability of Protocol-specified Treatment 
Study personnel will maintain accurate records of CO-1686 shipments/receipts, administration, 
and drug reconciliation. The study site is responsible for the return or destruction of CO-1686 as 
required. A drug management system will manage CO-1686 inventory at all sites. The system 
will be required to manage study treatment requests and shipments. 
Any CO-1686 accidentally or deliberately destroyed must be accounted for. All wallets or bottles 
must be accounted for prior to their destruction at the study center. Unused wallets or bottles 
should be destroyed locally. If destruction at the site is not possible, supply should be returned to 
the drug depot. During the course of the study and at completion of the study, the number of 
wallets or bottles of CO-1686 shipped, destroyed, and returned must be reconciled.  
7.6 
Blinding/Masking of Treatment 
This is an open-label study; the investigational product will not be blinded or masked. All 
patients enrolled will receive oral CO-1686. 
7.7 
Treatment Compliance 
Documentation of dosing will be recorded in a study specific diary card provided by the sponsor 
(or designee). Study site personnel will enter the scheduled daily doses and the number of tablets 
to be taken each day. Dosing non-compliance is defined as a patient missing > 14 days of 
medication in a 21 day visit window for 2 consecutive visits. Patients meeting non-compliance 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 78 of 151 
Confidential 
criteria will be required to discontinue study treatment. Study site personnel will review the 
dosing information with the patient (or legally authorized representative) on scheduled clinic 
visit days. Patients (or legally authorized representative) will be asked to record dosing 
information for oral CO-1686 taken at home in the diary card and to bring the diary card and all 
unused capsules or tablets with them to scheduled clinic visits. A compliance check and tablet 
count will be performed by study personnel. Study site personnel will record compliance 
information on the electronic case report form (eCRF) and retain the diary card in the patient’s 
medical record.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 79 of 151 
Confidential 
8 
PRIOR AND CONCOMITANT THERAPIES 
The investigational product of CO-1686 free base provided high daily doses of vitamin E in the 
form of vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS). Patients 
were required not take supplemental vitamin E, other than a daily multivitamin, while receiving 
study treatment with CO-1686 free base. These considerations do not apply to patients receiving 
CO-1686 HBr. Since November 2013, all patients are on CO-1686 HBr. 
Medications known to produce QT prolongation should be avoided during the study.  If a drug 
that has the potential to cause QT prolongation is indicated to control adverse events (e.g., 5HT3 
inhibitor for nausea/vomiting), and the investigator believes that the patient is benefiting from 
CO-1686 therapy, then additional ECGs should be performed to monitor QTc changes. The use 
of such concomitant medications and an appropriate ECG monitoring plan should be agreed 
between the investigator and the sponsor. Acceptable antiemetics with low potential to affect 
QTc include phenothiazines and corticosteroids. 
All procedures performed (e.g. thoracentesis, etc.) and medications used during the study must 
be documented on the eCRF.  
8.1 
Anticancer or Experimental Therapy 
No other anti-cancer therapies (including chemotherapy, radiation, hormonal treatment [except 
corticosteroids and megestrol acetate], antibody or other immunotherapy, or other experimental 
drugs) of any kind will be permitted while the patient is participating in the study.  
Palliative radiation therapy intended to provide relief of cancer-related symptoms is permitted 
while the patient is on study, as long as there is no evidence of disease progression per RECIST 
Version 1.1. Treatment should be held while the patient is undergoing radiotherapy. 
Additionally, a patient who continues treatment post-progression may undergo radiation or other 
procedures to specific lesions post-progression, if the patient continues to benefit from treatment 
overall. See Section 5.1.4 for more details. 
8.2 
Hematopoietic Growth Factors and Blood Products 
Erythropoietin, darbepoetin alfa, and/or hematopoietic colony-stimulating factors for treatment 
of cytopenias should be administered according to institutional guidelines. Prophylactic use of 
these agents is not permitted. 
Transfusion thresholds for blood product support will be in accordance with institutional 
guidelines. 
8.3 
CYP450 Isoenzyme Inhibitors and Inducers  
In vitro studies suggested the potential involvement of CYP2C8 in CO-1686 metabolism and 
thus, clinically, there is potential for CO-1686 plasma concentrations to be increased in the 
presence of co-administered potent inhibitors of CYP2C8. CYP 2D6 appears to play a minor 
role, but its involvement in CO-1686 metabolism cannot be fully ruled out. Therefore, caution 
should be exercised with strong inhibitors of CYP2C8 and CYP2D6. For example, CYP2C8 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 80 of 151 
Confidential 
inhibitors such as gemfibrozil, trimethoprim, glitazones, montelukast, and quercetin and 
CYP2D6 inhibitors such as bupropion, fluoxetine, paroxetine, and quinidine should be avoided.  
Inducers of CYP2C8 and CYP2D6 have the potential to decrease CO-1686 exposure. Therefore, 
caution should be exercised with rifampin, an inducer of CYP2C8. No inducers of CYP2D6 have 
been identified.  
With regards to strong inhibitors or inducers of CYP2C8 and CYP2D6, selection of an 
alternative concomitant medication with no or minimal enzyme inhibition potential is 
recommended. 
Caution should be exercised in patients receiving oral CO-1686 and requiring concomitant 
medication with warfarin (Coumadin), nonsteroidal anti-inflammatory drugs (NSAIDs), or 
clopidogrel, as CO-1686 moderately inhibited CYP2C8, CYP2C9 and CYP2C19 activities 
in vitro. Selection of an alternative concomitant medication with no or minimal enzyme 
inhibition potential is recommended. 
8.4 
P-gp Substrates, Inhibitors and Inducers 
Because CO-1686 is a P-gp inhibitor in vitro, caution should be exercised in patients receiving 
oral CO-1686 and requiring concomitant medication with digoxin, a P-gp substrate. Patients 
taking digoxin who are enrolled in the study are required to have digoxin levels monitored 
regularly via standard clinical practice. 
CO-1686 is a P-gp substrate and thus, P-gp inhibitors have the potential to increase CO-1686 
exposure. As such, caution should be exercised in patients receiving CO-1686 and the following 
P-gp inhibitors: amiodarone, azithromycin, captopril, carvedilol, clarithromycin, conivaptan, 
cyclosporine, diltiazem, dronedarone, erythromycin, felodipine, itraconazole, ketoconazole, 
lopinavir and ritonavir, quercetin, quinidine, ranolazine, verapamil. 
Conversely, P-gp inducers have the potential to decrease CO-1686 exposure. Caution should be 
exercised in patients receiving CO-1686 and the following P-gp inducers: avasimibe, 
carbamazepine, phenytoin, rifampin, St John’s wort, and tipranavir/ritonavir. 
8.5 
Other Concomitant Medications 
Therapies considered necessary for the patient’s well-being may be given at the discretion of the 
investigator and should be documented on the eCRF. Other concomitant medications, except for 
analgesics, chronic treatments for concomitant medical conditions, or agents required for 
life-threatening medical problems, should be avoided. Herbal and complementary therapies 
should not be encouraged because of unknown side effects and potential drug interactions, but 
any taken by the patient should be documented appropriately on the eCRF. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (Version 9.0), 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 81 of 151 
Confidential 
9 
STUDY PROCEDURES 
9.1 
Schedule of Assessments 
Table 10 summarizes the procedures and assessments to be performed for all Phase 1 patients in 
all cohorts.  
Table 11 summarizes the procedures and assessments to be performed for all patients enrolled in 
Phase 2 (Cohorts A-C). 
Table 12 provides the schedule of PK sampling for all patients in Phase 1 and Phase 2, and the 
schedule of full PK sampling in a subset of 10 patients at 500 mg BID and 625 mg BID, at a 
minimum, in Phase 2 and metabolite sampling in a subset of 3 of these Phase 2 patients at the 
625 mg BID dose level. 
Table 13 provides the schedule of PK sampling and ECG collection in Phase 1 and for the subset 
of Phase 2 patients participating in the RP2D (625 mg BID) detailed PK profiling. 
All procedures and assessments are to be completed within ±1 day of the scheduled time point 
and are synchronized with administration day of oral CO-1686 treatment unless otherwise 
indicated. NOTE: With the approval of this protocol version, all ongoing patients, both Phase 1 
and Phase 2, will be treated on the Extension Phase of the study and should follow the schedule 
of assessments provided in Appendix D.  

Clovis Oncology, Inc. 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
 
Clovis-CO-1686-008__PROTOCOL 
Page 82 of 151 
Confidential 
Table 10: 
Protocol CO-1686-008 Schedule of Assessments – Phase 1:  All Cohorts 
Procedureb 
Screening 
Period 
Treatment Period 
 
Dose-Escalation Period (Daily Dosing)a 
Optional 
Treatment-
Extension Period 
End of 
Treatment 
Day -28 to  
Day 0c 
Food-Effect Only  
Cycle 1 Day -7d 
Cycle 1  
Day 1e 
Cycle 1  
Days 8  
and 15 
Cycles 2+ 
Day 1f 
 
Informed Consent 
X 
 
 
 
 
 
Medical/Oncology History 
X 
 
 
 
 
 
Physical Examination  
X 
X 
X 
Xh 
X 
X 
ECOG Performance Status 
X 
X 
X 
 
X 
X 
Vital Signsg and Weight 
X 
X 
X 
X 
X 
X 
Prior/Concomitant Medications and Procedures 
X 
X 
X 
X 
X 
X 
Contraceptive Counselingi 
X 
 
 
 
 
X 
Serum Pregnancy Testj 
X 
 
 
 
 
X 
Hematology, Including Reticulocytesk 
X 
X 
X 
X 
X 
X 
Fasting Serum Chemistryl 
X 
X 
X 
X 
X  
X 
Urinalysism 
X 
 
 
 
 
 
Tumor Scans Including Brain Imagingn 
X 
 
 
 
X 
X 
Tumor Biopsyo 
X 
 
 
 
 
X 
Blood for biomarker/EGFR Mutational Testing and 
exploratory researchp 
X 
 
X 
X 
X 
X 
Blood for CYP Evaluation (Optional Sampling) 
 
 
X 
 
 
 
Adverse Eventsq 
X 
X 
X 
X 
X 
X 
CO-1686 Dispensing / Administration 
 
Xr 
Xr 
X 
X 
 
Patient Diarys 
 
 
Dispense diary 
X 
X 
X 
ECG Assessmentt 
X 
 
X 
X 
X 
X 
Quality of Life Questionnairesu 
 
 
X 
 
X 
X 
High-fat Breakfastv 
 
 
X 
 
 
 
Plasma PK and Serum AAG Samples (Table 12) 
 
X 
X 
X 
X 
 

Clovis Oncology, Inc. 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
 
Clovis-CO-1686-008__PROTOCOL 
Page 83 of 151 
Confidential 
Optional: Urine collection for biomarker research w 
 
 
X 
 
X 
X 
 
 
  AAG = alpha-1 acid glycoprotein; ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST – aspartate aminotranserase; BUN = blood urea nitrogen; CT = 
computed tomography; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; EGFR = epidermal growth factor receptor; EORTC QLQ-C30=European 
Organization for the Research and Treatment of Cancer Quality of Life Questionnaire, Core 30; EORTC QLQ LC13 = European Organization for the Research and Treatment 
of Cancer Quality of Life Questionnaire, Lung Cancer 13; MRI = magnetic resonance imaging; PET = positron emission tomography; PK = pharmacokinetics, RECIST = 
Response Evaluation Criteria in Solid Tumors; WBC = white blood cells. 
a 
= 
CO-1686 will be administered daily for the 21-day treatment period. 
b 
= 
Unless specified, procedure is completed ±1 day of scheduled time point and is synchronized with administration day of CO-1686. 
c 
= 
The screening period for patients participating in the food-effect evaluation will be between Days -28 to Day -8. 
d 
= 
Applies to patients participating in food-effect evaluation only. 
e 
= 
Procedures required on Day 1 of Cycle 1 may be omitted if completed 3 days earlier during the screening period. 
f 
= 
Starting on Day 1 of Cycle 2, patients may enter an optional Treatment-extension Period, during which CO-1686 is administered daily until the patient experiences 
disease progression, except as described in Section 5.1.4, unacceptable toxicity, request by patient or physician to discontinue treatment, death, or termination of 
the study by the sponsor. 
g 
= 
Vitals (blood pressure, pulse, temperature) should be taken predose on drug administration days 
h 
= 
Physical examination is limited/targeted on Days 8 and 15. 
i 
= 
Patients are to continue using effective contraception for 12 weeks after last dose of CO-1686 and report any pregnancies during this period. 
j 
= 
Serum ß-hCG (evaluated by local labs) will be performed only on women of childbearing potential 3days prior to Cycle 1, Day 1. If the serum pregnancy test 
results are not available on Day 1, a urine pregnancy test can be performed on Day 1 to confirm that the patient is not pregnant prior to dosing.  
k 
= 
Includes hemoglobin, hematocrit, WBC and differential (with ANC), platelet count, and reticulocyte count ≤14 days prior to the first day of dosing. Blood will be 
analyzed by a local laboratory and must be reviewed by the investigator prior to start of CO-1686 administration. Additional tests may be performed at the 
investigator’s discretion. 
l 
= 
Includes total protein, albumin, creatinine, BUN or urea, total bilirubin, alkaline phosphatase, ALT, AST, fasting glucose, sodium, potassium, chloride, CO2, 
calcium, phosphorus, total cholesterol ≤28 days prior to first day of dosing. Glucose must be measured following an 8 hour fast (no food or liquid other than water) 
at the screening and the start of every subsequent cycle. Hemoglobin A1c will be measured at screening and on Day 1 of every other cycle, starting at Cycle 3 
while the patient is on study. Samples may be analyzed by local laboratory.  
m 
= 
Includes dipstick for protein, glucose, blood, pH, and ketones. If dipstick findings are abnormal, then a microscopic evaluation will be performed to assess the 
abnormal findings. 
n 
= 
Tumor scans obtained within 28 days prior to Cycle 1, Day 1, may be used as the baseline scans. Scans will include the pelvis, chest, and abdomen (preferably CT 
scans with appropriate slice thickness per RECIST Version 1.1). Other studies (MRI, X-ray) may be performed if required. The same methods used to detect 
lesions at baseline are to be used to follow the same lesions throughout the study. Brain imaging is required at baseline and must be repeated at follow-up tumor 
assessments for patients with brain lesions. Scans to be performed at screening; at the end of Cycles 2, 4, and 6 (between Days 14-21); every 3 cycles after Cycle 6 
(between 
Days 14-21); and End of Treatment. Tumor scans do not need to be repeated at End of Treatment if < 2 weeks since last scan or the patient had disease progression 

Clovis Oncology, Inc. 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
 
Clovis-CO-1686-008__PROTOCOL 
Page 84 of 151 
Confidential 
at the last scan. If an initial CR or PR is noted at Cycle 7 or beyond, confirmatory scans must be performed 4-6 weeks later. In the case of SD, follow-up 
measurements must have met the SD criteria at least once after study entry at a minimum interval of no less than 6–8 weeks. 
o 
= 
Biopsy of either primary or metastatic tumor tissue. A corresponding blood specimen will be obtained prior to tumor specimen collection. If biopsy was performed 
within 28 days of Cycle 1, Day 1, and no intervening treatment was given, a repeat biopsy is not required if an FFPE tumor tissue block  from the recent biopsy can 
be provided to the sponsor during the Screening period. In this case, the blood specimen should be taken at least 7 days AFTER the biopsy was performed. At 
progression and/or End of Treatment, an optional tumor biopsy can be performed if the patient provides additional written consent. 
p 
= 
Blood sampling for biomarker/EGFR mutational testing and exploratory research will be collected at Screening (prior to biopsy, or at least 7 days AFTER the 
biopsy was performed); predose on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycle 2 and beyond; and at the End of Treatment visit. Refer to the Laboratory 
Manual for blood processing requirements and handling instructions.  
q 
= 
Patients will be monitored for AEs from the time the first dose of CO-1686 is administered through 28 days after the last dose. Study procedure-related AEs that 
occur after signing of the ICF and before administration of CO-1686 will also be collected.  
r 
= 
For the patients participating in the food-effect evaluation only, they will be instructed to fast for at least 8 hours prior to arrival at this visit, and to fast for 4 hours 
after dosing. 
s 
= 
Patient diaries should be collected and reviewed for compliance. 
t 
= 
Anytime during screening; On Cycle 1 Day 1, Cycle 1 Day 15 and Day 1 of each subsequent cycle and End of Treatment as described in Table 13.  
u 
= 
Quality of Life Questionnaires, the EORTC QLQ C30 and LC13 and the Dermatology Life Quality Index, should be collected from the patient prior to dosing at 
Cycle 1, Day 1; then on Day 1 of Cycles 3, 5, and 7. After Cycle 7, questionnaires will be collected every 3 cycles (on Day 1 Cycles 10, 13, 16, etc.), and at End of 
Treatment 
v 
= 
Patients in the food-effect cohort must start a high-fat breakfast (and complete within) 30 minutes prior to dosing with oral CO-1686. 
w 
= 
Urine collection for biomarker research is optional and requires additional consent. Instruct patients to collect 100 mL of the first morning void on Day 1 of Cycles 
1 – 6 and at End of Treatment. Patients will bring urine samples to the clinic during their regularly scheduled visits on the day of collection. Sample collection 
containers and instructions will be provided. Refer to the Laboratory Manual for sample handling and shipping instructions. 

Clovis Oncology, Inc. 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
 
Clovis-CO-1686-008__PROTOCOL 
Page 85 of 151 
Confidential 
Table 11: 
Protocol CO-1686-008 Schedule of Assessments – Phase 2:  All Patients 
Procedureb 
Screening 
Treatment Period 
Phase 2 – Dose-Expansion Period (Daily Dosing)a 
 
Post- Treatment  
Day -28to 
Day -1 
Cycle 1 
Day 1c 
 
 
Cycle 1 
Day 4 
±1 day 
 
 
Cycle 1 
Day 8 
±1 day 
Cycle 1 
Day 15 
Cycle 2 and 
Beyond 
Day 1 
 
 
Cycle 2 
Day 15 ±1 
day 
End of 
Treatment  
(28±7 days after 
last dose) 
 
 
          Follow-Up  
Every 8 ±1 weeks 
after EOT 
Informed Consent* 
X 
 
 
 
 
 
 
 
 
Medical/Oncology History 
X 
 
 
 
 
 
 
 
 
Physical Examination  
X 
X 
 
 
X 
X 
 
X 
 
ECOG Performance Status 
X 
X 
 
 
 
X 
 
X 
 
Vital Signsd and Weight 
X 
X 
 
 
X 
X 
 
X 
 
Prior/Concomitant 
Medications and Procedures 
X 
X 
 
 
X 
X 
 
X 
 
Contraceptive Counselinge 
X 
 
 
 
 
 
 
X 
 
Serum Pregnancy Testf 
X 
 
 
 
 
 
 
X 
 
Hematology, Including 
Reticulocytesg 
X 
X 
 
 
X 
X 
 
X 
 
Fasting Serum Chemistryh 
X 
X 
Fasting 
glucose 
only 
Fasting 
glucose 
only  
X 
X 
Fasting 
glucose only 
X 
 
Urinalysisi 
X 
 
 
 
 
 
 
 
 
Tumor Scans, Including 
Brain Imagingj 
X 
 
 
 
 
X 
 
X 
 
Tumor/Metastasis Biopsy 
for T790M Statusk 
X 
 
 
 
 
 
 
X 
 
Blood for biomarker/EGFR 
Mutational Testing and 
exploratory research l 
X 
X 
 
 
X 
X 
 
X 
 
Blood for CYP Evaluation  
 (Optional Sampling) 
 
X 
 
 
 
 
 
 
 
Adverse Eventsm 
X 
X 
 
 
X 
X 
 
X 
 

Clovis Oncology, Inc. 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
 
Clovis-CO-1686-008__PROTOCOL 
Page 86 of 151 
Confidential 
Procedureb 
Screening 
Treatment Period 
Phase 2 – Dose-Expansion Period (Daily Dosing)a 
 
Post- Treatment  
Day -28to 
Day -1 
Cycle 1 
Day 1c 
 
 
Cycle 1 
Day 4 
±1 day 
 
 
Cycle 1 
Day 8 
±1 day 
Cycle 1 
Day 15 
Cycle 2 and 
Beyond 
Day 1 
 
 
Cycle 2 
Day 15 ±1 
day 
End of 
Treatment  
(28±7 days after 
last dose) 
 
 
          Follow-Up  
Every 8 ±1 weeks 
after EOT 
CO-1686 Dispensing / 
Administration 
 
X 
 
 
X 
X 
 
 
 
Patient Diaryn  
 
Dispense 
Diary 
 
 
X 
X 
 
X 
 
ECG Assessmentso 
X 
X 
 
 
X 
X 
 
X 
 
Quality of Life 
Questionnairesp 
 
X 
 
 
 
X 
 
X 
 
Plasma PK and Serum AAG 
Samples (Table 12) 
 
X 
 
 
X 
X 
 
 
 
Metabolite Profiling 
(Table 12)  
 
X 
 
 
X 
 
 
 
 
Optional: Urine collection 
for biomarker research q 
 
X 
 
 
 
X 
 
X 
 
 
 
 
 
 
 
 
 
 
 
Subsequent Therapies for 
NSCLC 
 
 
 
 
 
 
 
X 
X 
AAG = alpha-1 acid glycoprotein; ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST – aspartate aminotranserase; BUN = blood urea nitrogen; CT = 
computed tomography; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; EGFR = epidermal growth factor receptor; EORTC QLQ-C30=European 
Organization for the Research and Treatment of Cancer Quality of Life Questionnaire, Core 30; EORTC QLQ LC13 = European Organization for the Research and Treatment of 
Cancer Quality of Life Questionnaire, Lung Cancer 13; MRI = magnetic resonance imaging; PET = positron emission tomography; PK = pharmacokinetics, RECIST = Response 
Evaluation Criteria in Solid Tumors; WBC = white blood cells. 
* = ICF signature is required before any protocol specific assessments, but signature of ICF does not start screening period timing. The first screening activity performed after      
ICF signature will begin the 28 day screening period (not including biopsy).  
a = CO-1686 will be administered daily at doses specific for cohorts A-C for the 21-day treatment period. 
b= Unless specified, procedure is completed ±1 day of scheduled time point and is synchronized with administration day of CO-1686. 
c = Procedures required on Day 1 of Cycle 1 may be omitted if completed 3 days earlier during the screening period. 
d = Vital signs (blood pressure, pulse, and temperature) taken predose on drug administration days. 
e = Patients are to continue using effective double-barrier contraception for 12 weeks after last dose of CO-1686 and report any pregnancies during this period. 

Clovis Oncology, Inc. 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
 
Clovis-CO-1686-008__PROTOCOL 
Page 87 of 151 
Confidential 
Procedureb 
Screening 
Treatment Period 
Phase 2 – Dose-Expansion Period (Daily Dosing)a 
 
Post- Treatment  
Day -28to 
Day -1 
Cycle 1 
Day 1c 
 
 
Cycle 1 
Day 4 
±1 day 
 
 
Cycle 1 
Day 8 
±1 day 
Cycle 1 
Day 15 
Cycle 2 and 
Beyond 
Day 1 
 
 
Cycle 2 
Day 15 ±1 
day 
End of 
Treatment  
(28±7 days after 
last dose) 
 
 
          Follow-Up  
Every 8 ±1 weeks 
after EOT 
f = Serum ß-hCG (evaluated by local labs) will be performed only on women of childbearing potential 3 days prior to Cycle 1, Day 1. If the serum pregnancy test results are not 
available on Day 1, a urine pregnancy test can be performed on Day 1 to confirm that the patient is not pregnant prior to dosing. 
g= Includes hemoglobin, hematocrit, WBC and differential (with ANC), platelet count, and reticulocyte count ≤14 days prior to the first day of dosing. Blood will be analyzed by 
a local laboratory and must be reviewed by the investigator prior to start of CO-1686 administration. Additional tests may be performed at the investigator’s discretion. 
h = Includes total protein, albumin, creatinine, BUN or urea, total bilirubin, alkaline phosphatase, ALT, AST, fasting glucose, c-peptide, sodium, potassium, chloride, CO2, 
calcium, magnesium, phosphorus, total cholesterol ≤28 days prior to first day of dosing. Glucose must be measured following an 8 hour fast (no food or liquid other than water). 
Hemoglobin A1c will be measured at screening and on Day 1 of every other cycle, starting at Cycle 3 while the patient is on study. Samples should be analyzed by local 
laboratory. C-peptide will be measured at screening, and Day 1 of every cycle. 
i = Includes dipstick for protein, glucose, blood, pH, and ketones. If dipstick findings are abnormal, then a microscopic evaluation will be performed to assess the abnormal 
findings. 
j = Tumor scans obtained within 28 days prior to Cycle 1, Day 1, may be used as the baseline scans. Scans will include the pelvis, chest, and abdomen (preferably CT scans with 
appropriate slice thickness per RECIST Version 1.1), using the same methods throughout the study that were used to detect lesions at baseline. Other studies (MRI, X-ray) may 
be performed if required. Brain imaging is required at baseline and must be repeated at follow-up tumor assessments for patients with known brain lesions only. Scans to be 
performed at screening; at the end of Cycles 2, 4, and 6 (between Days 14-21); every 3 cycles after Cycle 6 (between Days 14-21); and End of Treatment. Tumor scans do not 
need to be repeated at End of Treatment if < 2 weeks since last scan or the patient had disease progression at the last scan. If an initial CR or PR is noted at Cycle 7 or beyond, 
confirmatory scans must be performed 4-6 weeks later. In the case of SD, follow-up measurements must have met the SD criteria at least once after study entry at a minimum 
interval of no less than 6–8 weeks. 
k = Biopsy of either primary or metastatic tissue to determine EGFR T790M status for enrollment eligibility, and for the development of a validated tissue-based EGFR T790M 
test.   If a biopsy was performed within 60 days of Cycle 1, Day 1, and no intervening treatment was given, a repeat biopsy is not required provided adequate tumor tissue is 
available for EGFR mutation testing by the sponsor’s central laboratory testing to determine eligibility. At progression and/or End of Treatment, an optional tumor biopsy can be 
performed if additional patient consent is obtained. All tumor tissue will be processed locally as formalin-fixed paraffin-embedded (FFPE) tissue. Patients with a negative or 
insufficient result by central laboratory may be enrolled into Cohort C if they have a positive T790M result from a local test of the same biopsy. Assessments performed prior to 
patient signing informed consent are acceptable only if confirmed to have been standard of care.. 
l = Blood sampling for biomarker/EGFR mutational testing and exploratory research will be collected at Screening (prior to biopsy, or at least 7 days AFTER the biopsy was 
performed); predose on Days 1 and 15 of Cycle 1 and Day 1 of Cycle 2 and beyond; and at the End of Treatment visit. Refer to the Laboratory Manual for blood processing 
requirements and handling instructions.  
m = Patients will be monitored for AEs from the time the first dose of CO-1686 is administered through 28 days after the last dose. Study procedure-related AEs that occur after 
signing of the ICF and before administration of CO-1686 will also be collected.  

Clovis Oncology, Inc. 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
 
Clovis-CO-1686-008__PROTOCOL 
Page 88 of 151 
Confidential 
Procedureb 
Screening 
Treatment Period 
Phase 2 – Dose-Expansion Period (Daily Dosing)a 
 
Post- Treatment  
Day -28to 
Day -1 
Cycle 1 
Day 1c 
 
 
Cycle 1 
Day 4 
±1 day 
 
 
Cycle 1 
Day 8 
±1 day 
Cycle 1 
Day 15 
Cycle 2 and 
Beyond 
Day 1 
 
 
Cycle 2 
Day 15 ±1 
day 
End of 
Treatment  
(28±7 days after 
last dose) 
 
 
          Follow-Up  
Every 8 ±1 weeks 
after EOT 
n= Patient diaries should be collected and reviewed for compliance. 
o=Phase 2 patients not taking part in detailed PK profiling - anytime during screening, predose and approximately 2 hours postdose on Cycle 1 Day 1 and Cycle 1 Day 15, 
Predose and approximately 2 hours postdose on Day 1 of each Subsequent Cycle, and at End of Treatment, any time after treatment is discontinued.  
For the subset of Phase 2 patients taking part in the detailed full PK profiling - anytime during screening; On Cycle 1 Day 1,  Cycle 1 Day 15 and Day 1 of each subsequent cycle 
and End of Treatment as described in Table 13 
p = Quality of Life Questionnaires, the EORTC QLQ LC13 and the Dermatology Life Quality Index, should be collected from the patient prior to dosing at Cycle 1, Day 1; then 
on Day 1 of Cycles 3, 5, and 7. After Cycle 7, questionnaires will be collected every 3 cycles (on Day 1 Cycles 10, 13, 16 etc.), and at End of Treatment. 
q =Urine collection is optional and requires additional consent. Instruct patients to collect 100 mL of the first morning void on Day 1 of Cycles 1 – 6 and at End of Treatment. 
Patients will bring urine samples to the clinic during their regularly scheduled visits on the day of collection. Sample collection containers and instructions will be provided. 
Refer to the Laboratory Manual for sample handling and shipping instructions 
 

Clovis Oncology, Inc. 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
 
Clovis-CO-1686-008__PROTOCOL 
Page 89 of 151 
Confidential 
Table 12: 
Protocol CO-1686-008 Schedule of Pharmacokinetic Sampling and Metabolite Sampling – Phase 1 and 2 
Procedure 
For Phase 1 
Food-Effect 
PK Evaluation 
Only 
All Phase 1 Patients 
and 
Phase 2 - Subset of  Patients providing full PK 
profile  (at least 10 Patients at 500 mg BID and 
625 mg BID) 
Phase 2 All Other Patients 
Prior to  
Cycle 1 
 
Cycle 1 
 
Cycles 2+ 
(Phase1)  
(up to and 
including 
Cycle 9-
Phase 2 – 
subset of 
patients only) 
 
Cycle 1 
 
Cycles 2+  
(up to and including 
Cycle 9) 
Day -7 
Day 1 
Day 8 
(Phase 1 only) 
Day 15 
Day 1 
Day 1 
Day 15 
Day 1 
Pre-dose 
 Plasma PK and AAG Serum Samples 
Xa 
Xa 
Xb 
Xb 
Xa 
 
Xb 
Xa 
Post –dose 
Plasma PK Samples and AAG Serum 
Samples 
Xc 
Xc 
 
Xc 
 
 
 
 
Plasma Samples for Metabolite Profiling 
-  
 
Xd 
 
Xe 
 
 
 
 
a 
= 
Any time prior to dosing 
b 
= 
5-10 min prior to dosing 
c 
= 
at 15 (±2) min, 30 (±3) min, 1 hr (±5 min), 1.5 hr (±5 min), 2.5 hr (±5 min), 4 hr (±15 min), 6 hr (±15 min), 8 hr (±15 min), 10 hr (±30 min), and 24 hr (±30 min) 
after dosing 
d 
= 
In a minimum of 3 patients of the 10 patient subset in Phase 2 at 625 mg BID, an additional 2 mL sample will be collected prior to CO-1686 administration. This 
will serve as the baseline sample for subsequent profiling of CO-1686 circulating metabolites 
e 
= 
In a minimum of 3 patients of the 10 patient subset in Phase 2 at 625 mg BID, an additional 2 mL samples will be collected postdose at 30 (±3) min, 1.5 hr (±5 
min), 4 hr (±15 min),  8 hr (±15 min), and 24 hr (±30 min) postdose . This will be the on study sample for profiling of CO-1686 circulating metabolites 
 

Clovis Oncology, Inc. 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
 
Clovis-CO-1686-008__PROTOCOL 
Page 90 of 151 
Confidential 
Table 13: 
Time Points for Pharmacokinetic and 12-Lead ECGs (Triplicate) Evaluations 
 
Phase 1 and Phase 2 Subset of Patients 
Participating in full PK Profiling at 625 mg 
BID 
Other Phase 2 Patients 
All Patients 
 
Cycle 1 
Cycle 2+ 
Screening 
Cycle 1  
 
Cycle 2+ 
EOT 
 
Blood for 
PK 
12-Lead ECGs (Triplicate) 
Time Point 
Day 1 & 
Day 15 
Day 1 
 & Day 15 
Day 1of Cycle 
Screening 
(all patients) 
Day 1 
 & Day 15 
Day 1of Cycle 
EOT 
Predose 
X 
Xa  
Xa 
X 
Xa 
Xa 
Xe 
15 min 
X 
 
 
 
 
 
 
30 min 
X 
 
 
 
 
 
 
1h 
X 
Xb 
 
 
 
 
 
1.5h 
X 
 
 
 
 
 
 
2h 
 
 Xc 
Xc 
 
Xc 
Xc 
 
2.5h 
X 
 
 
 
 
 
 
4h 
X 
Xb 
 
 
 
 
 
6h 
X 
 
 
 
 
 
 
7h 
 
Xd 
 
 
 
 
 
8h 
X 
 
 
 
 
 
 
10h 
X 
Xb 
 
 
 
 
 
24h 
X 
Xb 
 
 
 
 
 
a 12-lead ECG taken (in triplicate) prior to dosing 
b 12-lead ECG taken (in triplicate) 10 minutes prior to PK sampling time point  
c 12-lead ECG taken (in triplicate) 2h postdose 
d 12-lead ECG taken (in triplicate) 7h postdose 
e 12-lead ECG taken (in triplicate) anytime within 28 days of treatment discontinuation 
Note 1:  Screening ECGs are required in triplicate for all patients. 
Note 2: Triplicate ECG monitoring will be conducted as outlined above up to and including Cycle 12. For patients who are ongoing at this time and for whom QT has been 
< 470 ms throughout the study, ECG monitoring may be subsequently reduced to predose evaluation and taken every 3rd cycle thereafter. If Patients do not meet this criteria, 
ECG evaluation should continue on Day 1 of each Cycle as defined above. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 91 of 151 
Confidential 
9.2 
Screening Period 
Following written informed consent, and unless otherwise specified, the following assessments 
should be performed during the 28-day period prior to the first dose of oral CO-1686. 
Assessments performed prior to patient signing informed consent are acceptable only if 
confirmed to have been standard of care. 
• Medical history, including demographic information (birth date, race, gender, etc.) smoking 
status, and oncology history including date of cancer diagnosis, and any surgical procedures. 
• Documented evidence of a tumor with one or more EGFR mutations excluding exon 20 
insertion. 
• Biopsy of primary or metastatic lesions to provide FFPE tumor tissue for EGFR mutational 
testing and companion diagnostic kit development within 60 days of study drug dosing. To 
ensure adequate viable tumor tissue is obtained, image-guided biopsies should be achieved 
with 18- to 20-gauge cutting needles to provide 1 to 3 cores measuring 1 to 1.5 cm in length. 
Tumor samples will be processed locally to yield FFPE tissue blocks. Entire FFPE blocks 
must be submitted to satisfy regulatory requirements for development of the companion 
diagnostic. Blocks will be returned upon request if required for legal or medical treatment 
purposes. EGFR T790M status testing for eligibility for Phase 2 will be done by the 
sponsor’s central lab.  
Patients with a negative or insufficient result by central laboratory may be enrolled into 
Cohort C if they have a positive T790M result from a local test of the same biopsy. 
• Blood sampling for biomarker/EGFR mutational testing and exploratory research. Matched 
blood samples are required and should be collected prior to the biopsy procedure, if possible. 
Detailed sample handling instructions are provided in the Laboratory Manual. 
- If a biopsy was performed within 60 days of Cycle 1/Day 1, and no intervening treatment 
was given, a repeat biopsy is not required if adequate tumor tissue can be provided to the 
sponsor during the screening period. In this case, blood sampling should be taken at least 
7 days AFTER the biopsy was performed.  
• Physical examination by body system, height, and weight. 
• ECOG performance status. 
• Vital signs (blood pressure, pulse, and temperature). 
• Prior and concomitant medications and procedures. 
• Contraceptive counseling. 
• Prior treatment for NSCLC. 
• 12-lead ECG (in triplicate, 10-sec tracings > 2 min apart). 
• Hematology [hemoglobin, hematocrit, white blood cells (WBC) and differential (with ANC), 
and platelet count] and reticulocyte count ≤14 days prior to the first day of dosing. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 92 of 151 
Confidential 
• Fasting serum chemistry [total protein, albumin, creatinine, c-peptide, blood urea nitrogen 
(BUN) or urea, total bilirubin, alkaline phosphatase, ALT, AST, fasting glucose, sodium, 
potassium, magnesium, chloride, CO2, calcium, and phosphorus], total cholesterol and 
hemoglobin A1c ≤ 28 days prior to the first day of dosing. Fasting is defined as an 8 hour fast 
(no food or liquid other than water).  
• Serum pregnancy test (by local laboratory)  3 days prior to the first day of dosing for 
women of childbearing potential. If the serum pregnancy test results are not available on 
Day 1, a urine pregnancy test can be performed on Day 1 to confirm that the patient is not 
pregnant prior to dosing. Both values should be entered in the eCRF. 
• Urinalysis performed on freshly voided clean sample (dipstick for protein, glucose, blood, 
pH, and ketones). If dipstick findings are abnormal based on investigator judgment, then a 
microscopic evaluation will be performed to assess the abnormal findings. 
• Tumor assessments of the chest, abdomen, and pelvis. Assessments should consist of clinical 
examination and appropriate imaging techniques (preferably computed tomography [CT] 
scans with appropriate slice thickness per RECIST Version 1.1); other studies  
(MRI and X-ray) may be performed if required. The same methods used to detect lesions at 
baseline are to be used to follow the same lesions throughout the clinical study. 
o 
Patients with known brain metastases or brain lesions detected at baseline are required 
to repeat brain imaging as part of the follow-up tumor assessments. The same methods 
used to detect brain lesions at baseline are to be used to follow the same lesions 
throughout the clinical study.  
• AE monitoring (from the time the first dose of CO-1686 is administered through 28 days 
after the last dose, including study procedure-related AEs that occur after signing of the ICF 
and before administration of CO-1686 ) 
• Blood sampling for biomarker/EGFR mutational testing and exploratory research that may 
lead to development of a plasma-based EGFR test. Detailed sample handling instructions are 
provided in the Laboratory Manual 
• Optional participation in urine sampling for exploratory research. Instruct patients who have 
provided additional consent to collect first morning void on Day 1 of Cycles 1 – 6, and at the 
End of Treatment visit. Sample collection kits and written instructions will be provided. 
Patients will bring urine samples to the clinic for freezer storage and subsequent batch 
shipping. Sample handling instructions are provided in the Laboratory Manual.  
9.3 
Phase 1 – Dose Escalation Period 
Before enrolling a patient into Phase 1, all eligibility criteria must be satisfied. Patients who 
qualify for the study will be enrolled into the first available cohort. Unless otherwise specified, 
all patients in Phase 1 will undergo the following procedures and assessments. 
Patients will take CO-1686 daily, as directed. Oral CO-1686 should be taken with 8 oz. of water 
and with a meal, or within 30 minutes after a meal. Patients will record the dose and timing of 
administration of oral CO-1686 in their daily dosing diary. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 93 of 151 
Confidential 
9.3.1 Day 1 of Cycle 1 
The following procedures will be completed before CO-1686 is administered: 
• Physical examination 
• Weight 
• ECOG performance status 
• Vital signs 
• 12-lead ECG (in triplicate, 10-sec tracings > 2 min apart) prior to dosing 
• Concomitant medications 
• Hematology, reticulocyte count and serum chemistry. 
• Predose blood sampling for biomarker/EGFR mutational testing and exploratory research 
• Blood sample for CYP evaluation (optional sampling requires additional consent) 
• Optional urine sampling prior to dosing. Instruct patients who have provided additional 
consent to collect first morning void in the sampling kit provided and bring the sample to the 
clinic for freezing and storage. (Cycles 1 – 6 only) 
• AE monitoring including study procedure-related AEs that occur after signing of the ICF and 
before administration of CO-1686  
• Quality of Life Questionnaires (EORTC QLQ Core 30 and Lung Cancer 13  and 
Dermatology Life Quality Index) 
• PK blood and AAG serum samples (any time prior to dosing)  
• Oral CO-1686 will be administered with a meal, or within 30 minutes after a meal. The 
patient must also drink at least 8 ounces (240 mL) of water when taking CO-1686. 
• CO-1686 capsules or tablets will be dispensed to the patient   
The following procedures will be performed over a 24-hour period after dosing. The frequency 
of the PK blood samples may require patients to stay overnight either at the clinic or in the 
vicinity.  
• Postdose PK blood sampling collected at the time points (over 24 hours) specified in 
Section 9.8.3 
• 12-lead ECG (in triplicate, 10-sec tracings > 2 min apart)  as outlined in Table 13, following 
dosing with CO-1686 
• AEs experienced by the patient since signing of informed consent will be documented 
• Concomitant medications administered since dosing will be recorded 
• Diary will be given to patient 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 94 of 151 
Confidential 
9.3.2 Days 8 and 15 of Cycle 1 
Patients will be instructed to refrain from taking their dose of oral CO-1686 at home because the 
dose will be taken during the clinic visit. The following procedures will be completed prior to 
administration of oral CO-1686 on Days 8 and 15 of Cycle 1.  
• Physical examination  
• Weight 
• Vital signs 
• Concomitant medications 
• Hematology (including reticulocyte count) and serum chemistry 
• AE monitoring 
• PK blood sample and AAG serum samples (5 to 10 min prior to dosing) (Day 8 and Day 15). 
• Predose blood sampling for biomarker/EGFR mutational testing and exploratory research.  
• Collection and review of patient diary. 
• Oral CO-1686 will be administered with a meal, or within 30 minutes after a meal. The 
patient must also drink at least 8 ounces (240 mL) of water when taking CO-1686. CO-1686 
capsules or tablets will be dispensed to the patient.  
• Day 15: 12-lead ECG (in triplicate, 10-sec tracings > 2 min apart) prior to dosing. 
• Day 15: postdose 12-lead ECG (in triplicate, 10-sec tracings > 2 min apart), as outlined in 
Table 13, following dosing with CO-1686. 
• Day 15: postdose PK blood sampling collected at the time points (over 24 hours) specified in 
Section 9.8.3. The frequency of the PK blood samples may require patients to stay overnight 
either at the clinic or in the vicinity. 
9.3.3 Phase 1:  Food-effect PK Evaluation 
Patients participating in the food-effect PK evaluation only will take a single dose of CO-1686 
1 week prior to the start of continuous daily dosing. These patients will undergo blood sampling 
for PK evaluation after dosing at the time points specified in Section 9.8.3. On Day 1 of Cycle 1, 
patients will consume a high-fat, high-calorie breakfast meal just prior to taking the dose of 
CO-1686, and will undergo blood sampling for PK evaluation at the time points specified in 
Section 9.8.1. The assessments and procedures are detailed below. 
9.3.3.1 
Day -7 Prior to Cycle 1  
The patient will be instructed to arrive for their visit having fasted for at least 8 hours. The 
following procedures will be completed before receiving the dose of oral CO-1686. Any 
procedure, may be omitted if completed 3 days earlier during the screening period.  
• Physical examination 
• Weight 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 95 of 151 
Confidential 
• ECOG performance status 
• Vital signs 
• Concomitant medications  
• Hematology (including reticulocyte count) and serum chemistry  
• AE monitoring 
• PK blood sample (any time prior to dosing) 
• A single dose of CO-1686 capsules or tablets administered to the patient, with 8 oz. (240 mL) 
of water. Patients must fast for at least 2 hours after dosing.  
The following procedures will be performed over a 24-hour period after dosing. The frequency 
of the PK blood samples may require patients to stay overnight either at the clinic or in the 
vicinity.  
• Postdose PK blood sampling collected at the time points specified in Section 9.8.3 
• AEs experienced by the patient since dosing and/or before leaving the clinic will be 
documented 
• Concomitant medications administered since dosing will be recorded 
9.3.3.2 
Day 1 of Cycle 1 
The procedures described in Section 9.3.1, Day 1 of Cycle 1 should be followed with the 
exception of the fasting requirements. For patients participating in the food-effect PK evaluation, 
the following meal should be ingested following an overnight fast of at least 8 hours  
• High-fat breakfast started (and completed within) 30 minutes prior to dosing with oral 
CO-1686  
9.4 
Phase 1 - Optional Treatment-Extension Period 
Patients may participate in an optional Treatment-Extension Period that begins on Day 1 of 
Cycle 2, if the patient has tolerated the drug, has not progressed and if the treating physician 
believes it is in the patient’s best interest to continue treatment. Patients will take CO-1686 at 
home at about the same time every day, except as noted below. Oral CO-1686 should be taken 
with 8 oz. of water. Patients will record the dose and timing of administration of oral CO-1686 in 
their daily dosing diary. 
9.4.1 Day 1 of Cycle 2 and Subsequent Cycles 
Patients will be instructed to refrain from taking their dose of oral CO-1686 at home on the day 
of their clinic visit because the dose will be taken during the clinic visit. On Day 1 of each cycle, 
patients participating in the optional Treatment-Extension Period will undergo the following 
procedures:   
The following procedures are conducted before dosing with CO-1686: 
• Physical examination 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 96 of 151 
Confidential 
• Weight 
• Vital signs and ECOG performance status 
• 12-lead ECG (in triplicate, 10-sec tracings > 2 min apart) prior to dosing up to and including 
Cycle 12 for all patients. For patients who are ongoing at this time and for whom QT has 
been < 470 ms throughout the study, ECG monitoring may be subsequently evaluated every 
3rd cycle thereafter (starting at Cycle 15). 
• Hematology, including reticulocyte count, and fasting serum chemistry (for assessment of 
fasting glucose). Fasting glucose is required on Day 1 of every cycle. Hemoglobin A1c will 
be measured on Day 1 of every other cycle (Cycle 3, 5, 7, etc.). 
• PK blood and AAG serum samples (any time prior to CO-1686 administration) 
• Blood sampling for biomarker/EGFR mutational testing and exploratory research  
• Optional urine sampling prior to dosing. Instruct patients who have provided additional 
consent to collect first morning void in the sampling kit provided and bring the sample to the 
clinic for freezing and storage. (Cycles 1 -  6 only) 
• Concomitant medications and procedures 
• AE monitoring 
• Collection and review of patient diary 
• Quality of Life Questionnaires (EORTC QLQ Core 30 and Lung Cancer 13 and Dermatology 
Life Quality Index) on Day 1 of Cycles 3, 5, and 7. After Cycle 7, questionnaires will be 
collected every 3 cycles (on Day 1 Cycles 10, 13, 16 etc.), and at End of Treatment.  
• CO-1686 tablets will be dispensed to the patient.  
• Oral CO-1686 will be administered with a meal, or within 30 minutes after a meal. The 
patient must also drink at least 8 ounces (240 mL) of water when taking CO-1686. 
The following procedures will be conducted after CO-1686 dosing: 
• 12-lead ECG (in triplicate, 10-sec tracings > 2 min apart) 2 hours postdose up to and 
including Cycle 12 for all patients. For patients who are ongoing at this time and for whom 
QT has been < 470 ms throughout the study, ECG monitoring at this time point may be 
discontinued.  
• Concomitant medications 
• AE monitoring 
The following procedure is conducted irrespective of dosing time: 
Tumor scans (using the same methodology as was used at screening) at the end of Cycles 2, 4, 
and 6 (between Days 14 to 21), and every 3 cycles after Cycle 6 (between Days 14 to 21) 
9.5 
Phase 2 
The assessments for Phase 2 Cohorts A to C will be identical. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 97 of 151 
Confidential 
Before enrolling a patient into Phase 2, all eligibility criteria must be satisfied. Except as noted, 
patients will take CO-1686 at home as directed, and record in the daily dosing diary.  
9.5.1 Day 1 of Cycle 1 
Procedures required on Day 1 of Cycle 1 may be omitted if completed 3 days earlier during the 
screening period.  Patients should have been fasted for at least 8 hours prior to collection of 
sample for fasting serum chemistry. 
The following procedures are conducted before dosing with CO-1686: 
• Physical examination 
• Weight 
• ECOG performance status 
• Vital signs 
• 12-lead ECG (in triplicate, 10-sec tracings > 2 min apart) prior to dosing 
• Concomitant medications and procedures 
• Hematology (including reticulocytes) and fasting serum chemistry (for assessment of fasting 
glucose). C-peptide will be measured at Day 1 of every cycle.  
• Blood sample for CYP evaluation (optional sampling requiring additional consent) 
• Blood sampling for biomarker/EGFR mutational testing and exploratory research 
• Phase 2 subset of patients taking part in dose level (500 mg BID and 625 mg BID) detailed 
PK profiling only: PK blood and AAG serum samples (any time prior to dosing). In addition 
3 of the patients dosed at 625 mg BID will participate in CO-1686 metabolite profiling 
evaluation as described in Section 9.8.3.2.  
• AE monitoring 
• Quality of Life Questionnaires (EORTC QLQ Core 30 and Lung Cancer 13 and Dermatology 
Life Quality Index) 
• Optional urine sampling prior to dosing. Instruct patients who have provided additional 
consent to collect first morning void in the sampling kit provided and bring the sample to the 
clinic for freezing and storage. (Cycles 1 to 6 only) 
• Dispense tablets to patient 
• Oral CO-1686 will be administered with a meal, or within 30 minutes after a meal. The 
patient must also drink at least 8 ounces (240 mL) of water when taking CO-1686. 
The following procedures will be conducted after CO-1686 dosing: 
• Phase 2 subset of patients taking part in dose level(500 mg BID and 625 mg BID) PK 
profiling only:  PK blood sampling collected at the time points (over 24 hours) as specified in 
Section 9.8.3 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 98 of 151 
Confidential 
• All patients: 12-lead ECG (in triplicate, 10-sec tracings > 2 min apart) 2 hours postdose 
• Phase 2 subset of patients taking part in dose level PK profiling only- 12-lead ECGs (in 
triplicate, 10-sec tracings > 2 min apart), will be measured at the time points outlined in 
Table 13. 
9.5.2 Day 4 of Cycle 1 (±1 Day) 
The following procedures will be performed at C1/Day 4 (±1 day): 
• Fasting Glucose 
9.5.3 Day 8 of Cycle 1 (±1 Day) 
The following procedures will be performed at C1/Day 8 (±1 day):  
• Fasting Glucose 
9.5.4 Day 15 of Cycle 1 (±1 Day) 
Patients will be instructed to refrain from taking their dose of oral CO-1686 at home on the day 
of their clinic visit because the dose will be taken during the clinic visit. The following 
procedures will be completed: 
The following procedures are conducted before dosing with CO-1686: 
• Physical examination 
• Weight 
• Vital signs 
• Concomitant medications  
• Hematology, reticulocyte count and fasting serum chemistry (for assessment of fasting 
glucose). 
• 12-lead ECG (in triplicate, 10-sec tracings > 2 min apart) prior to dosing 
• Blood sampling for biomarker/EGFR mutational testing and exploratory research   
• PK blood and AAG serum samples (5 to 10 min prior to dosing) 
• AE monitoring 
• Collection and review of patient diary 
• Dispense capsules or tablets to patient 
• Oral CO-1686 will be administered with a meal, or within 30 minutes after a meal. The 
patient must also drink at least 8 ounces (240 mL) of water when taking CO-1686. 
The following procedures will be conducted after CO-1686 dosing: 
• Phase 2 subset of patients taking part in dose level (500 mg BID and 625 mg BID) detailed 
PK profiling only:  PK blood sampling collected at the time points (over 24 hours) as 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 99 of 151 
Confidential 
specified in Section 9.8.3. In addition three of the patients dosed at 625 mg BID will 
participate in CO-1686 metabolite profiling evaluation as described in Section 9.8.3.2. 
• All patients: 12-lead ECG (in triplicate, 10-sec tracings > 2 minutes apart) 2 hours postdose 
• Phase 2 subset of patients taking part in dose level (500 mg BID and 625 mg BID) detailed 
PK profiling only - 12-lead ECGs (in triplicate, 10-sec tracings > 2 minutes apart), will be 
measured at the time points outlined in Table 13. 
9.5.5 Day 1 of Cycle 2 and Day 1 of Subsequent Cycles  
Patients will be instructed to refrain from taking their dose of oral CO-1686 at home on the day 
of their clinic visit (Day 1 of the cycle) because the dose will be taken during the clinic visit. The 
following procedures will be completed: 
The following procedures are conducted before dosing with CO-1686: 
• Physical examination 
• Weight 
• ECOG performance status 
• Vital signs 
• 12-lead ECG (in triplicate, 10-sec tracings > 2 min apart) prior to dosing up to and including 
Cycle 12. For patients who are ongoing at this time and for whom QT has been < 470 ms 
throughout the study, ECG monitoring may be subsequently taken every 3rd cycle thereafter.  
• Concomitant medications and procedures 
• Hematology (including reticulocyte count) and fasting serum chemistry (for assessment of 
fasting glucose). Fasting glucose is required on Day 1 of every cycle. Hemoglobin A1c will 
be measured on Day 1 of every other cycle (Cycle 3, 5, 7, etc.). C-peptide will be measured 
at Day 1 of every cycle. 
• PK blood and AAG serum sampling (any time prior to dosing), up to and including Cycle 9 
only 
• Blood sampling for biomarker/EGFR mutational testing and exploratory research 
• Optional urine sampling prior to dosing. Instruct patients who have provided additional 
consent to collect first morning void in the sampling kit provided and bring the sample to the 
clinic for freezing and storage. (Cycles 1 to 6 only) 
• AE monitoring 
• Collection and review of patient diary 
• Quality of Life Questionnaires (EORTC QLQ Core 30 and Lung Cancer 13 and Dermatology 
Life Quality Index) on Day 1 of Cycles 3, 5, and 7. After Cycle 7, questionnaires will be 
collected every 3 cycles (on Day 1 Cycles 10, 13, 16, etc.), and at End of Treatment. 
• Dispense capsules or tablets to patient 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 100 of 151 
Confidential 
Oral CO-1686 will be administered with a meal, or within 30 minutes after a meal. The patient 
must also drink at least 8 ounces (240 mL) of water when taking CO-1686. 
The following procedures will be conducted after CO-1686 dosing: 
• 12-lead ECG (in triplicate, 10-sec tracings > 2 minutes apart) 2 hours postdose up to and 
including Cycle 12. For patients who are ongoing at this time and for whom QT has been 
< 470 ms throughout the study, the 2 hour post dose  ECG monitoring may be discontinued 
The following procedure is conducted irrespective of dosing time: 
• Tumor scans (using the same methodology as was used at screening) at the end of Cycles 2, 
4, and 6 (between Days 14 and 21), and every 3 cycles after Cycle 6 (between Days 14 and 
21) 
9.5.6 Cycle 2 Day 15 (±1 Day) 
The following procedures will be performed at C2 Day 15 (±1 day):  
• Fasting Glucose 
9.6 
End of Treatment Visit 
The following procedures will be performed for all patients 28 days (±7 days) after the last dose 
of oral CO-1686 in both Phase 1 and 2 (Dose Escalation and Dose Expansion): 
• Physical examination 
• Weight 
• ECOG performance status 
• Vital signs 
• Concomitant medications and procedures since last visit 
• 12-lead ECG (in triplicate, 10-sec tracings > 2 min apart)  
• Hematology, reticulocyte count, fasting serum chemistry (for assessment of fasting glucose) 
• Serum pregnancy test for women of childbearing potential 
• Tumor scans (using the same methodology as was used at screening), unless it has been  
< 2 weeks since last scan or disease progression was noted on the last scan 
• Blood sampling for biomarker/EGFR mutational testing and exploratory research  
• Optional tumor biopsy (requires additional consent) 
• AE monitoring (until 28 days after last dose of oral CO-1686; then only ongoing serious 
adverse events (SAEs) are followed until resolution or stabilization) 
• Contraceptive counseling  
• Quality of Life Questionnaires (EORTC QLQ Core 30 and Lung Cancer 13 and Dermatology 
Life Quality Index) 
• Collection and review of patient diary 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 101 of 151 
Confidential 
• Optional urine sampling. Instruct patients who have provided additional consent to collect 
first morning void on the day the End of Treatment visit is scheduled. Urine sample 
collection kits are provided and bring the sample to the clinic for freezing and storage.  
9.7 
Follow-up 
The following data will be collected for all patients approximately every 2 months after 
treatment discontinuation until death, loss to follow-up, withdrawal of consent from study, or 
sponsor decision (Follow-up can be performed via the telephone): 
• Subsequent treatments for NSCLC 
• Overall survival information 
9.8 
Methods of Data Collection 
9.8.1 Safety Evaluations 
9.8.1.1 
Adverse Event Assessment 
The investigator has the responsibility for assessing the safety of the patients and for compliance 
with the protocol to ensure study integrity. Patients will be monitored for AEs from the time the 
first dose of CO-1686 is administered through 28 days after the last dose, including study 
procedure-related AEs that occur after signing of the ICF and before administration of CO-1686. 
Any ongoing SAEs will be followed until resolution or stabilization. AEs and laboratory 
abnormalities will be graded according to the NCI CTCAE grading system (Version 4.0) and 
recorded on the eCRF. 
Complete details for monitoring AEs, including the definition of drug-related AEs, are provided 
in Section 10. 
9.8.1.2 
Clinical Laboratory Investigations 
Certified local laboratories will perform study-related clinical laboratory tests according to 
institutional procedures, and the results will be reviewed by the investigator. The panels of 
laboratory tests to be performed are shown below: 
Hematology:  Hemoglobin, hematocrit, WBC and differential (with ANC), reticulocyte count, 
and platelet count per the three schedules of evaluation at screening, during treatment, and at the 
End of Treatment visit. Hematology results must be reviewed by the investigator prior to the start 
of treatment with oral CO-1686. 
Patients known to require concomitant therapy with anticoagulant therapy such as warfarin 
should have INR monitored at screening and during the study. 
Fasting glucose:  Must be measured following an 8 hour fast (no food or liquid other than water) 
at screening, Cycle 1/Day 1, Cycle 1/Day 4, Cycle 1/Day 8, Cycle 1/Day 15, Cycle 2/Day 1, 
Cycle 2/Day 15, and Day 1 of every cycle thereafter and at End of Treatment visit, also if 
clinically indicated on study. Fasting glucose measure are part of the clinical chemistry panel 
(see below) on all Cycles Day 1 visits, and measured individually on Cycle 1/Day 4, 
Cycle 1/Day 8, Cycle 1/Day 15, and Cycle 2/Day 15. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 102 of 151 
Confidential 
Clinical Chemistry:  Total protein, albumin, creatinine, BUN or urea, total bilirubin, alkaline 
phosphatase, ALT, AST, total cholesterol, fasting glucose, c-peptide, sodium, potassium, 
magnesium, chloride, CO2 (or bicarbonate), calcium, and phosphorus per the three schedules of 
evaluations at screening, during treatment, and at the End of Treatment visit. Serum levels of 
alpha-1 acid glycoprotein (AAG) will be determined on PK sampling days. Hemoglobin A1c 
will be measured at screening and on Day 1 of every other cycle (Cycle 3, 5, 7, etc.) while the 
patient is on study. C-peptide will be measured at screening, and Day 1 of every cycle. 
Urinalysis:  Performed on freshly voided clean sample by dipstick for protein, glucose, blood, 
pH, and ketones per the schedule of evaluations. If dipstick findings are abnormal, then a 
microscopic evaluation will be performed to assess the abnormal findings. Urinalysis will be 
performed at screening only.  
Serum ß-hCG Pregnancy Test:  Performed on women of childbearing potential  3 days before 
Day 1, Cycle 1, and at the End of Treatment visit. If the serum pregnancy test results are not 
available on Cycle 1/Day 1, a urine pregnancy test can be performed on Cycle 1/Day 1 to 
confirm that the patient is not pregnant prior to dosing. Both values should be entered in the 
eCRF. A negative result must be confirmed by a physician before the first dose of oral CO-1686 
can be administered.  
Laboratory reports will be reviewed by the investigator or delegated physician who will then 
comment on out-of-range parameters and assess clinical significance. Clinically significant 
abnormalities and associated panel results, as well as results of any additional tests performed as 
follow-up to the abnormalities, will be documented on the eCRF as an AE. 
9.8.1.3 
Vital Signs 
Vital signs will include blood pressure, pulse, and body temperature. All vital signs will be 
obtained after the patient has been resting for at least 5 minutes. Vital signs will be performed at 
screening and at each study visit including the End of Treatment visit.  
9.8.1.4 
12-Lead Electrocardiograms 
Phase 1 
For patients enrolled in Phase 1, serial 12-lead ECGs (10-sec ECG tracings collected in triplicate 
[> 2 min apart]) will be taken at the following time points and as clinically indicated: 
• Screening:  Anytime during the screening period  
• Cycle 1, Day 1:  predose and at multiple time points as outlined in Table 13, following 
dosing with CO-1686 
• Cycle 1, Day 15:  predose and at multiple time points as outlined in Table 13, following 
dosing with CO-1686 
• All subsequent cycles:  predose and at the estimated Tmax (2 hours) postdose at Day 1 of each 
cycle 
• End of Treatment:  Any time after dosing has been discontinued, but within 28 days of last 
dose 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 103 of 151 
Confidential 
Phase 2 – Subset of Patients Enrolled in Phase 2 and Participating in Detailed PK Profiling 
at 625 mg BID. 
12-lead ECGs (10-sec ECG tracings collected in triplicate [> 2 minutes apart]) will be taken at 
the following time points and as clinically indicated: 
• Screening:  Anytime during the screening period  
• Cycle 1, Day 1:  predose, and at multiple time points as outlined in Table 13, following 
dosing with CO-1686 
• Cycle 1, Day 15:  predose, and at multiple time points as outlined in Table 13, following 
dosing with CO-1686 
• All subsequent cycles:  predose, and at the estimated Tmax (2 hours) postdose at Day 1 of 
each cycle 
• End of Treatment:  Any time after dosing has been discontinued, but within 28 days of last 
dose 
Phase 2 – All Other Patients 
For patients enrolled in Phase 2 and not participating in full R2PD PK profiling, serial 12-lead 
ECGs (10-sec ECG tracings collected in triplicate [> 2 minutes apart]) will be performed at the 
following time points and as clinically indicated:  
• Screening:  within 28 days of first CO-1686 dose 
• Cycle 1, Day 1:  pre-dose and at the estimated Tmax (2 hours) postdose 
• Cycle 1, Day 15:  pre-dose and at the estimated Tmax (2 hours) postdose 
• All subsequent cycles:  predose and at the estimated Tmax (2 hours) postdose at Day 1 of each 
cycle 
• End of Treatment:  Any time after dosing has been discontinued, but within 28 days of last 
dose 
ECGs should be performed after the patient has been resting for at least 5 min. The 12-lead 
ECGs collected will be analyzed at a central ECG laboratory. Details on recording ECGs and 
preparation for central interpretation will be included in the investigator’s file.  
All Patients (Phase 1 and Phase 2) 
Triplicate ECG monitoring will be conducted as outlined above up to and including Cycle 12. 
For patients who are ongoing at this time and for whom QT has been < 470 ms throughout the 
study, ECG monitoring may be subsequently reduced to predose evaluation and taken every 3rd 
cycle thereafter.  
9.8.1.5 
Body Weight and Height 
Height will be measured during the screening visit only. Weight will be measured at all clinic 
visits (the patient should be in light indoor clothes).  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 104 of 151 
Confidential 
9.8.1.6 
Physical Examinations 
Physical examinations will include an assessment of all the major body systems. Complete 
physical examinations will be performed at screening and at most study visits.  
9.8.1.7 
ECOG Performance Status 
ECOG performance status (Appendix B) will be assessed at screening, on Day 1 of each cycle, 
and at the End of Treatment visit. ECOG performance status should be assessed by the same 
study personnel at each visit, if possible. Care will be taken to accurately score performance 
status, especially during screening for study eligibility purposes. Additional consideration should 
be given to borderline ECOG performance status to avoid enrolling patients with significant 
impairment. 
9.8.2 Efficacy Evaluations 
9.8.2.1 
Tumor Assessments 
Tumor assessments will be performed at screening; at the end of Cycles 2, 4, and 6 (between 
Days 14 and 21); every 3 cycles after Cycle 6 (between Days 14 and 21); and at the End of 
Treatment visit. Tumor response will be interpreted using RECIST Version 1.1 (Appendix A).  
If an initial CR or PR is noted at Cycle 7 or beyond, confirmatory scans must be performed 4 to 
6 weeks later. In the case of SD, follow-up measurements must have met the SD criteria at least 
once after study entry at a minimum interval of no less than 6 to 8 weeks. 
Patients who continue treatment with CO-1686 post-progression should continue to be scanned 
according to the protocol until they discontinue from the study. 
Tumor assessments should consist of clinical examination and appropriate imaging techniques 
(preferably CT scans of the chest, abdomen, and pelvis with appropriate slice thickness per 
RECIST Version 1.1); other studies (MRI and X-ray) may be performed if required. The same 
methods used to detect lesions at baseline are to be used to follow the same lesions throughout 
the clinical study.  
Brain imaging (MRI/CT) is required at baseline. Patients with known brain metastases and/or 
brain lesions detected at baseline are required to repeat brain imaging as part of the follow-up 
tumor assessments. The same methods used to detect brain lesions at baseline are to be used to 
follow the same lesions throughout the clinical study.  
9.8.3 Pharmacokinetic Evaluations  
9.8.3.1 
Phase 1 
For patients in Phase 1, a serum AAG sample will be collected on each PK sampling day, and 
2 mL venous blood samples for the PK analysis of oral CO-1686 will be drawn at the following 
time points: 
• Cycle 1, Day 1:  Prior to CO-1686 administration (any time prior to dosing), and at 
15 (±2) minutes, 30 (±3) minutes, 1 hour. (±5 minutes), 1.5 hours (±5 minutes), 2.5 hours 
(±5 minutes), 4 hours (±15 minutes), 6 hours (±15 minutes), 8 hours (±15 minutes), 10 hours 
(±30 minutes), and 24 hours (±30 minutes) after dosing. 
• Cycle 1, Day 8:  At 5 to 10 minutes prior to CO-1686 administration. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 105 of 151 
Confidential 
• Cycle 1, Day 15:  At 5 to 10 minutes prior to CO-1686 administration, and at 15 (±2) 
minutes, 30 (±3) minutes, 1 hour (±5 minutes), 1.5 hours (±5 minutes), 2.5 hours 
(±5 minutes), 4 hours (±15 minutes), 6 hours (±15 minutes), 8 hours (±15 minutes), 10 hours 
(±30 minutes), and 24 hours (±30 minutes) after dosing. 
• Cycle 2 and beyond, Day 1:  Any time prior to CO-1686 administration. 
• On Cycle 1, Day 1 and Cycle 1, Day 15 a sample for AAG will be collected at the time of the 
pre-dose PK sample collection. On Cycle 1, Day 8 and Cycle 2 Day 1 and beyond, AAG will 
be collected at the time of PK sampling.  
Food-Effect PK Evaluation 
• Day -7 prior to Cycle 1:  Prior to CO-1686 administration (any time prior to dosing), and at 
15 (±2) minutes, 30 (±3) minutes, 1 hour (±5 minutes), 1.5 hours (±5 minutes), 2.5 hours 
(±5 minutes), 4 hours (±15 minutes), 6 hours (±15 minutes), 8 hours (±15 minutes), 10 hours 
(±30 minutes), and 24 hours (±30 minutes) after dosing. 
9.8.3.2 
Phase 2 (Cohorts A to C) 
For all patients in Phase 2, a serum AAG sample will be collected on each PK sampling day and 
a 2-mL venous blood samples for PK analysis of CO-1686 will be drawn at the following time 
points: 
• Cycle 1 Day 15:  5 to 10 minutes prior to dosing with CO-1686 
• Cycle 2 and beyond, Day 1 (up to and inclusive of Cycle 9, Day 1):  any time prior to dosing 
with CO-1686 
A sample for AAG will be collected at the time of PK sampling.  
10 Patient Subset in Phase 2 at 500 mg BID and 625 mg BID. 
For a subset of 10 patients in Phase 2 and at 500 mg BID and 625 mg BID, at a minimum, a 
serum AAG sample will be collected on each PK sampling day and 2-mL venous blood samples 
for the PK analysis of CO-1686 will be drawn at the following time points: 
• Cycle 1, Day 1:  Prior to CO-1686 administration (any time prior to dosing), and at 
15 (±2) minutes, 30 (±3) minutes, 1 hour (±5 minutes), 1.5 hours (±5 minutes), 2.5 hours 
(±5 minutes), 4 hours (±15 minutes), 6 hours (±15 minutes), 8 hours (±15 minutes), 10 hours 
(±30 minutes), and 24 hours (±30 minutes) after dosing.. 
• Cycle 1, Day 15:  At 5–10 minutes prior to CO-1686 administration, and at 15 (±2) minutes, 
30 (±3) minutes, 1 hour (±5 minutes), 1.5 hours (±5 minutes), 2.5 hours (±5 minutes), 
4 hours (±15 minutes), 6 hours (±15 minutes), 8 hours (±15 minutes), 10 hours 
(±30 minutes), and 24 hours (±30 minutes) after dosing. 
• Cycle 2 and beyond, Day 1 (up to and inclusive of Cycle 9, Day 1): any time prior to dosing 
with CO-1686 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 106 of 151 
Confidential 
On Cycle 1, Day 1 and Cycle 1, Day 15 a sample for AAG will be collected at the time of the 
pre-dose PK sample collection. On Cycle 2 Day 1 and beyond, AAG will be collected at the time 
of PK sampling. 
PK evaluation will be based on the determination of (not limited to) AUC0–t, AUC0–∞, Cmax, Tmax, 
T1/2, and elimination rate constant (kel), volume of distribution at steady state after non-IV 
administration (Vss/F), and total plasma clearance after PO administration (Cl/F). 
At least 3 of the full PK profile patients at the 625 mg BID dose level will participate in 
CO-1686 metabolite profiling at Cycle 1 Day 15.  
• Cycle 1, Day 1:  Prior to CO-1686 administration (any time prior to dosing). 
• Cycle 1 Day 1:  An additional 2 mL sample will be collected prior to CO-1686 
administration. This will serve as the baseline sample for subsequent profiling of 
CO-1686 circulating metabolites. 
• Cycle 1 Day 15:  An additional 2 mL samples will be collected postdose at 
30 (±3) minutes, 1.5 hours (±5 minutes), 4 hours (±15 minutes), 8 hours (±15 minutes), 
and 24 hours (±30 minutes) postdose. 
Patients participating in Phase 2 full PK and metabolite assessments will be enrolled at a subset 
of sites. 
For all Phase 1 and Phase 2 patients, the blood draw time relative to the last dosing time will be 
recorded at each PK sample occasion for each patient. 
Central laboratories will be used for bioanalysis of oral CO-1686 and its metabolites in human 
plasma. In Phase 1 and Phase 2, a proportion of samples will be sent for routine analyses and a 
proportion of samples will be banked. Banked samples may subsequently be analyzed for 
exploratory PK/PD analyses.  
Please refer to the laboratory manual for details on collection and processing of blood PK, 
metabolite and serum AAG samples.  
9.8.4 Baseline Tumor Biopsy and Matched Blood Sampling Requirements  
EGFR mutational status will be assessed in matching blood and tumor tissue from each patient. 
Tumor tissue from the primary tumor, or an accessible local/distal metastatic lesion, will be 
obtained during the screening period or within 60 days prior to dosing. Biopsy of either primary 
or metastatic tumor tissue collected within 60 days of C1D1 is acceptable for use in screening 
only if: a) Biopsy is collected after signing ICF and all other screening activities occur within the 
28-day screening window prior to C1D1, or b) Biopsy performed prior to patient signing 
informed consent is confirmed to have been done as routine standard of care and performed 
within 60 days of C1D1. To ensure adequate viable tumor tissue is obtained for mutational 
testing and diagnostic kit development, image-guided biopsies should be achieved with 18- to 
20-gauge cutting needles to provide 1 to 3 cores measuring 1 to 1.5 cm in length. Tumor samples 
will be processed locally to yield FFPE tissue blocks. Entire FFPE blocks must be submitted to 
satisfy regulatory requirements for development and validation of the tissue-based companion 
diagnostic. Blocks will be returned upon request if required for legal or medical treatment 
purposes.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 107 of 151 
Confidential 
EGFR T790M eligibility testing for Phase 2 will be done by the sponsor’s central laboratory. 
Matched blood sampling (up to 25 mL) should be collected prior to the biopsy procedure, if 
possible. Blood samples will be processed locally for plasma and stored frozen for subsequent 
batch shipping to the sponsor’s lab.  
- If a biopsy was performed within 60 days of Cycle 1, Day 1, and no intervening treatment 
was given, a repeat biopsy is not required if adequate tumor tissue can be provided to the 
sponsor during the screening period. In this case, blood sampling should be taken at least 
7 days AFTER the biopsy was performed.  
When sufficient tissue is available from the baseline tumor biopsy, samples may be tested for 
molecular alterations that may modulate response or resistance to EGFR-targeted therapy.  
Sample handling instructions will be provided in a separate laboratory manual.  
9.8.5 Pharmacodynamic Evaluations 
For all patients in Phase 1 and Phase 2 of the study, up to 25 mL of whole blood will be collected 
pre-dose on Days 1, 8 (Phase 1 only), 15 of Cycle 1, Day 1 of each treatment cycle, and at the 
End of Treatment visit  for detection and quantification of mutant EGFR and further biomarker 
assessments in plasma. Samples may be used for the development of a blood-based diagnostic 
test.  
Blood may also be used to test for biomarkers of response or resistance to EGFR-targeted 
therapy. Analysis may not be performed or only performed on a subset of patients if it becomes 
clear that the analysis will have limited scientific value (e.g., because of a very low titer of 
ctDNA in some patients, or if there are not enough serially collected samples from individual 
patients to allow for adequate biomarker evaluation). 
Please refer to the Laboratory Manual for details on collecting and processing of blood PD 
samples. 
9.8.6 Optional Tumor Biopsy 
For patients who provide additional consent, an optional tumor biopsy may be collected at End 
of Treatment.  This tissue may be analyzed for molecular alterations that modulate resistance to 
EGFR-targeted therapy.7,19 Tissue preparation requirements are the same as listed in 
Section 9.8.4. Sample handling instructions will be provided in a separate laboratory manual. 
9.8.7 Pharmacogenetic Evaluations 
For patients who provide additional consent, genomic DNA will be extracted from a blood 
sample from each patient to detect genetic polymorphisms in CYP isoenzymes in order to 
explore the correlation between potential polymorphisms and drug exposure. For all patients in 
Phase 1 and Phase 2 of the study who provide additional consent, a single sample of up to 9 mL 
whole blood will be collected at Cycle 1, Day 1, to genotype the alleles of cytochrome P450 
enzymes and drug transport proteins. Please see the Laboratory Manual for shipping and 
handling details. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 108 of 151 
Confidential 
9.8.8 Optional Urine Sampling for Exploratory Research of Transrenal Nucleic Acids 
Sparse urine sampling will be collected from patients who choose to participate in this optional 
exploratory research. On Day 1 of Cycles 1 through 6, patients will collect approximately 
100 mL of the first morning void using sampling kits provided and bring each sample to the 
clinic for freezing and storage. Frozen urine samples will be batched shipped to the sponsor’s 
lab. Detailed sample handling instructions will be provided in the Laboratory Manual.  
9.8.9 Quality-of-Life Assessments 
Quality of life will be measured using the EORTC QLQ Core 30 and Lung Cancer 13 and the 
Dermatology Life Quality Index (DLQI), which will be administered at baseline, every two 
cycles through Cycle 6 and then every 3 cycles thereafter. 
9.8.10 Patient Diary Cards 
Patient diary cards will be provided to patients. Patient will use diary cards to note the date, time 
and dose of CO-1686 administration. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 109 of 151 
Confidential 
10 
ADVERSE EVENT MANAGEMENT 
10.1 Definition of an Adverse Event 
An AE is defined as any untoward medical occurrence in a patient administered a medicinal 
product that does not necessarily have a causal relationship with this treatment. An AE can, 
therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of an investigational product, whether or 
not related to the investigational medicinal product. This includes an exacerbation of pre-existing 
conditions or events, intercurrent illnesses, drug interaction, or the significant worsening of the 
indication under investigation that is not recorded elsewhere on the eCRF under specific efficacy 
assessments. Anticipated fluctuations of pre-existing conditions, including the disease under 
study, that do not represent a clinically significant exacerbation or worsening are not considered 
AEs. 
It is the responsibility of the investigator to document all AEs that occur during the study. AEs 
should be elicited by asking the patient a non-leading question (e.g., “Have you experienced any 
new or changed symptoms since we last asked/since your last visit?”). AEs will be reported on 
the AE eCRF. Symptoms reported spontaneously by the patient during the physical examination 
will also be documented on the AE eCRF (not on the physical examination eCRF, which is 
reserved for physical signs or findings). 
10.2 Definition of a Serious Adverse Event 
An SAE is any untoward medical occurrence that occurs at any dose (from the time the first dose 
of CO-1686 is administered through 28 days after the last dose, including study 
procedure-related AEs that occur after signing of the ICF and before administration of CO-1686) 
that: 
• Results in death. Death may occur as a result of the underlying disease process. Nevertheless, 
any event resulting in death during the reporting period must be treated as an SAE and 
reported as such. All deaths occurring within 28 days of the last administration of oral 
CO-1686 will be reported as SAEs. 
• Is life-threatening (patient is at immediate risk of death from the event as it occurred) 
• Requires in-patient hospitalization (formal admission to a hospital for medical reasons) or 
prolongation of existing hospitalization 
• Results in persistent or significant disability/incapacity 
• Results in a congenital anomaly/birth defect 
Important medical events that may not result in death, are not life-threatening, or do not require 
hospitalization may be considered SAEs when, based on appropriate medical judgment, they 
may jeopardize the patient and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Examples of such events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or seizures that 
do not result in in-patient hospitalization, or the development of drug dependency or drug abuse. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 110 of 151 
Confidential 
10.3 Events or Outcomes Not Qualifying as Serious Adverse Events 
The following are not considered SAEs: 
• Pre-planned or elective hospitalization including social and/or convenience situations 
(e.g., respite care) 
• Overdose of either Clovis study drug or concomitant medication unless the event meets SAE 
criteria (e.g., hospitalization). However, the event should still be captured as a non-serious 
AE on the appropriate eCRF page 
• Events of progression of the patient’s underlying cancer as well as events clearly related to 
progression of the patient’s cancer (signs and symptoms of progression) should not be 
reported as a serious adverse event unless the outcome is fatal during the study or within the 
safety reporting period. If the event has a fatal outcome during the study or within the safety 
reporting period, then the event of Progression of Disease must be recorded as an AE and as 
an SAE with CTC Grade 5 (fatal outcome) indicated. 
• Diagnosis of progression of disease or hospitalization due to signs and symptoms of disease 
progression alone should not be reported as serious adverse events 
10.4 Clinical Laboratory Assessments and Other Abnormal Assessments as Adverse 
Events and Serious Adverse Events 
It is the responsibility of the investigator to assess the clinical significance of all abnormal values 
as defined by the list of reference ranges from the local laboratory. In some cases, significant 
changes in lab values within the normal range will require similar judgment. 
An abnormal laboratory value that is not already associated with an AE is to be recorded as an 
AE only if any one of the following criteria is met: 
• an action on the study drug is made as a result of the abnormality 
• intervention for management of the abnormality is required 
• at the discretion of the investigator should the abnormality be deemed clinically significant 
10.5 Pregnancy 
If a patient becomes pregnant during the study the investigator is to stop dosing with study 
drug(s) immediately. 
A pregnancy is not considered to be an AE or SAE; however, it must be reported to the sponsor 
using the Pregnancy Report Form within the same timelines as an SAE. This applies to female 
patients as well as female partners of male patients. 
A pregnancy should be followed through to outcome, whenever possible. Once the outcome of 
the pregnancy is known, the Pregnancy Outcome Report Form should be completed and reported 
to the sponsor. 
AEs or SAEs that occur during pregnancy will be assessed and processed according to the AE or 
SAE processes using the appropriate AE or SAE forms.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 111 of 151 
Confidential 
10.6 Recording of Adverse Events and Serious Adverse Events 
Any AE from the time the first dose of CO-1686 is administered through 28 days after the last 
dose, including study procedure-related AEs that occur after signing of the ICF and before 
administration of CO-1686 will be recorded on the AE eCRF. In order to avoid vague, 
ambiguous, or colloquial expressions, the AE should be recorded in standard medical 
terminology rather than the patient’s own words. Whenever possible, the investigator should 
combine signs and symptoms that constitute a single disease entity or syndrome into a final 
diagnosis. For example, fever, cough, and shortness of breath may be reported as pneumonia, if 
that is a reasonable diagnosis. 
The existence of an AE may be concluded from a spontaneous report of the patient; from the 
physical examination; or from special tests such as the ECG, laboratory assessments, or other 
study-specified procedure (source of AE). 
Each AE is to be evaluated for duration, severity, seriousness, and causal relationship to the 
investigational drug. The action taken and the outcome must also be recorded. 
SAEs that occur during the study or within 28 days after receiving the last dose of CO-1686, 
whether or not related to CO-1686, must be immediately reported to the sponsor’s SAE designee. 
10.6.1 Intensity of Adverse Events 
The severity of the AE will be graded according to the NCI CTCAE Version 4.0 grading scale. 
For AEs not covered by NCI CTCAE, the severity will be characterized as mild, moderate, 
severe, or life-threatening according to the following definitions: 
• Mild events are usually transient and do not interfere with the patient’s daily activities. 
• Moderate events introduce a low level of inconvenience or concern to the patient and may 
interfere with daily activities. 
• Severe events interrupt the patient’s usual daily activities and hospitalization (or prolongation 
of hospitalization) may be required. 
• Life-threatening events require urgent intervention to prevent death. 
10.6.2 Relationship of Adverse Events to Investigational Medicinal Products 
Medical judgment should be used to determine the cause of the AE considering all relevant 
factors such as, but not limited to, the underlying study indication, coexisting disease, 
concomitant medication, relevant history, pattern of the AE, temporal relationship to the study 
medication, dechallenge or rechallenge. 
Not Related  
• An AE that is clearly due to extraneous causes (e.g., concurrent disease, concomitant 
medications, disease under study, etc.) 
• It does not follow a reasonable temporal sequence from administration of study drug 
• It does not follow a known pattern of response to study drug 
• It does not reappear or worsen when study drug is restarted 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 112 of 151 
Confidential 
• An alternative explanation is likely but not clearly identifiable 
Related  
• An AE that is difficult to assign to alternative causes 
• It follows a strong or reasonable temporal sequence from administration of study drug 
• It could not be reasonably explained by the patient’s clinical state, concurrent disease, or 
other concomitant therapy administered to the patient 
• It follows a known response pattern to study drug 
• It is confirmed with a positive rechallenge or supporting laboratory data 
10.6.3 Outcome and Action Taken 
The investigator will record the action taken and outcome for each AE according to the 
following criteria: 
Action Taken with Study Drug 
• None 
• Dose reduced/delayed 
• CO-1686 temporarily interrupted 
• CO-1686 permanently discontinued 
• Other (specify) 
Outcome 
• Recovered 
• Recovered with sequelae 
• Improved 
• Ongoing 
• Death 
• Lost to follow-up 
10.7 Follow-up of Adverse Events and Serious Adverse Events 
All AEs occurring during the study are to be followed up in accordance with good medical 
practice until resolved; judged no longer clinically significant; or, if a chronic condition, until 
fully characterized through 28 days after the last dose of CO-1686. Any SAEs must be followed 
until resolution or stabilization. 
10.8 Regulatory Aspects of Adverse Event Reporting 
All SAEs, regardless of relationship to study drug, must be reported to the sponsor or designee 
within 24 hours of knowledge of the event, according to the procedures below. It is important 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 113 of 151 
Confidential 
that the investigator provide an assessment of relationship of the SAE to study treatment at the 
time of the initial report. The Clinical Trial Serious Adverse Event Report Form must be used for 
reporting SAEs.  
The sponsor or its designee is responsible for submitting reports of AEs associated with the use 
of the drug that are both serious and unexpected to the U.S. Food and Drug Administration 
(FDA), according to 21 Code of Federal Regulations (CFR) 312.32; to the Japanese 
Pharmaceuticals and Medical Devices Agency (PMDA); to the European regulatory authorities 
according to the European Commission Clinical Trials Directive (2001/20/EC); and to other 
regulatory authorities, according to national law and/or local regulations. All investigators 
participating in ongoing clinical studies with the study medication will receive copies of these 
reports for prompt submission to their Institutional Review Board (IRB) or Independent Ethics 
Committee (IEC). In accordance with the European Commission Clinical Trials Directive 
(2001/20/EC), the sponsor or its designee will notify the relevant ethics committees in concerned 
member states of applicable suspected unexpected serious adverse reactions (SUSARs) as 
individual notifications or through periodic line listings. 
The sponsor or its designee will submit all safety updates and periodic reports to the regulatory 
authorities as required by applicable regulatory requirements. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 114 of 151 
Confidential 
11 
STATISTICAL METHODS  
11.1 Populations 
The following analysis populations are defined for the study: 
PK-evaluable Population—all patients who received at least one dose of CO-1686 and have 
adequate PK assessments drawn for determination of the PK profile. Adequacy will be 
determined on a case-by-case basis and will be assessed prior to analysis of the blood samples. 
Food-effect PK Population—all patients who enrolled into a food-effect PK evaluation cohort 
who received CO-1686 on both Day -7 and Day 1, complied with the fed and fasted 
requirements, and have sufficient PK data for a comparison to be made between the fasted and 
fed state. 
ECG/PK Comparison-Evaluable Population—all patients in Phase 1 and Phase 2 who have 
received CO-1686 and have had adequate PK and ECG assessments performed for determination 
of the ECG effects and the relationship between PK and ECG. 
Safety Population— all patients who have received at least one dose of CO-1686. 
DLT-evaluable Population—all patients enrolled into Phase 1 of the study who received at 
least 80% of scheduled doses of CO-1686 and completed Cycle 1 of treatment, or who 
experienced a DLT in Cycle 1. 
Tumor-evaluable Population—all patients who received at least one dose of CO-1686, have 
measurable tumor lesions at baseline, and have at least one post-baseline disease assessment. 
11.2 Statistical Methods 
11.2.1 General Considerations 
Quantitative variables will be summarized using descriptive statistics (N, mean, standard 
deviation, median, minimum, and maximum) and/or frequency and percentages for medically 
relevant categories. Categorical variables will be presented using frequencies and percentages. 
The Kaplan-Meier methodology will be used to summarize time-to-event variables. If estimable, 
the 25th, 50th (median), and 75th percentiles will be presented. The number of patients with 
events and the number of censored patients will also be presented.  
Individual patient data listings will be provided to support summary tables. All data will be used 
to their maximum possible extent but without any imputations for missing data. 
All statistical analyses will be conducted with the statistical analysis software (SAS®) System, 
Version 9.1 or higher. 
11.2.2 Patient Disposition  
Separately for Phase 1 and Phase 2 of the study, the frequency and percentage of patients in each 
analysis population will be presented. The primary reason for discontinuation of CO-1686 will 
be summarized. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 115 of 151 
Confidential 
11.2.3 Baseline Characteristics  
Separately for Phase 1 and Phase 2 of the study, baseline characteristics and demographic data 
will be summarized for the safety population. 
11.2.4 Efficacy Analyses  
11.2.4.1 
Phase 1 
Overall Response Rate - Secondary Endpoint 
A secondary endpoint in Phase 1 of the study (overall response rate) is the best overall response 
recorded from the start of the treatment until disease progression or recurrence. The overall 
response rate will be summarized for the tumor-evaluable population enrolled in Phase 1 with 
frequencies and percentages.  
For patients who continue treatment post-progression, the first date of progression will be used 
for the analysis.  
Duration of Response - Secondary Endpoint 
Duration of response for complete response (CR) and partial response (PR) will be measured 
from the date that any of these best responses is first recorded until the first date that progressive 
disease is objectively documented. Duration of response will be summarized using descriptive 
statistics (N, mean, standard deviation, median, minimum, and maximum) as well as 
categorically. 
11.2.4.2 
Phase 2 (Cohorts A to C) 
The efficacy results from Phase 1 and Phase 2 may be presented together for certain dose groups 
of interest. 
Objective Response Rate (ORR) - Primary Endpoint 
A primary endpoint in Phase 2 of the study (objective response rate) is the best response 
recorded from the start of the treatment until disease progression or recurrence. The frequency 
and percentages of patients with a best response of CR, PR, stable disease (SD), or progressive 
disease (PD) will be summarized for the tumor-evaluable and safety populations enrolled in 
Phase 2. The response rate (CR+PR) will also be presented with frequencies and percentages. 
For patients who continue treatment post-progression, the first date of progression will be used 
for the analysis.  
The ORR will be evaluated by the investigator with the primary analysis based on investigator 
assessment. 
Duration of Response - Primary Endpoint 
Duration of response for CR and PR will be measured from the date that any of these best 
responses is first recorded until the first date that PD is objectively documented. Duration of 
response will be summarized using descriptive statistics (N, mean, standard deviation, median, 
minimum, and maximum) as well as categorically. 
The duration of response will be evaluated by the investigator with the primary analysis based on 
investigator assessment. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 116 of 151 
Confidential 
Objective Response Rate (ORR) by IRR- Secondary Endpoint 
A secondary endpoint in Phase 2 of the study (objective response rate) is the best response 
recorded from the start of the treatment until disease progression or recurrence. The frequency 
and percentages of patients with a best response of CR, PR, SD, or PD will be summarized for 
the tumor-evaluable and safety populations enrolled in Phase 2. The response rate (CR+PR) will 
also be presented with frequencies and percentages. 
For patients who continue treatment post-progression, the first date of progression will be used 
for the analysis.  
The ORR will be evaluated by the central independent radiology review (IRR). 
Duration of Response by IRR – Secondary Endpoint 
Duration of response for CR and PR will be measured from the date that any of these best 
responses is first recorded until the first date that PD is objectively documented. Duration of 
response will be summarized using descriptive statistics (N, mean, standard deviation, median, 
minimum, and maximum) as well as categorically. 
The duration of response will be evaluated by the IRR with the analysis based on independent 
assessment. 
Overall Survival (OS) - Secondary Endpoint 
Overall survival (OS) will be calculated as 1+ the number of days from the first dose of study 
drug to death due to any cause. Patients without a documented date of death will be censored on 
the date the patient was last known to be alive. 
Disease Control Rate (DCR) - Secondary Endpoint 
The DCR is the percentage of patients with a best response of CR, PR, or SD for at least 
12 weeks. 
The DCR will be evaluated by the investigator and the IRR. 
Progression-free Survival (PFS) - Secondary Endpoint 
Progression-free survival will be calculated as the number of days from the date of the first dose 
of CO-1686 to the date of disease progression or death due to any cause + 1. Patients without a 
documented event of disease progression will be censored on the date of their last adequate 
tumor assessment (i.e., radiologic assessment) or date of first dose of study drug if no tumor 
assessments have been performed. Any valid tumor measurements are considered adequate for 
efficacy assessments. Patients with measurable disease at baseline will have disease progression 
determined by RECIST Version 1.1 criteria.  
The Kaplan-Meier methodology will be used to summarize progression-free survival. The 25th, 
50th (median), and 75th percentiles will be presented. 
PFS will be evaluated by the investigator and by IRR. 
11.2.5 Pharmacokinetic Analyses – Secondary Endpoint 
As a primary endpoint in Phase 1 and a secondary endpoint in Phase 2 of the study, PK 
parameters will be determined using noncompartmental methods. AUC from Time 0 to the last 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 117 of 151 
Confidential 
observation will be calculated using the trapezoid rule. The kel will be calculated using log-linear 
regression on the terminal part of the concentration time curve. The terminal half-life and the 
AUC from the last observation to infinity will be calculated from the estimated kel. Other 
parameters to be determined are Cmax, Tmax, Vss/F, and Cl/F.  
As a secondary endpoint in Phase 1, the effect of food on PK parameters including, but not 
limited to, Cmax and AUC, will be compared using analysis of variance (ANOVA) techniques. 
As a secondary endpoint in Phase 2, additional plasma samples will be collected on Day 15 from 
a minimum of three patients enrolled at the RP2D. Individual pooled plasma samples, one from 
each of these patients, will be prepared using the method proposed by Hamilton.24 The pooled 
plasma samples will be further processed before being analyzed by high-performance liquid 
chromatography coupled in-line with ultraviolet spectrophotometric and tandem mass 
spectrometric detection (HPLC-UV-MS/MS). 
A specific population PK data analysis plan will be developed and will outline the detailed 
approach to data handling, model development and diagnostics, individual model parameter 
estimation, exploration of covariate effects, and final model evaluation techniques. 
11.2.6 Patient Reported Outcomes – Secondary Endpoint  
Patient reported outcome questionnaires, the EORTC QLQ C30 and LC13 and the Dermatology 
Life Quality Index will be summarized with descriptive statistics on observed data for all three 
PRO instruments and their subscales. Specifically, the domain and item scores from the 
EORTC-QLQ-C30 (global health status; physical, role, emotional, cognitive, and social 
functioning; fatigue, nausea and vomiting, and pain symptoms; dyspnea; insomnia; appetite loss; 
constipation; diarrhea; and financial difficulties), from the lung cancer module (dyspnea, 
coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, 
pain in arm or shoulder, and pain in other parts) and from the DLQI (DLQI total score, daily 
activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school) 
will be summarized using descriptive statistics (i.e., N, mean, StDev, median, Q1, Q3, min, and 
max) at each scheduled assessment point by phase and overall. Additionally, change from 
baseline in the domain and item scores at the time of each assessment will be summarized. 
Mean changes from baseline (including standard deviation bars) in EORTC-QLQ-C30 lung 
cancer module symptom scores and DLQI domain scores will be plotted at each assessment 
point. At each assessment point on the x axis the number of patients completing the assessment 
for each treatment group should be listed. The y axis should encompass only the range of values 
reported by patients in the study (as opposed to the full range of the scale).  
Additional details on the analysis of the patient reported outcome data will be provided in the 
statistical analysis plan. 
11.2.7 Relationship Between PK and QTc – Secondary Endpoint 
In Phase 1 patients and in a subset of Phase 2 patients participating in full PK profiling, an 
endpoint of the study will be to examine the relationship between the concentration of oral 
CO-1686 (PK) and potential changes in QTc. A linear and nonlinear mixed effect modeling 
approach will be used to quantify the relationship between the plasma concentration and the 
ΔQTc baseline-adjusted difference in QTc interval. Plots of the mean QT/QTc versus drug 
concentrations and a concentration-QT variables correlation will be explored.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 118 of 151 
Confidential 
11.2.8 Time to Treatment Failure - Exploratory Endpoint 
The time to treatment failure will be computed as 1+ the number of days from the first dose of 
study drug to the last dose of study drug. 
The subgroup of patients that continue receiving study drug past an event of disease progression 
will be summarized separately.  
11.2.9 Concordance of T790M in Tumor versus Blood – Exploratory Endpoint  
An exploratory pharmacodynamic endpoint is the detection and quantification of mutant EGFR 
cell-free DNA in blood collected at baseline and with every tumor assessment. The presence of 
the T790M mutation at baseline and subsequent time points will be presented both with 
frequencies and percentages. In addition, the relationship between T790M detected in tumor 
compared with that detected in blood, and urine where applicable, will be explored. This will 
involve determining the sensitivity, specificity, positive and negative predictive values with 95% 
confidence intervals (CIs) of blood with respect to tumor assuming that EGFR mutational status 
in tumor is a true reflection of tumor biology. Blood collected at these time points may also be 
assessed for cell-free DNA related to biomarkers of response or resistance to EGFR-targeted 
therapy. 
11.2.10 
Safety Analyses  
The safety analyses will be performed using the safety population (all patients who have received 
at least one dose of CO-1686).  
11.2.10.1 
Extent of Exposure 
The following will be summarized by dose group using descriptive statistics:  
• Number of patients dosed in Phase 1 (Dose-escalation Period and Treatment-extension 
Period and RP2D Exploratory cohort), and in Phase 2 
• Number of patients at each dose group, average dose amount, total cumulative dose (Phase 1 
and 2) 
• Number of cycles initiated (Phase 1 and 2)  
• Number of dose reductions/delays (Phase 1 and 2) 
• Number of dose interruptions (Phase 1 and 2) 
• Duration of exposure (Phase 1 and 2) 
The number of patients at each dose group or study phase will be summarized with frequencies 
and percentages; the average dose, total cumulative dose, and duration of exposure will be 
summarized with descriptive statistics and frequency counts for relevant categories. The number 
of cycles initiated will be investigated by summarizing the number of cycles started by each 
patient in each period. The number of patients with at least one dose reduction/delay or 
interruption will be summarized with frequencies and percentages.   
11.2.10.2 
Adverse Events 
AE coding will be performed using the Medical Dictionary for Drug Regulatory Activities, 
Version 13.0 or greater. The severity of the toxicities will be graded according to the NCI 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 119 of 151 
Confidential 
CTCAE Version 4.0 whenever possible. Treatment-emergent AEs are defined as AEs with an 
onset date on or after the date of first dose of CO-1686 until the date of the last CO-1686 dose 
plus 28 days. AEs will be considered treatment-emergent if all or part of the date of onset of the 
AE is missing and it cannot be determined if the AE meets the definition for treatment-emergent. 
The number and percentage of patients who experienced treatment-emergent AEs for each 
system organ class and preferred term will be presented by dose group. Multiple instances of the 
treatment-emergent AEs in each system organ class and multiple occurrences of the same 
preferred term are counted only once per patient. The number and percentage of patients with at 
least one treatment-emergent AE will also be summarized by dose group.  
Separate tables will present the following by dose group and study phase: 
• All treatment-emergent AEs 
• Treatment-emergent AEs by CTCAE grade 
• Grade 3 or greater treatment-emergent AEs 
• Treatment-related, treatment-emergent AEs 
• Dose-limiting toxicity AEs 
• Serious treatment-emergent AEs 
• Serious treatment-related AEs 
• Treatment-emergent AEs with an outcome of death 
• Treatment-emergent AEs leading to discontinuation of oral CO-1686 
• Treatment-emergent AEs resulting in interruption or reduction/delay of CO-1686 
The incidence of treatment-emergent AEs will be summarized by relationship to oral CO-1686 
using “treatment-related” and “not treatment-related” categories. The category of treatment-
related is defined as a relationship of Possible/Probable, Definite, or Missing. If a patient 
experiences multiple occurrences of the same AE with different relationship categories, the 
patient will be counted once as a relationship category of treatment-related.  
If a patient experiences multiple occurrences of the same AE with different intensity toxicity 
grades, the patient will be counted once for the maximum (most severe) toxicity grade. AEs with 
a missing intensity will be presented in the summary table with a toxicity grade of “Missing.”  
For each toxicity grade, the number and percentage of patients with at least one 
treatment-emergent AE of the given grade will be summarized.   
Non-treatment-emergent AEs (pretreatment and posttreatment) will be presented in the 
by-patient data listings.  
11.2.10.3 
Clinical Laboratory Evaluations 
Clinical laboratory evaluations include the continuous variables for hematology, serum 
chemistry, and urinalysis. Laboratory values will be presented in Systeme International units. 
The baseline laboratory value will be defined as the last value prior to or on the day of the first 
dose of oral CO-1686. The on-treatment period will be defined as the day after the first dose of 
oral CO-1686 to 28 days after the last dose of CO-1686. Laboratory values collected during the 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 120 of 151 
Confidential 
on-treatment period will be included in the summary tables. The laboratory values collected after 
the on-treatment period will only be presented in the data listings.  
The summary of laboratory data will include descriptive statistics (N, mean, standard deviation, 
minimum, median, and maximum) of the maximum, minimum, and last value during the 
treatment period by dose group and study phase. Summaries using descriptive statistics of the 
change from baseline to the maximum, minimum, and last value during the on-treatment period 
will also be given by dose group and study phase. Supporting laboratory data including normal 
ranges and abnormal laboratory flags will be provided using by-patient listings. Separate listings 
will be produced for clinically significant laboratory abnormalities (i.e., those that meet Grade 3 
or 4 criteria according to CTCAE Version 4.0) by dose group.  
11.2.10.4 
Vital Sign Measurements 
The baseline vital sign measurement will be defined as the last value prior to or on the day of the 
first dose of CO-1686. The on-treatment period will be defined as the day after the first dose of 
CO-1686 to 28 days after the last dose of CO-1686. Vital sign measurements collected during the 
on-treatment period will be included in the summary tables. The vital sign measurements 
collected after the on-treatment period will only be presented in the data listings.  
The summary of vital sign data will include descriptive statistics (N, mean, standard deviation, 
minimum, median, and maximum) of the maximum, minimum, and last value during the 
on-treatment period by dose group and study phase. Summaries using descriptive statistics of the 
change from baseline to the maximum, minimum, and last value during the on-treatment period 
will also be given by dose group.  
11.2.10.5 
12-Lead Electrocardiograms 
ECG intervals will be stratified into categories indicative of potential clinical significance. Each 
patient’s maximum QT and QTc intervals from the pretreatment visit and treatment period visits 
will be classified as 450 msec, > 450 to 480 msec, > 480 to 500 msec, and > 500 msec. For 
each patient’s maximum change from the pretreatment ECG visit for QT and QTc, intervals will 
be classified into < 30 msec, 30 to < 60 msec, and 60 msec. The number and percentage of 
patients in each classified category will be presented. Additional endpoints will include abnormal 
T waves and U waves and other ECG intervals and diagnostic parameters.  
Descriptive statistics will be used to summarize other ECG parameters of PR, QRS, QT, and RR 
interval, and the corresponding changes from pretreatment ECG visit at each time point. Plots of 
the mean QT/QTc over time for Day 1 and Day 15 of Cycle 1 and End of 
Treatment/pretreatment ECG day measurements will be provided.  
11.2.10.6 
Other Safety Measurements 
Body weight and ECOG performance status will be summarized with descriptive statistics (N, 
mean, standard deviation, median, minimum, and maximum). Concomitant 
medications/procedures will be tabulated and summarized. 
11.3 Interim Analyses 
Separately within each new dose level in Cohorts A and B (Cohort A and B - 500 mg BID and 
625 mg BID), the ORR will be evaluated in the first 12 patients. Within Cohort C, the ORR will 
be evaluated separately for patients from the 2 patient populations represented by Cohorts A and 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 121 of 151 
Confidential 
B. If zero responses are observed in the first 12 patients within each dose level (Cohorts A and 
B) or patient population (Cohort C) are observed, then the respective level or population may be 
discontinued due to a lack of efficacy. If zero PR or CR responses are observed in 12 patients 
then there is a high probability that the true objective response rate is less than 20%. In addition 
to the futility analyses within each cohort, formal safety data reviews will occur following the 
enrollment of every 50 patients and approximately every 6 months once enrollment is completed 
and as long as patients remain on treatment. The review committee will include external experts 
and sponsor personnel. The external experts will include, but not be limited to, the coordinating 
PIs of the study. The sponsor’s reviewers will include the Medical Monitor, Chief Medical 
Officer, and Biostatistician. The protocol will be amended as appropriate to incorporate 
additional patient safety monitoring if new safety signals are noted at any review.  
11.4 Sample Size Considerations 
Amendment 6 allowed for at least approximately 380 efficacy-evaluable patients to be enrolled 
into Cohorts A and B for the Phase 2 portion of the study (up to approximately 75 patients per 
dose level 625 mg BID and 500 mg BID, up to approximately 40 patients at 750 mg BID). The 
patients eligible for Cohort A and B under this amendment will be assigned to receive either 
500 mg BID or 625 mg BID by the sponsor, so that Cohort B will contain up to approximately 
150 patients and Cohort A may contain up to approximately 275 patients. Amendment 7 allowed 
the later-line patient population in Cohort A (more prevalent population) to continue enrollment 
as long as the earlier line patient population, Cohort B, is open for enrollment. Based on current 
enrollment rates, the size of Cohort A will increase from 150 patients to approximately 
275 patients. 
Up to approximately 100 efficacy-evaluable patients will be enrolled into Cohort C in the 
Phase 2 portion of the study.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 122 of 151 
Confidential 
12 
PATIENT DISPOSITION 
12.1 Patient Discontinuations 
A patient must be discontinued from protocol-prescribed therapy if any of the following apply: 
• Consent withdrawal at the patient’s own request or at the request of their legally authorized 
representative 
• Progression of patient’s underlying disease, except as noted in Section 5.1.4. 
• Any event, adverse or otherwise, that, in the opinion of the investigator, would pose an 
unacceptable safety risk to the patient 
• An intercurrent illness that, in the opinion of the investigator, would affect assessments of the 
clinical status to a significant degree and requires discontinuation of therapy 
• Non-compliance as described in Section 7.7 
• A positive pregnancy test at any time during the study 
In addition, the sponsor may discontinue the trial early for any of the reasons noted in 
Section 13.6. 
The sponsor (or designee) should be notified of all study terminations as soon as possible. The 
date and reason for cessation of oral CO-1686 must be documented in the eCRF and source 
documents. To the extent possible, End of Treatment procedures should be performed on all 
patients who receive CO-1686. The End of Treatment visit should occur 28 (±7) days following 
the last dose of CO-1686. Patients will be followed for 28 days after the last dose of CO-1686 for 
safety; those with ongoing SAEs will be followed until either resolution or stabilization has been 
determined. 
12.2 Study Stopping Rules 
In the event a DLT rate of greater than 33% is observed at the starting dose (150 mg) and 
schedule (daily for 21 days), then other dosing schedules may be explored.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 123 of 151 
Confidential 
13 
STUDY ADMINISTRATION 
13.1 Regulatory and Ethical Considerations 
This study will be conducted in compliance with the protocol; Good Clinical Practices (GCPs), 
including ICH Technical Requirements for Registration of Pharmaceuticals for Human Use 
Guidelines; FDA regulatory requirements; and in accordance with the ethical principles of the 
Declaration of Helsinki.  
13.1.1 Regulatory Authority Approvals 
The sponsor or designee will submit the study protocol plus all relevant study documents to 
concerned regulatory agencies for approval prior to the study start. No patient will be admitted to 
the study until appropriate regulatory approval of the study protocol has been received. 
Each investigator must complete a Form FDA 1572 and provide the completed form according to 
written instructions to the sponsor (or designee). Each investigator must submit to the sponsor 
(or designee) financial disclosure information according to national law and/or local regulations. 
US-generated data will be handled in accordance with the Health Information Portability and 
Accountability Act (HIPAA). The trial will be registered at www.clinicaltrials.gov using the 
Protocol Registration System. 
13.1.2 Independent Ethics Committee/Institutional Review Board 
This protocol and any material to be provided to the patient (such as advertisements, patient 
information sheets, or descriptions of the study used to obtain informed consent) will be 
submitted by the investigator to an IEC/IRB. This also applies to protocol amendments.  
The sponsor will supply relevant data for the investigator to submit the study protocol and 
additional study documents to the IEC/IRB. The principal investigator will submit the study 
protocol for review and approval by an IEC/IRB, according to national law and/or local 
regulations, and will provide the IEC/IRB with all appropriate materials.  
Verification of the IEC’s/IRB’s unconditional approval of the study protocol and the written 
informed consent form will be transmitted to the sponsor. This approval must refer to the study 
by exact study protocol title and number, identify the documents reviewed, and state the date of 
the review. 
No patient will be admitted to the study until appropriate IEC/IRB approval of the study protocol 
has been received, the investigator has obtained the signed and dated informed consent form, and 
the sponsor is notified.  
The principal investigator will submit appropriate reports on the progress of the study to the 
IEC/IRB at least annually in accordance with applicable national law and/or local regulations 
and in agreement with the policy established by the IEC/IRB and the sponsor.  
The IEC/IRB must be informed by the principal investigator of all subsequent study protocol 
amendments and of SAEs or suspected unexpected adverse reactions (SUSARs) occurring 
during the study that are likely to affect the safety of the patients or the conduct of the study. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 124 of 151 
Confidential 
13.2 Confidentiality of Information 
The investigator must assure that patients’ anonymity is strictly maintained and that their 
identities are protected from unauthorized parties. Only patient initials and an identification code 
(i.e., not names) should be recorded on any form submitted to the sponsor and the IEC/IRB. The 
investigator must keep logs on screened and enrolled patients. In addition, the investigator must 
have a list where the identity of all treated patients can be found. 
The investigator agrees that all information received from the sponsor, including, but not limited 
to, the Investigator’s Brochure, this protocol, eCRFs, the protocol-specified treatment, and any 
other study information, remain the sole and exclusive property of the sponsor during the 
conduct of the study and thereafter. This information is not to be disclosed to any third party 
(except employees or agents directly involved in the conduct of the study or as required by law) 
without prior written consent from the sponsor. The investigator further agrees to take all 
reasonable precautions to prevent the disclosure by any employee or agent of the study center to 
any third party or otherwise into the public domain. 
13.3 Patient Informed Consent 
All information about the clinical study, including the patient information and the informed 
consent form, is prepared and used for the protection of the human rights of the patient according 
to ICH GCP guidelines and the Declaration of Helsinki. 
It is the responsibility of the investigator to obtain signed informed consent forms from each 
patient participating in this study after adequate explanation of the aims, methods, objectives, 
and potential hazards of the study and prior to undertaking any study-related procedures.  
The informed consent form, prepared by the investigator with the assistance of the sponsor, must 
be approved along with the study protocol by the IEC/IRB and be acceptable to the sponsor. 
The patient must be provided with the patient information and informed consent form consistent 
with the study protocol version used and approved by the relevant IEC/IRB. The informed 
consent form must be in a language fully comprehensible to the prospective patient. Patients 
(and/or relatives, guardians, or legal representatives, if necessary) must be given sufficient time 
and opportunity to inquire about the details of the study and to discuss and decide on their 
participation in the study with the investigator concerned. The patient and the person explaining 
about the study and with whom they discuss the informed consent will sign and date the 
informed consent form. A copy of the signed informed consent form will be retained by the 
patient and the original will be filed in the investigator file unless otherwise agreed.  
13.4 Study Monitoring 
A monitor will contact and visit the investigator at the study center prior to the entry of the first 
patient and as necessary during the study until after the last patient has completed. A monitor 
will also perform a study closure visit.  
In accordance with ICH GCP guidelines, the investigator must ensure provision of sufficient 
time, reasonable space, and adequate qualified personnel for the monitoring visits. The visits are 
for the purpose of verifying adherence to the study protocol and the completeness, consistency, 
and accuracy of data entered on the eCRF and other documents.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 125 of 151 
Confidential 
The investigator will make all source data (i.e., the various study records, the eCRFs, laboratory 
test reports, other patient records, drug accountability forms, and other pertinent data) available 
for the monitor and allow access to them throughout the entire study period. Monitoring is done 
by comparing the relevant site records of the patients with the entries on the eCRF (i.e., source 
data verification). It is the monitor’s responsibility to verify the adherence to the study protocol 
and the completeness, consistency, and accuracy of the data recorded on the eCRFs.  
By agreeing to participate in the study, the investigator agrees to cooperate with the monitor to 
ensure that any problems detected in the course of the monitoring visits are resolved. Contact 
information for the study monitor is located in the investigator file. Representatives from the 
sponsor may also contact and visit the investigators and monitor data during the study. 
13.5 Case Report Form 
The data will be collected using an electronic data capture (EDC) system by remote data entry on 
eCRFs. Sites will receive training on the EDC system. All users will be supplied with unique 
login credentials. 
Prior to study start, the investigator will prepare a list showing the signature and handwritten 
initials of all individuals authorized to make or change entries on eCRFs. This “study center 
personnel and delegation list” must be kept current throughout the study. 
For each patient enrolled, an eCRF must be completed, reviewed, signed, and dated by the 
principal investigator or co-investigator within a reasonable time period (< 3 weeks) after data 
collection. This also applies to records for those patients who fail to complete the study. If a 
patient withdraws from the study, the reason must be noted on the eCRF. If a patient is 
withdrawn from the study because of a treatment-limiting AE, thorough efforts should be made 
to clearly document the outcome. 
All laboratory data and investigator observations on the results and any other clinically 
significant test results must be documented on eCRFs. 
Full information regarding EDC and completing eCRFs is included in the investigator files. All 
questions or comments related to electronic capture should be directed to the assigned monitor. 
13.6 Study Termination and Site Closure 
Both the sponsor and the investigator reserve the right to terminate the study at any time. Should 
this be necessary, both parties will arrange discontinuation procedures. In terminating the study, 
the sponsor and the investigator will assure that adequate consideration is given to the protection 
of the patients’ interests. 
The sponsor reserves the right to discontinue the study at any time for medical or administrative 
reasons. When feasible, a 30-day written notification will be given. 
The entire study will be stopped if: 
• The protocol-specified treatment is considered too toxic to continue the study. 
• Evidence has emerged that, in the opinion of the sponsor or the investigator(s), makes the 
continuation of the study unnecessary or unethical. 
• The stated objectives of the study are achieved. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 126 of 151 
Confidential 
• The sponsor discontinues the development of oral CO-1686. 
Regardless of the reason for termination, all data available for the patient at the time of 
discontinuation of follow-up must be recorded on the eCRF. All reasons for discontinuation of 
treatment must be documented. In terminating the study, the investigator will ensure that 
adequate consideration is given to the protection of the patients’ interests. 
13.7 Modification of the Study Protocol 
Protocol amendments, except when necessary to eliminate an immediate hazard to patients, must 
be made only with the prior approval of the sponsor. Agreement from the investigator must be 
obtained for all protocol amendments and amendments to the informed consent document. The 
IEC/IRB must be informed of all amendments and give approval prior to their implementation. 
The sponsor will submit any study protocol amendments to the concerned regulatory authorities 
for approval and keep the investigator(s) updated as detailed in the ICH GCP guidelines. 
13.8 Retention of Study Documents 
The study site will maintain a study file, which should contain, at minimum, the Investigator’s 
Brochure, the protocol and any amendments, drug accountability records, correspondence with 
the IEC/IRB and the sponsor, and other study-related documents. 
The investigator agrees to keep records and those documents that include (but are not limited to) 
the identification of all participating patients, medical records, study-specific source documents, 
source worksheets, all original signed and dated informed consent forms, copies of all eCRFs, 
query responses, and detailed records of drug disposition to enable evaluations or audits from 
regulatory authorities and the sponsor or its designees. 
The investigator shall retain records required to be maintained for a period of 5 years following 
the date a marketing application in an ICH region is approved for the drug for the indication for 
which it is being investigated or, if no application is to be filed or if the application is not 
approved for such indication, until at least 5 years after the investigation is discontinued. 
However, these documents should be retained for a longer period if required by the applicable 
regulatory requirement(s) or if needed by the sponsor. In addition, the investigator must make 
provision for the patients’ medical records to be kept for the same period of time. 
No data should be destroyed without the agreement of the sponsor. Should the investigator wish 
to assign the study records to another party or move them to another location, the sponsor must 
be notified in writing of the new responsible person and/or the new location. The sponsor will 
inform the investigator, in writing, when the trial-related records are no longer needed. 
Patients’ medical records and other original data will be archived in accordance with the 
archiving regulations or facilities of the investigational site. 
13.9 Clinical Study Report 
A clinical study report will be prepared under the responsibility and supervision of the sponsor 
and signed by the sponsor’s chief medical officer, thereby indicating their agreement with the 
analyses, results, and conclusions of the clinical study report.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 127 of 151 
Confidential 
13.10 Study Publication 
All data generated from this study are the property of the sponsor and shall be held in strict 
confidence along with all information furnished by the sponsor. Independent analysis and/or 
publication of these data by the investigator(s) or any member of their staff are not permitted 
without the prior written consent of the sponsor. Written permission to the investigator will be 
contingent on the review by the sponsor of the statistical analysis and manuscript, and will 
provide for nondisclosure of the sponsor’s confidential or proprietary information. In all cases, 
the parties agree to submit all manuscripts or abstracts to all other parties 30 days prior to 
submission. This will enable all parties to protect proprietary information and to provide 
comments based on information that may not yet be available to other parties. 
13.11 Quality Assurance Audits 
An audit visit to clinical centers may be conducted by a quality control auditor appointed by the 
sponsor. The purpose of an audit, which is independent of and separate from routine monitoring 
or quality control functions, is to evaluate trial conduct and compliance with the protocol, SOPs, 
ICH GCPs, and the applicable regulatory requirements. The investigator and the sponsor may 
also be subject to an inspection by FDA, European Regulatory authorities, or other applicable 
regulatory authorities at any time. The auditor and regulatory authorities will require authority 
from the investigator to have direct access to the patients’ medical records. It is important that 
the investigator(s) and their staff cooperate with the auditor or regulatory authorities during this 
audit or inspection. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 128 of 151 
Confidential 
14 
REFERENCES 
1. Herbst RS, Heymach JV, Lippman SM. Molecular origins of cancer:  Lung cancer. N 
Engl J Med, 2008; 359:13; 1367-80. 
2. Mok TS, Wu YL, Thongprasert S, et al. Getfitinib or carboplatin-paclitaxel in pulmonary 
adenocarcinoma. N Engl J Med, 2009; 361(10):947-57. 
3. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor 
mutations in lung cancer. N Engl J Med, 2009; 361(10):958-67. 
4. Herbst R, LoRusso P, Purdom M, Ward D. Dermatologic side effects associated with 
gefitinib therapy: clinical experience and management. Clin Lung Cancer, 2003; 4:366-9. 
5. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR targeted agents: is 
there a silver lining?  J Clin Oncol, 2005; 23:5235-46. 
6. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a 
review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol, 
2003; 4:397-406. 
7. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to 
gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. 
PLoS Med, 2005; 2(3):e73. 
8. Sharma SV., et al. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal Growth 
Factor Receptor Mutations in Lung Cancer. Nat Rev Cancer. 2007; 7(3):169-81. 
9. Su et al. Detection of a K-ras mutation in urine of patients with colorectal cancer, Cancer 
Biomarkers 1 (2005) 177–182 
10. National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 
http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.0_2009-05-
29_QuickReference_8.5x11.pdf. 
11. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical 
measure for routine clinical use. Clin Exp Dermatol, 1994; 19: 210-216. 
12. Aaronson NK, Ahmedzai S, Bullinger M, et al. For the EORTC Study Group on Quality 
of Life. The EORTC Core Quality of Life Questionnaire:  Interim results of an 
international field study. In:  Osoba D, ed. Effect of Cancer on Quality of Life. Boca 
Raton: CRC Press Inc; 1991; 185-203. 
13. WHO Fact Sheet N°297. Cancer. October 2011. 
14. Ries L, Eisner M, Kosary C, et al, eds. Cancer Statistics Review, 1975-2002. Bethesda, 
Md: National Cancer Institute, 2005.  
15. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic Lymphoma Kinase Inhibition in 
Non–Small-Cell Lung Cancer. N Engl J Med, 2010; 363(18):1693-703. 
16. Gridelli C, Ardizzoni A, Ciardiello F, et al. Second-line treatment of advanced non-small 
cell lung cancer. J Thorac Oncol, 2008; 3:430-440. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 129 of 151 
Confidential 
17. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival 
results from a phase III, randomized, open-label, first-line study of gefitinib versus 
carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung 
cancer in Asia (IPASS).  J Clin Oncol, 2011; 29(21):2866-74. 
18. Rosell R, Gervais R, Vergnenegre A, et al. Erlotinib versus chemotherapy (CT) in 
advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor 
receptor (EGFR) mutations:  Interim results of the European Erlotininb versus 
Chemotherapy (EURTAC) phase III Randomized Trial. J Clin Oncol, 2011; 29; Abstract 
7503. 
19. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution 
of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl Med, 2011; 3:75ra26.  
20. Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-ErbB receptor 
tyrosine kinase inhibitor:  Results of a phase II trial in patients with advanced non-small-
cell lung cancer. J Clin Oncol, 2010; 28(18):3076-83. 
21. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, 
Ladanyi M, Riely GJ. Analysis of Tumor Specimens at the Time of Acquired Resistance 
to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung cancers. Clin Cancer 
Res 2013 April 15, 19:2240. 
22. Walter AO, Sjin RT, Haringsma HJ, et al. Discovery of a mutant-selective covalent 
inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer 
Discov. 2013 Dec;3(12):1404-15 
23. Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 
diabetes mellitus. Postgrad Med. 2011 Jan; 123(1):15-23. 
24. Hamilton RA, Garnett WR, Kline BJ. Determination of mean valproic acid serum level 
by assay of a single pooled sample. Clin Pharmacol Ther, 1981; 29(3):408–413. 
25. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. New response 
evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J 
Cancer, 2009; 45(2):228–247. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 130 of 151 
Confidential 
15 
APPENDICES 
Appendix A. Response Evaluation Criteria in Solid Tumors Criteria 
Appendix B. Eastern Cooperative Oncology Group Performance Status Scale 
Appendix C.  Bayesian Dose Escalation Design for CO-1686-008 
Appendix D.  Study CO-1686-008 Extension Phase 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 131 of 151 
Confidential 
Appendix A 
Response Evaluation Criteria in Solid Tumors Criteria 
The RECIST guidelines (Version 1.1) are described in Eisenhauer (2009)25 and at 
http://www.eortc.be/Recist/Default.htm. A short summary is given below. 
Measurable Disease: 
Tumor lesions:  measurable lesions are defined as those that can be accurately measured in at 
least one dimension (longest diameter to be recorded) with the following: 
1. A minimum size of 10 mm by CT scan (CT scan thickness no greater than 5 mm). 
2. A minimum size of 10 mm caliper measurement by clinical exam (lesions that cannot be 
accurately measured with calipers should be recorded as nonmeasurable). 
3. A minimum size of 20 mm by chest X-ray. 
All tumor measurements must be recorded n millimeters (or decimal fractions of centimeters). 
Malignant lymph nodes:  to be considered pathologically enlarged and measurable, a lymph node 
must be 15 mm in short axis when assessed by CT scan (CT scan slice thickness recommended 
to be not greater than 5 mm). At baseline and in follow-up, only the short axis will be measured 
and followed.  
Nonmeasurable Disease: 
All other lesions (or sites of disease), including small lesions (longest diameter < 10 mm or 
pathological lymph nodes with 10 to < 15 mm short axis), as well as truly nonmeasurable 
lesions, are considered nonmeasurable disease. Lesions considered truly nonmeasurable include 
leptomeningeal disease, ascites, pleural/pericardial effusions, inflammatory breast disease, 
lymphangitic involvement of skin and lung, and abdominal masses/abdominal organomegaly 
identified by physical exam that is not measurable by reproducible imaging techniques.  
Bone Lesions 
Bone lesions, cystic lesion, and lesions previously treated with local therapy require particular 
comment. Bone scan, PET scan, or plain films are not considered adequate imaging techniques 
to measure bone lesions. However, these techniques can be used to confirm the presence or 
disappearance of bone lesions. 
Lytic bone lesions or mixed lytic–blastic lesions with identifiable soft tissue components that can 
be evaluated by cross-sectional imaging techniques such as CT or MRI can be considered as 
measurable lesions if the soft tissue component meets the definition of measurability described 
above. 
Blastic bone lesions are nonmeasurable. 
Cystic Lesions 
Lesions that meet the criteria for radiographically defined simple cysts should not be considered 
as malignant lesions (neither measurable nor nonmeasurable) because they are, by definition, 
simple cysts. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 132 of 151 
Confidential 
Cystic lesions thought to represent cystic metastases can be considered as measurable lesions if 
they meet the definition of measurability described above. However, if noncystic lesions are 
present in the same patient, these are preferred as target lesions. 
Lesions with Prior Local Treatment 
Tumor lesions situated in a previous irradiated area or in an area subjected to other locoregional 
therapy are usually not considered measurable unless there has been demonstrated progression in 
the lesion. 
Target Lesions 
All measurable lesions up to a maximum of two lesions per organ and five lesions in total, 
representative of all involved organs, should be identified as target lesions and recorded and 
measured at baseline. Target lesions should be selected on the basis of their size (lesions with the 
longest diameter) and their suitability for accurate repeated measurements (either by imaging 
techniques or clinically). A sum of the longest diameter (LD) for all target lesions will be 
calculated and reported as the baseline sum LD. The baseline sum LD will be used as reference 
by which to characterize the objective tumor response.  
Nontarget Lesions 
RECIST criteria require unequivocal quantification of the changes in tumor size for adequate 
interpretation of the sum of target lesions. Consequently, when the boundaries of the primary are 
difficult to delineate, this tumor should not be considered a target lesion. 
Guidelines for Evaluation of Measurable Disease 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is 
preferred to evaluation by clinical examination when both methods have been used to assess the 
antitumor effect of a treatment. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 133 of 151 
Confidential 
Evaluation of Target Lesions 
Complete Response 
Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or nontarget) must have reduction in short axis to < 10 
mm. 
Partial Response 
At least a 30% decrease in the sum of the LD of target lesions, taking as 
reference the baseline sum LD. 
Stable Disease 
Neither sufficient shrinkage to qualify for partial response nor sufficient 
increase to qualify for PD, taking as reference the smallest sum LD since 
the treatment started. 
Progressive Disease 
At least a 20% increase in the sum of the LD of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if 
that is the smallest on study). In addition to the relative increase of 20%, 
the sum must also demonstrate an absolute increase of at least 5 mm. 
The appearance of one or more new lesions is also considered 
progression. 
Evaluation of Nontarget Lesions 
Complete Response 
Disappearance of all nontarget lesions and normalization of tumor 
marker level. Any pathological lymph nodes (whether target or non-
target) must have reduction in short axis to < 10 mm. 
Stable Disease/Incomplete 
Response 
Persistence of one or more nontarget lesion(s) or/and maintenance of 
tumor marker level above the normal limits. 
Progressive Disease 
Appearance of one or more new lesions and/or unequivocal progression 
of existing nontarget lesions. 
If tumor markers are initially above the institutional ULN, they must normalize for a patient to 
be considered a complete responder.  
Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements recorded 
since the treatment started). The patient’s best response assignment will depend on the 
achievement of both measurement and confirmation criteria.  
Time Point Response 
A response assessment will occur at the protocol-specified time points. The tables below provide 
a summary of the overall response status calculation at each time point for patients who have 
measureable and non-measureable disease (non-target disease only).  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 134 of 151 
Confidential 
Time Point Response: Patients with Target (+/– non-target) Disease 
Target Lesions 
Nontarget Lesions 
New Lesions 
Overall Response 
CR 
CR 
No 
CR 
CR 
Non-CR/non-PD 
No 
PR 
CR 
Not evaluated 
No 
PR 
PR 
Non-PD or not 
evaluated 
No 
PR 
SD 
Non-PD or not 
evaluated 
No 
SD 
Not Evaluated 
Non-PD 
No 
NE 
PD 
Any 
Yes or No 
PD 
Any 
PD 
Yes or No 
PD 
Any 
Any 
Yes 
PD 
NE=Not evaluable. 
 
Evaluation of Best Overall Response When Confirmation of CR and PR Required 
Overall Response  
First Time Point 
Overall Response 
Subsequent Time 
Point 
Best Overall Response 
CR 
CR 
CR 
CR 
PR 
SD, PD or PRa 
CR 
SD 
SD provided minimum criteria for SD duration 
met, otherwise, PD 
CR 
PD 
SD provided minimum criteria for SD duration 
met, otherwise, PD 
CR 
NE 
SD provided minimum criteria for SD duration 
met, otherwise, NE 
PR 
CR 
PR 
PR 
PR 
PR 
PR 
SD 
SD 
PR 
PD 
SD provided minimum criteria for SD duration 
met, otherwise, PD 
PR 
NE 
SD provided minimum criteria for SD duration 
met, otherwise, NE 
NE 
NE 
NE 
a If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR criteria 
relative to baseline, makes this disease PD at that point (since disease must have reappeared after CR). Best response 
would depend on whether minimum duration for SD was met. However sometimes ‘CR’ may be claimed when 
subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not CR at the first time 
point. Under these circumstances, the original CR should be changed to PR and the best response is PR.  

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 135 of 151 
Confidential 
Missing Assessments and Not Evaluable Designation 
When no imaging/measurement is done at all at a particular time point, the patient is not 
evaluable (NE) at that time point. If only a subset of lesion measurements are made at an 
assessment, usually the case is also considered NE at that time point, unless a convincing 
argument can be made that the contribution of the individual missing lesion(s) would not change 
the assigned time point response, which is most likely to occur in the case of PD; e.g., if only 2 
of 3 baseline target lesions are assessed and result in a > 20% increase in the sum, then the 
patient would be assessed as a PD regardless of the missing lesion. 
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be classified as having 
symptomatic deterioration. Every effort should be made to document the objective progression, 
even after discontinuation of treatment. 
In some circumstances, it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of CR depends on this determination, it is recommended that the residual 
lesion be investigated (fine needle aspiration/biopsy) prior to confirming the complete response 
status. 
Confirmatory Measurement/Duration of Response 
Confirmation 
CT scans are required within 7 days prior to the start of Cycles 3, 5, and 7, and then within 
7 days prior to the start of every third cycle of treatment thereafter, beginning with Cycle 10. If 
an initial CR or PR is noted at Cycle 7 or beyond, confirmatory scans must be performed 4 to 
6 weeks later. In the case of SD, follow-up measurements must have met the SD criteria at least 
once after study entry at a minimum interval of no less than 6 to 8 weeks.  
Duration of Overall Response 
The duration of overall response is measured from the time measurement criteria are met for CR 
or PR (whichever is first recorded) until the first date that recurrent or PD is objectively 
documented (taking as reference for PD the smallest measurements recorded since the treatment 
started). 
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that recurrent disease is objectively documented. 
Duration of Stable Disease 
SD is measured from the start of the treatment until the criteria for progression are met, taking as 
reference the smallest measurements recorded since the treatment started. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 136 of 151 
Confidential 
Appendix B 
Eastern Cooperative Oncology Group Performance Status Scale 
ECOG Performance Status 
0 
Fully active, able to carry on all predisease performance without restriction. 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature (e.g., light house work or office work). 
2 
Ambulatory and capable of all self care but unable to carry out any work activities. Up and 
about more than 50% of waking hours. 
3 
Capable of only limited self care; confined to bed or chair more than 50% of waking hours. 
4 
Completely disabled. Cannot carry on any self care. Totally confined to bed or chair. 
5 
Dead. 
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 137 of 151 
Confidential 
Appendix C 
Bayesian Dose Escalation Design for CO-1686-008 
1.0 Introduction 
 
This appendix provides a description of the trial design along with details of the statistical 
model and simulation results. 
 
Dose escalation will be conducted according to a continual reassessment method (CRM) 
based on a statistical model for dose limiting toxicities (DLTs). The treatment cycle length is 
21 days, with DLT evaluated during the first cycle.  
 
2.0 Endpoints 
 
The primary safety endpoint is the rate of dose-limiting toxicity. The MTD is defined as the 
highest dose that has an estimated DLT rate less than 33%. 
 
3.0 Dose Range 
 
In the model, dose d refers to the total daily dose administered. The starting dose for the 
study will be d = 1000 mg (500 mg administered twice daily). The anticipated maximum 
daily dose will be d = 2250 mg and the anticipated minimum will be 500 mg. 
 
4.0 Statistical Model 
 
Dose escalation will be conducted according to a CRM algorithm. We construct a statistical 
model to describe the relationship between dose and DLT rate. 
 
We let Y be an indicator of DLT (1 = DLT and 0 = no DLT) and define θd to be the 
probability of DLT at dose d. We model the log-odds of θd with a two-parameter model: 
 
⁡ 
 
 
where d is the magnitude of dose (mg). 
 
We create a prior distribution for the parameters capturing the correlation between the 
parameters that is expected. In order to accomplish this we create independent priors and use 
pseudo-prior observations in the likelihood function to create prior distributions that are more 
appropriate. We place the following independent prior distributions on the parameters: 
 
α ~ N(−4, 22) 
 
β ~ N(0.1, 0.252). 
log
qd
1-qd
æ
èç
ö
ø÷ = a + b
d
100
æ
èç
ö
ø÷

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 138 of 151 
Confidential 
 
We use “pseudo-prior” weighting to impose the appropriate weight in the prior distribution. 
We assume ½ an observation on the highest and lowest dose, with 0 DLTs on the lowest dose 
and ½ DLT on the highest dose. 
 
After each patient is treated and assessed for DLT, the distributions of these parameters are 
updated and a next dose level is suggested based on the posterior probability of the DLT rate 
at each dose. 
 
Additionally, we define a dose as unsafe if there is more than 50% probability that the DLT 
rate exceeds 33%: 
 
Pr(θd > 33%) > 50%. 
 
Patients cannot be assigned to a dose that is unsafe by this definition. 
 
5.0 Adaptive Design 
 
In addition to the CRM-modeling, there are additional rules governing entry into the study 
and assignment of dose level. 
 
5.1 Entry into the Study 
 
There is open enrollment into the study with the following restrictions: 
 
• There can be no more than 6 patients with unknown DLT information at any time. We 
refer to the number of subjects waiting for DLT information as the “queue.” 
• Complete DLT information is required for at least 3 patients at a dose before escalation to 
a higher dose.  
 
5.2 Assignment of Dose Level 
 
The CRM will be used to assign patients to doses. However, the maximum increment from 
one dose to the next is anticipated to be 250 mg total daily dose. The design is structured to 
assign one of the following 7 doses: 750 mg, 1000 mg, 1250 mg, 1500 mg, 1750 mg, 
2000 mg or 2250 mg. 
 
 
5.3 Safety Monitoring 
 
If no doses are safe, that is, Pr(θd > 33%) > 50% for all d, then the trial may de-escalate to 
750 mg or 500 mg. If 500 mg is also unsafe, then the study will pause enrollment for further 
evaluation. 
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 139 of 151 
Confidential 
5.4 Success in Identifying the MTD 
 
Dose escalation is considered successful – and an MTD identified – when at least 10 patients 
have been enrolled at the estimated MTD. Once the MTD has been identified, additional 
patients will be enrolled at that dose (if R2PD is the same as the MTD), to approximately 40 
patients eligible for Phase 2 Cohort A and up to approximately 40 patients eligible for 
Phase 2 Cohort B.  
 
6.0 Example Dose Escalation 
 
In this section, we present selected snapshots from an example trial to illustrate the dose 
escalation process. 
 
The trial begins by allocating subjects to a total daily dose of 1000 mg. The first opportunity 
for escalation will be after DLT information is available from 3 patients at this dose, but we 
allow additional patients to enroll while waiting for these subjects to reach the end of 
Cycle 1. The total queue of incomplete data may never exceed 6 patients. 
 
Table 4.1 shows a snapshot of the data when a 7th patient becomes available to enter the trial. 
The row Pr(DLT) gives the model-estimated DLT rate for each dose and Pr(Safe) is the 
probability that the DLT rate is below 33%. As discussed in Section 5.3, no patients may be 
assigned to a dose where this probability is below 50%. 
 
Table 4.1 
 
500 
750 
1000 
1250 
1500 
1750 
2000 
2250 
Enrolled 
-- 
-- 
6 
-- 
-- 
-- 
-- 
-- 
Complete 
-- 
-- 
3 
-- 
-- 
-- 
-- 
-- 
DLT 
-- 
-- 
1 
-- 
-- 
-- 
-- 
-- 
Pr(DLT) 
0.131 
0.206 
0.316 
0.443 
0.561 
0.656 
0.727 
0.780 
Pr(Safe) 
0.923 
0.807 
0.584 
0.373 
0.245 
0.170 
0.127 
0.103 
 
At this time, 6 patients are enrolled at 1000 mg, three of which have completed Cycle 1, and 
one DLT. Thus, the queue is 3 subjects with unknown information. The next highest dose of 
1250 mg is not considered safe at this time, so enrollment continues at the 1000 mg dose. 
 
When the 10th patient arrives, complete information is available from 5 patients at 1000 mg, 
as shown in Table 4.2. No additional DLTs were observed, and the estimated probabilities 
have decreased across all doses. The next highest dose is considered safe with Pr(θ < 33%) = 
0.558. Thus, the 1250 mg dose is opened for enrollment. 
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 140 of 151 
Confidential 
Table 4.2 
 
500 
750 
1000 
1250 
1500 
1750 
2000 
2250 
Enrolled 
-- 
-- 
9 
-- 
-- 
-- 
-- 
-- 
Complete 
-- 
-- 
5 
-- 
-- 
-- 
-- 
-- 
DLT 
-- 
-- 
1 
-- 
-- 
-- 
-- 
-- 
Pr(DLT) 
0.092 
0.140 
0.220 
0.328 
0.444 
0.549 
0.634 
0.699 
Pr(Safe) 
0.973 
0.934 
0.786 
0.558 
0.381 
0.269 
0.201 
0.162 
 
Table 4.3 shows the updated model after 3 patients have completed the DLT period at the 
1250 mg dose. One DLT was observed in this cohort. The model estimates that the next highest 
dose is unsafe, so enrollment continues at the current dose. 
 
Table 4.3 
 
500 
750 
1000 
1250 
1500 
1750 
2000 
2250 
Enrolled 
-- 
-- 
9 
8 
-- 
-- 
-- 
-- 
Complete 
-- 
-- 
9 
3 
-- 
-- 
-- 
-- 
DLT 
-- 
-- 
1 
1 
-- 
-- 
-- 
-- 
Pr(DLT) 
0.065 
0.099 
0.159 
0.253 
0.372 
0.493 
0.596 
0.676 
Pr(Safe) 
0.995 
0.992 
0.953 
0.736 
0.464 
0.295 
0.203 
0.153 
 
The next patient completes Cycle 1 without DLT. We update the model to incorporate the 
accumulating data (Table 4.4). The 1500 mg dose is considered safe and will now be opened for 
enrollment. 
 
Table 4.4 
 
500 
750 
1000 
1250 
1500 
1750 
2000 
2250 
Enrolled 
-- 
-- 
9 
9 
-- 
-- 
-- 
-- 
Complete 
-- 
-- 
9 
4 
-- 
-- 
-- 
-- 
DLT 
-- 
-- 
1 
1 
-- 
-- 
-- 
-- 
Pr(DLT) 
0.063 
0.093 
0.144 
0.227 
0.335 
0.450 
0.552 
0.634 
Pr(Safe) 
0.995 
0.994 
0.969 
0.803 
0.538 
0.355 
0.251 
0.193 
 
The next opportunity for escalation occurs after 3 subjects complete the DLT period at 1500 mg. 
There are actually 4 evaluable patients at that time, and no DLT (Table 4.5). Additionally, all 
patients at the 1250 mg dose have now completed the DLT period. Dose 1750 mg is considered 
safe, and the next patient is assigned to 1750 mg. 
 
Table 4.5 
 
500 
750 
1000 
1250 
1500 
1750 
2000 
2250 
Enrolled 
-- 
-- 
9 
9 
8 
-- 
-- 
-- 
Complete 
-- 
-- 
9 
9 
4 
-- 
-- 
-- 
DLT 
-- 
-- 
1 
2 
0 
-- 
-- 
-- 
Pr(DLT) 
0.063 
0.080 
0.108 
0.152 
0.216 
0.297 
0.385 
0.467 
Pr(Safe) 
0.995 
0.997 
0.997 
0.979 
0.842 
0.619 
0.543 
0.349 
 
Table 4.6 shows the data and model estimates after 4 patients have complete information at 
1750 mg. The next highest dose is considered safe, so new patients will be allocated to 2000 mg. 
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 141 of 151 
Confidential 
Table 4.6 
 
500 
750 
1000 
1250 
1500 
1750 
2000 
2250 
Enrolled 
-- 
-- 
9 
9 
8 
7 
-- 
-- 
Complete 
-- 
-- 
9 
9 
8 
4 
-- 
-- 
DLT 
-- 
-- 
1 
2 
0 
1 
-- 
-- 
Pr(DLT) 
0.065 
0.077 
0.096 
0.125 
0.168 
0.225 
0.295 
0.369 
Pr(Safe) 
0.993 
0.997 
0.999 
0.997 
0.968 
0.820 
0.622 
0.215 
 
After 2 patients have been enrolled at 2000 mg, all remaining patients at 1750 mg have complete 
data. We observed a total of 4 DLTs out of 7 patients at that dose. In reaction to this 
accumulating data, the model now believes that 1500 mg is the highest dose that is safe. 
 
Table 4.7 
 
500 
750 
1000 
1250 
1500 
1750 
2000 
2250 
Enrolled 
-- 
-- 
9 
9 
8 
7 
2 
-- 
Complete 
-- 
-- 
9 
9 
8 
7 
0 
-- 
DLT 
-- 
-- 
1 
2 
0 
4 
-- 
-- 
Pr(DLT) 
0.049 
0.073 
0.110 
0.171 
0.261 
0.380 
0.508 
0.624 
Pr(Safe) 
0.998 
0.999 
0.998 
0.987 
0.805 
0.363 
0.151 
0.081 
 
When 10 patients are enrolled at 1500 mg, escalation stops. The final follow-up data are shown 
in Table 4.8.  
 
Table 4.8 
 
500 
750 
1000 
1250 
1500 
1750 
2000 
2250 
Enrolled 
-- 
-- 
9 
9 
10 
7 
2 
-- 
Complete 
-- 
-- 
9 
9 
10 
7 
2 
-- 
DLT 
-- 
-- 
1 
2 
1 
4 
1 
-- 
Pr(DLT) 
0.051 
0.076 
0.116 
0.180 
0.275 
0.398 
0.530 
0.648 
Pr(Safe) 
0.999 
0.998 
0.997 
0.983 
0.771 
0.283 
0.093 
0.043 
 
7.0 Simulations and Operating Characteristics 
 
In order to evaluate the performance of the dose escalation design, we simulated the study under 
different dose-toxicity scenarios. 
 
7.1 Dose-toxicity Profiles 
 
We considered six scenarios for the underlying DLT rate on each dose. Scenario 1 is a flat dose-
toxicity curve in which all doses are safe. In Scenario 2, the curve is increasing, but all doses are 
below the target toxicity level. Scenarios 3 through 5 assume that the MTD is at the low, middle, 
or high end of the dose range. In Scenario 6, all doses are unsafe. 
 
These profiles are shown in Table 5.1 and are displayed graphically in Figure 5.1. The true MTD 
appears as red italic font in the table. 
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 142 of 151 
Confidential 
Table 5.1 
Dose-toxicity Profiles 
Scenario 
DLT Rate 
500 
750 
1000 
1250 
1500 
1750 
2000 
2250 
1 
0.001 
0.001 
0.001 
0.001 
0.001 
0.001 
0.001 
0.001 
2 
0.030 
0.050 
0.070 
0.090 
0.110 
0.130 
0.150 
0.170 
3 
0.050 
0.200 
0.350 
0.450 
0.550 
0.600 
0.650 
0.700 
4 
0.080 
0.160 
0.270 
0.380 
0.600 
0.750 
0.800 
0.850 
5 
0.030 
0.080 
0.110 
0.170 
0.270 
0.370 
0.600 
0.800 
6 
0.400 
0.440 
0.480 
0.520 
0.560 
0.600 
0.640 
0.680 
 
Figure 5.1 
Dose-toxicity Profiles 
 
 
7.2 Accrual 
 
We simulated patient accrual to the trial from a Poisson process. We assumed that accrual will be 
at the rate of 6 patients per month.  
 
7.3 Operating Characteristics 
 
We simulated the six scenarios for 1000 trials per scenario. 
 
Table 5.2 shows the proportion of simulated trials for which each dose was selected as the MTD 
after all subjects had complete DLT information, and the average number of patients treated at 
each dose. The true MTD is shown in bold italics. The last column shows the proportion of trials 
for which no MTD was identified, due to toxicity. 
 
In scenarios 1-5, the dose that is the true MTD has the highest probability of being selected, and 
also receives a large proportion of patients. Doses below the MTD tend to receive a fair number 
of patients as well due to the expected rate of enrollment and the size of the allowable queue. In 
the last scenario, no doses are safe, and the trial stops without identifying an MTD in 36.4% of 
trials. 
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 143 of 151 
Confidential 
Table 5.2 
Operating Characteristics 
Scenario 
Parameter 
500 
750 
1000 
1250 
1500 
1750 
2000 
2250 
None 
1 
Pr(MTD) 
Mean N 
0.000 
0.0 
0.000 
0.0 
0.000 
6.5 
0.000 
6.5 
0.000 
6.5 
0.000 
6.5 
0.000 
6.5 
1.000 
10.0 
0.000 
2 
Pr(MTD) 
Mean N 
0.000 
0.1 
0.002 
0.2 
0.022 
7.0 
0.056 
6.5 
0.068 
6.3 
0.086 
5.9 
0.101 
5.4 
0.665 
6.4 
0.000 
3 
Pr(MTD) 
Mean N 
0.043 
1.7 
0.433 
4.5 
0.389 
8.3 
0.114 
2.4 
0.011 
0.4 
0.001 
0.0 
0.000 
0.0 
0.000 
0.0 
0.008 
4 
Pr(MTD) 
Mean N 
0.022 
1.0 
0.237 
2.9 
0.469 
8.6 
0.245 
4.0 
0.023 
0.9 
0.001 
0.1 
0.000 
0.0 
0.000 
0.0 
0.004 
5 
Pr(MTD) 
Mean N 
0.000 
0.1 
0.012 
0.5 
0.099 
7.5 
0.277 
6.8 
0.391 
5.9 
0.195 
3.3 
0.023 
0.9 
0.002 
0.1 
0.001 
6 
Pr(MTD) 
Mean N 
0.285 
4.9 
0.213 
3.7 
0.113 
6.9 
0.024 
0.9 
0.002 
0.1 
0.000 
0.0 
0.000 
0.0 
0.000 
0.0 
0.364 
 
Figure 5.2 shows a graphical representation of the operating characteristics. The height of each 
bar represents the proportion of simulated trials for which that dose was selected as the MTD. 
The true underlying dose-toxicity curve is overlaid on the plot, with a dashed red reference line 
depicting the target DLT rate of 33%. 
 
Figure 5.2 
MTD Selection Proportions 
 
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 144 of 151 
Confidential 
Appendix D 
Study CO-1686-008 Extension Phase 
OBJECTIVE OF THE EXTENSION PHASE 
The purpose of the Extension Phase is to allow patients to continue on study but to avoid 
unnecessary collection of data that will no longer be analyzed or required for regulatory 
purposes, whilst maintaining an appropriate level of safety monitoring.   
In addition, Amendment 8 also introduces the availability of NAT2 testing for patients, an 
indirect indicator of the likelihood of developing hyperglycemia and QTc prolongation.  The 
availability and disclosure of this information to the patient’s treating physician will not affect 
the monitoring and associated treatment guidelines for these adverse events.  
INTRODUCTION 
Additional information on efficacy/safety aspects 
The most current clinical and non-clinical updates, in particular those pertaining to efficacy and 
safety data, are provided in the current Investigator’s Brochure, in which integrated summaries 
of efficacy and safety data are presented.  
Additional information relating to Hyperglycemia and QTc prolongation 
The polymorphic enzyme NAT2 mediates the N-acetylation of M502 to form M544 and also 
plays a role in the elimination of M460. NAT2 genotype polymorphism was assessed for the 
group of patients who received rociletinib at 500 mg BID, 625 mg BID, 750 mg BID, and 1000 
mg BID and who gave additional informed consent for genomic testing. The NAT2 genotype 
polymorphism testing was performed using an assay based on polymerase chain reaction (PCR) 
followed by mass spectrometry to identify single nucleotide polymorphisms in NAT2. Based on 
NAT2 genotype results, patients were classified as having “low”, “intermediate”, and “rapid” 
acetylator phenotype.24 Acetylator status is currently available for 635 patients. Additional 
testing will be completed as additional samples are received. 
Adverse event and laboratory data based on NAT2 phenotype are summarized in Appendix D, 
Appendix D, Table , Appendix D, Table , and Appendix D, Table . Analyses are presented by 
acetylator status for all doses combined, since the combined-dose findings were consistent with 
the findings within each dose group. 
Appendix D, Table  demonstrates that Grade 3 events are less common in patients who are 
classified as “rapid” acetylators. As expected, the relationship is most clear for hyperglycemia 
and QT-prolongation, while other adverse events of special interest (AESIs) appear to be less 
closely associated with acetylator status.  Appendix D, Table  shows that hyperglycemia appears 
to be less frequent and less severe in rapid acetylators. Appendix D, Table  shows that QTcF 
prolongation on ECG appears to be less frequent and less severe in rapid acetylators. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 145 of 151 
Confidential 
Appendix D, Table 1. 
Grade 3 or Greater Treatment-emergent Adverse Events by 
Acetylator Status 
Abbreviation: CT=combined terms. 
 
Overall 
(N = 635) 
Slow 
(n=300) 
Intermediate 
(n=259) 
Rapid 
(n=76) 
Overall 
243 (81%) 
194 (75%) 
48 (63%) 
Hyperglycemia (CT) 
131 (44%) 
66 (26%) 
13 (17%) 
QTc prolongation (CT) 
44 (15%) 
19 (7%) 
1 (1%) 
Malignant neoplasm progression 
39 (13%) 
39 (15%) 
8 (11%) 
Cataracts (CT) 
12 (4%) 
9 (4%) 
7 (9%) 
Pneumonitis (CT) 
3 (1%) 
4 (2%) 
0 
Diarrhea 
13 (4%) 
16 (6%) 
1 (1%) 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 146 of 151 
Confidential 
Appendix D, Table 2. 
Hyperglycemia Lab-shift by Acetylator Status 
Appendix D, Table 3. 
QTcF Changes on ECG by Acetylator Status 
Abbreviation: ECG=electrocardiogram. 
For those patients ongoing on rociletinib trials, informed consent and testing for NAT2 
polymorphism status will be offered and the results will be shared with the treating physician.  It 
will be up to the patient in consultation with the treating physician to decide continued 
participation in the trial in light of the acetylator status results or whether alternative treatment 
options should be sought.    
Regardless of acetylator status, monitoring should be the same for all patients receiving 
rociletinib whilst on treatment.  
STUDY DESIGN 
Treatment Regimen and Duration of Therapy 
All patients will sign an informed consent which explains the rationale for closing the CO-1686 
clinical development program for NSCLC and the option for ongoing patients to continue 
 
Overall 
(N = 635) 
Slow 
(n = 300) 
Intermediate 
(n = 259) 
Rapid 
(n = 76) 
Subjects with any post-baseline glucose 
values > 250 mg/dL 
121 (40%) 
65 (25%) 
17 (22%) 
Subjects with 2 or more post-baseline 
glucose values > 250 mg/dL 
51 (17%) 
36 (14%) 
7 (9%) 
Subjects with any post-baseline glucose 
values > 500 mg/dL 
11 (4%) 
7 (3%) 
1 (1%) 
Subjects with 2 or more post-baseline 
glucose values > 500 mg/dL 
3 (1%) 
0 (0.0) 
0 (0.0) 
 
Overall 
(N = 635) 
Slow 
(n = 300) 
Intermediate 
(n = 259) 
Rapid 
(n = 76) 
QTcF Post-baseline ≥ 450 msec 
198 (66%) 
131 (51%) 
34 (45%) 
QTcF Post-baseline ≥ 481 msec 
92 (31%) 
44 (17%) 
7 (9%) 
QTcF Post-baseline ≥ 501 msec 
59 (31%) 
22 (9%) 
1 (1%) 
Two of more within 3 days ≥ 501 msec 
19 (6%) 
10 (4%) 
0 (0.0) 
QTcF Change from Baseline >  30 msec 
246 (82%) 
171 (66%) 
47 (62%) 
QTcF Change from Baseline >  60 msec 
141 (47%) 
57 (22%) 
9 (12%) 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 147 of 151 
Confidential 
receiving study treatment, should they decide to do so and/or if in the opinion of their treating 
physician they continue to receive clinical benefit.  No patient will commence treatment under 
this amendment until appropriate IEC/IRB approval of the study protocol has been received. 
Patients may continue to receive CO-1686 if the PI and patient deem it is appropriate for the 
patient though the availability and suitability of alternative treatment options should be 
considered by the treating physician and discussed with the patient.  CO-1686 will be 
administered daily on a 21-day cycle.  Dosing will be delayed or decreased according to 
protocol-specified toxicity criteria (Section 7.4.3).  Each dose should continue to be taken with 8 
oz. (240 mL) of water and with a meal or within 30 minutes after a meal two times per day. 
Tablets should be swallowed whole. 
Treatment may continue until disease progression or intolerable toxicity. Please note, patients 
may opt to continue to receive treatment with CO-1686 following radiographic progression as 
outlined in the NCCN guidelines for treatment of NSCLC with EGFR TKIs if patient provides 
additional consent, the investigator feels it is in the patient’s best interest and with sponsor 
approval. In general, eligible patients may include those with asymptomatic systemic progression 
or locally symptomatic progression, such as brain metastases amenable to local treatment, with 
concomitant asymptomatic systemic progression or continued systemic disease control. This 
must be discussed with the sponsor and will be reviewed on a case-by-case basis.  
If a patient continues treatment post-progression, all Extension Phase study assessments should 
continue per protocol and data should be captured in the eCRF. The patient should be 
discontinued from treatment once it is clear that no further clinical benefit can be achieved. 
Both the hyperglycemia and QTc management guidelines (Section 7.4.3) should be followed 
during this extension phase and any modifications/deviations from these guidances should be 
discussed and agreed upon with the sponsor prior to implementation.  
Formal safety data reviews will continue approximately every 6 months once enrollment is 
completed and as long as patients remain on treatment. The review committee includes external 
experts and sponsor personnel. The external experts will include, but not be limited to, the 
coordinating PIs of the study. The sponsor’s reviewers will include the Medical Monitor and 
additional Clovis medical experts, and a biostatistician. The protocol will be amended as 
appropriate to incorporate additional patient safety monitoring if new safety signals or a change 
in risk:benefit are noted at any review. 
Once study treatment has been discontinued and the End of Treatment visit has been completed, 
study participation will cease. Investigational centers will interpret tumor scans locally for the 
purpose of making treatment decisions and for final tumor response evaluation. The study 
will close once all patients have either completed participation, have transferred to a locally 
approved treatment access program (e.g. a named patient program) in accordance with relevant 
local regulations or the sponsor decides to close the study. 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 148 of 151 
Confidential 
PATIENT ELIGIBILITY AND WITHDRAWAL CRITERIA  
Eligibility and Number of Patients 
This amendment applies to patients who remain on CO-1686 treatment in the CO-1686-008 
study. No additional patients will be enrolled. 
Withdrawal Criteria 
The patient has the right to stop treatment or to withdraw from the study at any time. 
Patients will continue to receive treatment until one of the following cessation criteria applies: 
• Disease progression (PD) based on tumor scans or clinical status assessed by the 
investigator. 
▪ Post-progression treatment is permitted, at the discretion of the Investigatory and with 
the approval of the sponsor.   
• Intercurrent illness that prevents administration of treatment (Reference Section 7.7) 
• Unacceptable toxicity. 
• Patient withdrawal of consent to further treatment. 
• Major noncompliance that may affect patient safety. 
• Pregnancy. 
• Investigator decision. 
In addition, the sponsor may discontinue the trial early for any of the reasons noted in 
Section 13.6 of the protocol. 
The date and reason for cessation of treatment will be documented.  Patients with ongoing SAEs 
will be followed until either resolution or stabilization has been determined.   
STUDY PROCEDURES 
Schedule of Assessments 
The procedures and assessments to be performed are outlined in the Schedule of Assessments 
presented in Appendix D, Table 4.  Procedures are synchronized with administration day of 
treatment unless indicated.  The revised evaluations should commence immediately after the 
patient is consented, maintaining previous treatment cycle and day sequence. 
Appendix D, Table 4: 
Protocol CO-1686-008 Schedule of Assessments – Extension 
Phase (Phase 1 and Phase 2 Patients) 
 
Prior to beginning 
Amendment 8 Evaluations 
Day 1 of 
each cycle 
End of Treatment 
(28±7 days after last dose) 
Informed consent 
X 
 
 
Physical Examination including vision check 
 
X 
X 
Vital Signsa and Weight 
 
X 
X 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 149 of 151 
Confidential 
a = Vital signs (blood pressure, pulse, and temperature) taken predose on drug administration days. 
b = Patients are to continue using effective contraception for 12 weeks after last dose of CO-1686 and report any pregnancies 
during this period. 
c = Serum ß-hCG to be evaluated by local lab and  performed only on women of childbearing potential. 
d = Glucose must be measured following an 8 hour fast (no food or liquid other than water). Hemoglobin A1c will be 
measured on Day 1 of every other cycle while the patient is on study. Samples should be analyzed by local laboratory.  
e = Patients will be monitored for AEs from the time the first dose of CO-1686 is administered through 28 days after the last 
dose.  
f= Patient diaries should be collected and reviewed for compliance at each visit. No diary will be dispensed at end of 
treatment. 
g=12-lead ECG (in triplicate, 10-sec tracings > 2 min apart) prior to dosing up to and including Cycle 12, at a minimum. For 
patients who are ongoing at this time and for whom QT has been < 470 ms throughout the study, ECG monitoring may be 
subsequently taken every 3rd cycle thereafter.  ECGs will be performed and interpreted locally for patient care decisions; 
however, tracings should be submitted to the central lab for independent evaluation.  
h=Tumor scans will no longer be required to be submitted to a central reviewer; Disease progression to continue to be assessed 
locally by the Investigator.  If a patient discontinues treatment before progression or is continuing treatment post progression 
(approval from Sponsor is required), then the decision to conduct additional scans and the frequency of those scans to monitor 
disease progression will be the responsibility of the treating physician. 
i=Only one sample is needed and may be collected at any visit to enable NAT2 analysis. 
 
Day 1 of Each Cycle  
Patients will be instructed to refrain from taking their dose of oral CO-1686 at home on the day 
of their clinic visit (Day 1 of the cycle) because the dose will be taken during the clinic visit. The 
following procedures will be completed: 
The following procedures are conducted before dosing with CO-1686: 
• Physical examination 
o Including a vision check as part of a standard physical exam 
• Weight 
• Vital signs (blood pressure, pulse, and temperature) 
Concomitant Medications and Procedures 
 
X 
X 
Contraceptive Counselingb 
 
 
X 
Serum Pregnancy Testc 
 
 
X 
Local fasting Serum Chemistryd 
 
X 
X 
Local Hematologyd 
 
X 
X 
Adverse Events (AE) Monitoringe 
 
X 
X 
Patient Diaryf 
 
X 
X 
CO-1686 Dispensing / Administration 
 
X 
 
ECG Assessments using central ECG machineg 
 
X 
X 
Tumor Scansh 
To be performed per institutional standard of care or every 3 cycles; scans 
are not required at the End of Treatment Visit 
Blood for CYP Evaluation  
 (Optional Sampling)i 
 
X 
 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 150 of 151 
Confidential 
• 12-lead ECG (in triplicate, 10-sec tracings > 2 min apart) using central ECG machineprior to 
dosing up to and including Cycle 12. For patients who are ongoing at this time and for whom 
QT has been < 470 ms throughout the study, ECG monitoring may be subsequently taken 
every 3rd cycle thereafter.  ECGs will be performed and interpreted locally for patient care 
decisions; however, tracings should be submitted to the central lab for independent 
evaluation.  
• Fasting serum chemistry (includes fasting glucose) HbA1c will be measured every other 
cycle (Day 1 of Cycle 3, 5, 7 etc). 
• Hematology 
• Concomitant medications and procedures 
• AE monitoring 
• Collection and review of patient diary 
• Dispense capsules or tablets to patient 
o Oral CO-1686 will be administered with a meal, or within 30 minutes after a meal. The 
patient must also drink at least 8 ounces (240 mL) of water when taking CO-1686. 
Tablets should be swallowed whole. 
• Dispense patient diary to patient 
•  (Optional) Blood for CYP Evaluation 
o Patient may consent for optional CYP sample collection if not previously collected 
already, and have the sample collected for  NAT2 analysis 
o Sample should only be collected at a single visit 
The following procedure is conducted irrespective of dosing time: 
• Tumor scans per institutional standard of care or every 3 cycles (between Days 14 and 21).  
until disease (tumor or clinical) progression.  Disease progression to continue to be assessed 
locally by the Investigator. If a patient discontinues treatment before progression or is 
continuing treatment post progression (with approval from Sponsor), then the decision to 
conduct additional scans and the frequency of those scans to monitor disease progression will 
be the responsibility of the treating physician. 
End of Treatment Visit 
The following procedures will be performed for all patients 28 days (±7 days) after the last dose 
of oral CO-1686: 
• Physical examination 
o Including a vision check as part of a standard physical exam 
• Weight 
• Vital signs (blood pressure, pulse, and temperature) 
• Concomitant medications and procedures since last visit 

Clovis Oncology, Inc. 
 
Clinical Protocol 
CO-1686 
CO-1686-008 
 
Amendment 8 (version 9.0) 3 August 2016 
 
Clovis-CO-1686-008__PROTOCOL 
Page 151 of 151 
Confidential 
• 12-lead ECG (in triplicate, 10-sec tracings > 2 min apart)  
• Fasting serum chemistry (includes fasting glucose) 
• Hematology 
• Serum pregnancy test for women of childbearing potential 
• AE monitoring (until 28 days after last dose of oral CO-1686; then only ongoing serious 
adverse events (SAEs) are followed until resolution or stabilization) 
• Collection and review of patient diary 
• Contraceptive counseling